# Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

| # | Paper | IF | Citations |
|---|-------|----|-----------|
| 2217 | The current role of MRI in differentiating multiple sclerosis from its imaging mimics. **2018**, 14, 199-213 | | 95 |
| 2216 | Free light chains in the cerebrospinal fluid. Do we still need oligoclonal IgG?. **2018**, 56, 1011-1014 | | 3 |
| 2215 | Complexity of MS management in the current treatment era. **2018**, 90, 761-762 | | 2 |
| 2214 | Coexistence of systemic lupus erythematosus and multiple sclerosis. A case report and literature review. **2018**, 4, 2055217318768330 | | 5 |
| 2213 | Challenges and needs in experimental therapies for multiple sclerosis. **2018**, 31, 263-267 | | 5 |
| 2212 | Diagnosing MRI-negative autoimmune diseases. **2018**, 5, e457 | | 3 |
| 2211 | Evaluation of Cobas 8000 for the quantification of albumin and IgG in serum and cerebrospinal fluid. **2018**, 56, 105-108 | | 0 |
| 2210 | To diagnose or not to diagnose? Timing is the question: balancing early diagnosis of multiple sclerosis with misdiagnosis. **2018**, 18, 355-357 | | 0 |
| 2209 | 2017 McDonald MS diagnostic criteria: Evidence-based revisions. **2018**, 24, 92-95 | | 20 |
| 2208 | Paediatric multiple sclerosis: early diagnosis as a first step. **2018**, 2, 161-162 | | 1 |
| 2207 | Optimal Intereye Difference Thresholds in Retinal Nerve Fiber Layer Thickness for Predicting a Unilateral Optic Nerve Lesion in Multiple Sclerosis. **2018**, 38, 451-458 | | 33 |
| 2206 | Clinical applications of ultra-high field magnetic resonance imaging in multiple sclerosis. **2018**, 18, 221-230 | | 13 |
| 2205 | Multiple sclerosis in 2017: Progress in multiple sclerosis - from diagnosis to therapy. **2018**, 14, 72-74 | | 5 |
| 2204 | Evolving diagnostic criteria for multiple sclerosis. *Lancet Neurology, The*, **2018**, 17, 118 | 24.1 | 5 |
| 2203 | Preservation of neuronal function as measured by clinical and MRI endpoints in relapsing-remitting multiple sclerosis: how effective are current treatment strategies?. **2018**, 18, 203-219 | | 4 |
| 2202 | MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. **2018**, 2, 191-204 | | 57 |
| 2201 | 2017 Japanese guidelines for multiple sclerosis and neuromyelitis optica: Achievements and challenges. **2018**, 9, 4-6 | | |

| 2182 | Multiple Sclerosis and Variants. **2018**, 1-41 | 1 |
| 2181 | Investigating the Role of MicroRNA and Transcription Factor Co-regulatory Networks in Multiple Sclerosis Pathogenesis. **2018**, 19, | 25 |
| 2180 | [Optical Coherence Tomography in Disorders of the Central Nervous System]. **2018**, 235, 1242-1258 | 1 |
| 2179 | Multiple sclerosis. **2018**, 4, 43 | 372 |
| 2178 | [Recommendations About Multiple Sclerosis Management During Pregnancy, Partum and Post-Partum: Consensus Position of The Portuguese Multiple Sclerosis Study Group and The Portuguese Society of Obstetrics and Maternal-Fetal Medicine]. **2018**, 31, 785-795 | 1 |
| 2177 | Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders: Toward a New Spectrum of Inflammatory Demyelinating CNS Disorders?. **2018**, 9, 2753 | 31 |
| 2176 | Central Nervous System Involvement in Common Variable Immunodeficiency: A Case of Acute Unilateral Optic Neuritis in a 26-Year-Old Italian Patient. **2018**, 9, 1031 | 3 |
| 2175 | Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland. **2018**, 4, 2055217318814562 | 6 |
| 2174 | Should Spinal MRI Be Routinely Performed in Patients With Clinically Isolated Optic Neuritis?. **2018**, 38, 502-510 | 1 |
| 2173 | Anti-Myelin Oligodendrocyte Glycoprotein and Human Leukocyte Antigens as Markers in Pediatric and Adolescent Multiple Sclerosis: on Diagnosis, Clinical Phenotypes, and Therapeutic Responses. **2018**, 2018, 8487471 | 6 |
| 2172 | Clinical Neurophysiology in the Treatment of Disease. **2018**, 58, 203-212 | |
| 2171 | Multiple Sclerosis: A Global Concern with Multiple Challenges in an Era of Advanced Therapeutic Complex Molecules and Biological Medicines. **2018**, 6, | 10 |
| 2170 | The Persisting Significance of Oligoclonal Bands in the Dawning Era of Kappa Free Light Chains for the Diagnosis of Multiple Sclerosis. **2018**, 19, | 23 |
| 2169 | Genome-wide DNA methylation changes in CD19 B cells from relapsing-remitting multiple sclerosis patients. **2018**, 8, 17418 | 28 |
| 2168 | Differences in Intercellular Communication During Clinical Relapse and Gadolinium-Enhanced MRI in Patients With Relapsing Remitting Multiple Sclerosis: A Study of the Composition of Extracellular Vesicles in Cerebrospinal Fluid. **2018**, 12, 418 | 12 |
| 2167 | [Clinical analysis of opticospinal multiple sclerosis (OSMS) presentation detecting anti-myelin oligodendrocyte glycoprotein (MOG) antibody]. **2018**, 58, 737-744 | 2 |
| 2166 | Multiplex Matrix Metalloproteinases Analysis in the Cerebrospinal Fluid Reveals Potential Specific Patterns in Multiple Sclerosis Patients. **2018**, 9, 1080 | 8 |
| 2165 | Determining the Etiology of Internuclear Ophthalmoplegia in a Patient with a Cardiac Pacemaker and Complex Neurological Presentation. **2018**, 14, 574-576 | |

2164  Incidence and prevalence of MS in children: A population-based study in Ontario, Canada. **2018**, 91, e1579-e1590  28

2163  Detection of Leukocortical Lesions in Multiple Sclerosis and Their Association with Physical and Cognitive Impairment: A Comparison of Conventional and Synthetic Phase-Sensitive Inversion Recovery MRI. **2018**, 39, 1995-2000  10

2162  [Autoimmune reactions and paraneoplastic syndromes]. **2018**, 58, 1080-1090

2161  Biopsying a spinal cord lesion: A diagnostic dilemma. Case report and review of literature. **2018**, 64, 425-430  6

2160  The MRI central vein marker; differentiating PPMS from RRMS and ischemic SVD. **2018**, 5, e496  9

2159  Serum GFAP as a biomarker for disease severity in multiple sclerosis. **2018**, 8, 14798  74

2158  Relevance of KFLC quantification to differentiate clinically isolated syndrome from multiple sclerosis at clinical onset. **2018**, 174, 220-229  8

2157  Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis. **2018**, 78, 1549-1566  24

2156  Functional Connectivity in Multiple Sclerosis: Recent Findings and Future Directions. **2018**, 9, 828  34

2155  Differential Gray Matter Vulnerability in the 1 Year Following a Clinically Isolated Syndrome. **2018**, 9, 824  12

2154  Visual Evoked Potentials as a Biomarker in Multiple Sclerosis and Associated Optic Neuritis. **2018**, 38, 350-357  19

2153  NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab fingolimod efficacy in multiple sclerosis. **2018**, 11, 1756286418805713  7

2152  Guidelines of the Polish Medical Society of radiology for the routinely used MRI protocol in patients with multiple sclerosis. **2018**, 52, 638-642  2

2151  Multiple sclerosis: clinical aspects. **2018**, 31, 752-759  135

2150  Is the dual-task cost of walking and texting unique in people with multiple sclerosis?. **2018**, 125, 1829-1835  5

2149  Rebound After Fingolimod and a Single Daclizumab Injection in a Patient Retrospectively Diagnosed With NMO Spectrum Disorder-MRI Apparent Diffusion Coefficient Maps in Differential Diagnosis of Demyelinating CNS Disorders. **2018**, 9, 782  4

2148  The Central Vein: FLAIR Signal Abnormalities Associated with Developmental Venous Anomalies in Patients with Multiple Sclerosis. **2018**, 39, 2007-2013  8

2147  [Care pathway diversity of patients with multiple sclerosis between French regions]. **2018**, 66, 385-394  2

2146 Clinical utility of anti-MOG antibody testing in a Danish cohort. **2018**, 26, 61-67  7

2145 Pediatric Multiple Sclerosis: an Update. **2018**, 18, 76  21

2144 Brazilian Consensus for the Treatment of Multiple Sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis. **2018**, 76, 539-554  13

2143 [Neuroimmunology and rheumatology: overlap and differential diagnoses]. **2018**, 89, 1095-1105  1

2142 Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis. **2018**, 141, 2834-2847  35

2141 Glial Fibrillary Acidic Protein Antibody: Another Antibody in the Multiple Sclerosis Diagnostic Mix. **2018**, 38, 281-284  2

2140 Interleukin-6, S-Nitrosothiols, and Neurodegeneration in Different Central Nervous System Demyelinating Disorders: Is There a Relationship?. **2018**, 14, 327-332  8

2139 Laboratory Performance on Reporting Monoclonal Gammopathy During Cerebrospinal Fluid Oligoclonal Banding Analysis from External Quality Assessment Surveys. **2018**, 3, 261-266  0

2138 2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes. **2018**, 265, 2684-2687  25

2137 Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course. **2018**, 265, 2540-2547  21

2136 Neurologische Fachpflege von Menschen mit Multipler Sklerose. **2018**, 71, 36-40

2135 Search for a prognostic biomarker in multiple sclerosis: a step in the right direction?. **2018**, 89, 1015

2134 Impact of the 2017 revisions to McDonald criteria on the diagnosis of multiple sclerosis. **2018**, 24, 1786-1787  17

2133 Applying the 2017 McDonald diagnostic criteria for multiple sclerosis. *Lancet Neurology, The*, **2018**, 17, 497  24.1  2

2132 Conventional and advanced MRI in multiple sclerosis. **2018**, 174, 391-397  5

2131 Applying the 2017 McDonald diagnostic criteria for multiple sclerosis. *Lancet Neurology, The*, **2018**, 17, 496-497  24.1  5

2130 Applying the 2017 McDonald diagnostic criteria for multiple sclerosis. *Lancet Neurology, The*, **2018**, 17, 498  24.1  9

2129 Applying the 2017 McDonald diagnostic criteria for multiple sclerosis. *Lancet Neurology, The*, **2018**, 17, 497-498  24.1  5

2128    Applying the 2017 McDonald diagnostic criteria for multiple sclerosis. *Lancet Neurology, The*, **2018**, 17, 498-499 — 24.1    2

2127    Applying the 2017 McDonald diagnostic criteria for multiple sclerosis - Authors' reply. *Lancet Neurology, The*, **2018**, 17, 499-500 — 24.1    22

2126    Aktuelles aus der Forschung. **2018**, 45, 215-217 — 1

2125    Causas no inflamatorias de consulta urgente en esclerosis mĺtiple. **2018**, — 1

2124    MRI in multiple sclerosis: what is changing?. **2018**, 31, 386-395 — 13

2123    The Role of Extracellular Adenosine Generation in the Development of Autoimmune Diseases. **2018** , 2018, 7019398 — 23

2122    Increases in fatigue do not change spasticity scores in persons with multiple sclerosis. **2018**, 8, 143-150 — 1

2121    Consensus Recommendations of the Multiple Sclerosis Study Group and Portuguese Neuroradiological Society for the Use of the Magnetic Resonance Imaging in Multiple Sclerosis in Clinical Practice: Part 1. **2018**, 31, 281-289

2120    Radiologically isolated syndrome in children: Current knowledge and future directions. **2018**, 24, 79-84 — 1

2119    Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview. **2018**, 32, 499-526 — 16

2118    Monitoring Progressive Multiple Sclerosis with Novel Imaging Techniques. **2018**, 7, 265-285 — 11

2117    Multiple Sklerose und andere autoimmune ZNS-Erkrankungen. **2018**, 1-103

2116    Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study. **2018**, 89, 1259-1265 — 56

2115    Neurofilaments and 10-year follow-up in multiple sclerosis. **2018**, 24, 1301-1307 — 42

2114    Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers. **2018**, 13, e0194828 — 21

2113    Application of the 2017 Revised McDonald Criteria for Multiple Sclerosis to Patients With a Typical Clinically Isolated Syndrome. **2018**, 75, 1392-1398 — 57

2112    Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - No. **2018**, 24, 1537-1539 3

2111    Neuromyelitis optica spectrum disorder and multiple sclerosis in a Sardinian family. **2018**, 25, 73-76 — 3

| 2110 | Cerebrospinal fluid free kappa light chains and kappa index perform equal to oligoclonal bands in the diagnosis of multiple sclerosis. **2018**, 57, 210-220 | 17 |

| 2109 | Clinical trials in multiple sclerosis: milestones. **2018**, 11, 1756286418785499 | 7 |

| 2108 | Establishing the diagnosis of multiple sclerosis in Croatian patients with clinically isolated syndrome: 2010 versus 2017 McDonald criteria. **2018**, 25, 99-103 | 17 |

| 2107 | Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study. **2018**, 141, 2605-2618 | 74 |

| 2106 | Applicability of McDonald 2010 and Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) 2016 Magnetic Resonance Imaging Criteria for the Diagnosis of Multiple Sclerosis in Sri Lanka. **2018**, 14, 339-344 | 1 |

| 2105 | Consensus recommendations for the diagnosis and treatment of primary progressive multiple sclerosis in Latin America. **2018**, 393, 4-13 | 3 |

| 2104 | Neurological Disease in Lupus: Toward a Personalized Medicine Approach. **2018**, 9, 1146 | 19 |

| 2103 | Inflammasome Proteins As Biomarkers of Multiple Sclerosis. **2018**, 9, 135 | 49 |

| 2102 | Progressive Demyelination in the Presence of Serum Myelin Oligodendrocyte Glycoprotein-IgG: A Case Report. **2018**, 9, 340 | 4 |

| 2101 | Emerging Biosensing Technologies for Neuroinflammatory and Neurodegenerative Disease Diagnostics. **2018**, 11, 164 | 19 |

| 2100 | Genetic Determinants of Antibody Levels in Cerebrospinal Fluid in Multiple Sclerosis: Possible Links to Endogenous Retroviruses. **2018**, 19, | 3 |

| 2099 | The Effect of Three Different Strategies Based on Motor Task Performance on Neuromuscular Fatigue in Healthy Men and Men with Multiple Sclerosis. **2018**, 54, | 3 |

| 2098 | Clinical Application of 2017 McDonald Diagnostic Criteria for Multiple Sclerosis. **2018**, 14, 387-392 | 15 |

| 2097 | Mapping Deep Gray Matter Iron in Multiple Sclerosis by Using Quantitative Magnetic Susceptibility. **2018**, 289, 497-498 | 3 |

| 2096 | Clinical Presentations and Phenotypic Spectrum of Multiple Sclerosis at a University Hospital in Saudi Arabia. **2018**, 14, 359-365 | 8 |

| 2095 | ANN Classification of MS Subgroups with Diffusion Limited Aggregation. **2018**, 121-136 | 4 |

| 2094 | Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis. **2018**, 15, 209 | 64 |

| 2093 | Structural cortical network reorganization associated with early conversion to multiple sclerosis. **2018**, 8, 10715 | 10 |

| | | |
|---|---|---|
| 2092 | Identification of Chronic Active Multiple Sclerosis Lesions on 3T MRI. **2018**, 39, 1233-1238 | 53 |
| 2091 | Evolution of Visual Outcomes in Clinical Trials for Multiple Sclerosis Disease-Modifying Therapies. **2018**, 38, 202-209 | 13 |
| 2090 | Vitamin D-binding protein and multiple sclerosis: Evidence, controversies, and needs. **2018**, 24, 1526-1535 | 10 |
| 2089 | Optic neuritis in the diagnosis of MS: More than meets the eye. **2018**, 91, 545-546 | 2 |
| 2088 | Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis. **2018**, 25, 246-250 | 20 |
| 2087 | Cerebrospinal fluid GAP-43 in early multiple sclerosis. **2018**, 4, 2055217318792931 | 4 |
| 2086 | Intrathecal K free light chain synthesis in multiple sclerosis at clinical onset associates with local IgG production and improves the diagnostic value of cerebrospinal fluid examination. **2018**, 25, 241-245 | 19 |
| 2085 | Age-adjusted CSF ⵧ-microglobulin and lactate are increased and ACE is decreased in patients with multiple sclerosis, but only lactate correlates with clinical disease duration and severity. **2018**, 323, 19-27 | 4 |
| 2084 | Three Japanese adult cases of brain lesions with anti-myelin oligodendrocyte glycoprotein antibodies lacking optic neuritis and myelitis. **2018**, 9, 162-168 | 1 |
| 2083 | Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs. **2018**, 32, 939-949 | 44 |
| 2082 | Diagnostics of autoimmune neurodegeneration using fluorescent probing. **2018**, 8, 12679 | 0 |
| 2081 | The relevance of ceramides and their synthesizing enzymes for multiple sclerosis. **2018**, 132, 1963-1976 | 22 |
| 2080 | Retinal imaging with optical coherence tomography: a biomarker in multiple sclerosis?. **2018**, 10, 47-63 | 41 |
| 2079 | Inclusion of optic nerve involvement in dissemination in space criteria for multiple sclerosis. **2018**, 91, e1130-e1134 | 20 |
| 2078 | Multiple sclerosis and mixed microbial infections. Direct identification of fungi and bacteria in nervous tissue. **2018**, 117, 42-61 | 23 |
| 2077 | The Radiologically Isolated Syndrome: An Opportunity to Prevent Multiple Sclerosis in Children. **2018**, 85, 13-15 | 1 |
| 2076 | [Diagnosis of multiple sclerosis: revision of the McDonald criteria 2017]. **2018**, 89, 1344-1354 | 8 |
| 2075 | Precision medicine for multiple sclerosis promotes preventative medicine. **2018**, 1420, 62-71 | 5 |

| 2074 | Improved Detection of New MS Lesions during Follow-Up Using an Automated MR Coregistration-Fusion Method. **2018**, 39, 1226-1232 | 9 |

| 2073 | Multiple sclerosis pathogenesis: missing pieces of an old puzzle. **2018**, 30, 67-83 | 12 |

| 2072 | Three-Tesla MRI does not improve the diagnosis of multiple sclerosis: A multicenter study. **2018**, 91, e249-e257 | 18 |

| 2071 | Commentary on Al Hussona et al. 'New-onset seizures as a sole clinical presentation of multiple sclerosis'. **2019**, 25, 298-299 | |

| 2070 | Application of the 2017 McDonald diagnostic criteria for multiple sclerosis in Korean patients with clinically isolated syndrome. **2019**, 25, 1488-1495 | 21 |

| 2069 | Cortical and meningeal pathology in progressive multiple sclerosis: a new therapeutic target?. **2019**, 30, 221-232 | 4 |

| 2068 | Pure spinal multiple sclerosis: A possible novel entity within the multiple sclerosis disease spectrum. **2019**, 25, 1189-1195 | 3 |

| 2067 | Magnetic resonance imaging as a prognostic disability marker in clinically isolated syndrome: A systematic review. **2019**, 139, 18-32 | 10 |

| 2066 | Abnormal venous postural control: multiple sclerosis-specific change related to gray matter pathology or age-related neurodegenerative phenomena?. **2019**, 29, 329-338 | 3 |

| 2065 | MRI quality control for the Italian Neuroimaging Network Initiative: moving towards big data in multiple sclerosis. **2019**, 266, 2848-2858 | 7 |

| 2064 | Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS. **2019**, 35, 196-202 | 5 |

| 2063 | Changing patterns of multiple sclerosis in Korea: Toward a more baseline MRI lesions and intrathecal humoral immune responses. **2019**, 35, 209-214 | 0 |

| 2062 | Lipid profile of cerebrospinal fluid in multiple sclerosis patients: a potential tool for diagnosis. **2019**, 9, 11313 | 21 |

| 2061 | Ensayo pictórico: Diagnóstico diferencial radiológico en Esclerosis Múltiple. **2019**, 25, 5-18 | |

| 2060 | Pregnancy and multiple sclerosis: Clinical effects across the lifespan. **2019**, 18, 102360 | 12 |

| 2059 | The predictive value of CSF multiple assay in multiple sclerosis: A single center experience. **2019**, 35, 176-181 | 7 |

| 2058 | Targeted metabolomics approach for identification of relapsing-remitting multiple sclerosis markers and evaluation of diagnostic models. **2019**, 10, 1803-1809 | 9 |

| 2057 | Aktuelle Therapieempfehlungen bei multipler Sklerose im Kindes- und Jugendalter. **2019**, 167, 282-291 | 0 |

| 2038 | Brain volume dynamics in multiple sclerosis. A case-control study. **2019**, 41, 936-942 | | 3 |
| 2037 | A single nucleotide polymorphism within Ninjurin 2 is associated with risk of multiple sclerosis. **2019**, 34, 1415-1419 | | 7 |
| 2036 | Free light chains in cerebrospinal fluid of multiple sclerosis patients negative for IgG oligoclonal bands. **2019**, 496, 117-120 | | 8 |
| 2035 | GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis. **2019**, 25, 1290-1300 | | 86 |
| 2034 | A unique case of multiphasic ADEM or what else?. **2019**, 35, 73-75 | | 1 |
| 2033 | Plasma proteome in multiple sclerosis disease progression. **2019**, 6, 1582-1594 | | 11 |
| 2032 | Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. *Lancet Neurology, The*, **2019**, 18, 973-980 | 24.1 | 49 |
| 2031 | TREM2 R47H (rs75932628) variant is unlikely to contribute to Multiple Sclerosis susceptibility and severity in a large Greek MS cohort. **2019**, 35, 116-118 | | 7 |
| 2030 | Coming off cannabis: a cognitive and magnetic resonance imaging study in patients with multiple sclerosis. **2019**, 142, 2800-2812 | | 13 |
| 2029 | Improving acute demyelinating lesion detection: which T1-weighted magnetic resonance acquisition is more sensitive to gadolinium enhancement?. **2019**, 77, 485-492 | | 0 |
| 2028 | Diagnosis and Management of Progressive Multiple Sclerosis. **2019**, 7, | | 26 |
| 2027 | Using biomarkers to predict clinical outcomes in multiple sclerosis. **2019**, 19, 342-349 | | 3 |
| 2026 | Improving Detection of Multiple Sclerosis Lesions in the Posterior Fossa Using an Optimized 3D-FLAIR Sequence at 3T. **2019**, 40, 1170-1176 | | 4 |
| 2025 | Gadolinium Retention in the Brain: An MRI Relaxometry Study of Linear and Macrocyclic Gadolinium-Based Contrast Agents in Multiple Sclerosis. **2019**, 40, 1265-1273 | | 13 |
| 2024 | [Neuroradiology in ophthalmology]. **2019**, 116, 689-706 | | |
| 2023 | Advances in brain imaging in multiple sclerosis. **2019**, 12, 1756286419859722 | | 31 |
| 2022 | Correlation between auto/mitophagic processes and magnetic resonance imaging activity in multiple sclerosis patients. **2019**, 16, 131 | | 20 |
| 2021 | Patients With Epileptic Seizures and Multiple Sclerosis in a Multiple Sclerosis Center in Southern Germany Between 2003-2015. **2019**, 10, 613 | | 10 |

2020 | Hair cortisol concentration, cognitive, behavioral, and motor impairment in multiple sclerosis. **2019**, 126, 1145-1154 | 4

2019 | Neuronal damage and neuroinflammation markers in patients with autoimmune encephalitis and multiple sclerosis. **2019**, 34, 1473-1485 | 12

2018 | Does CSF pleocytosis have a predictive value for disease course in MS?. **2019**, 6, e584 | 9

2017 | Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology. **2019**, 93, e414-e420 | 14

2016 | Recessive Charcot-Marie-Tooth and multiple sclerosis associated with a variant in. **2019**, 1, fcz011 | 1

2015 | Paediatric acquired demyelinating syndromes. **2019**, 29, 468-475 | 1

2014 | Sexual Dysfunction in Patients with Multiple Sclerosis from Argentina: What are the Differences Between Women and Men?. **2019**, 37, 521-539 | 5

2013 | Granger causality analysis in combination with directed network measures for classification of MS patients and healthy controls using task-related fMRI. **2019**, 115, 103495 | 16

2012 | Metronidazole induced encephalopathy: case report and discussion on the differential diagnoses, in particular, Wernicke's encephalopathy. **2019**, 13, 1-7 | 0

2011 | Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs-A Systematic Review. **2019**, 8, | 11

2010 | Transcranial Magnetic Stimulation as a Potential Biomarker in Multiple Sclerosis: A Systematic Review with Recommendations for Future Research. **2019**, 2019, 6430596 | 13

2009 | Therapeutic Plasma Exchange in Multiple Sclerosis and Autoimmune Encephalitis: a Comparative Study of Indication, Efficacy and Safety. **2019**, 9, | 7

2008 | Are oligoclonal bands associated to lower retinal layer thickness at the time of relapsing remitting multiple sclerosis diagnosis? Evidence from an exploratory study. **2019**, 18, 102365 |

2007 | Association of cerebrospinal fluid kappa free light chains with the intrathecal polyspecific antiviral immune response in multiple sclerosis. **2019**, 498, 148-153 | 4

2006 | Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis. **2019**, 10, 1008 | 28

2005 | Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course. **2019**, 12, 1756286419878340 | 18

2004 | Ocrelizumab: A New Generation of anti-CD20 mAb for Treatment of Multiple Sclerosis. **2019**, 169-199 |

2003 | Evozierte Potenziale. **2019**, 50, 149-155 |

| 2002 | Prevalence of multiple sclerosis in Cuenca, Ecuador. **2019**, 5, 2055217319884952 | |
| 2001 | Diagnostic ability of multifocal electroretinogram in early multiple sclerosis using a new signal analysis method. **2019**, 14, e0224500 | 5 |
| 2000 | An asymptomatic new lesion on MRI is a relapse and should be treated accordingly - No. **2019**, 25, 1843-1845 | 2 |
| 1999 | An asymptomatic new lesion on MRI is a relapse and should be treated accordingly - Commentary. **2019**, 25, 1845-1847 | 2 |
| 1998 | Immunomodulatory receptors are differentially expressed in B and T cell subsets relevant to autoimmune disease. **2019**, 209, 108276 | 10 |
| 1997 | Spinal cord syndromes in patients with systemic lupus erythematosus: differentiating lupus myelitis, neuromyelitis optica, and multiple sclerosis. **2019**, 28, 1656-1662 | 7 |
| 1996 | The correlation between dyslipidemia and cognitive impairment in multiple sclerosis patients. **2019**, 36, 101415 | 14 |
| 1995 | Ocrelizumab for multiple sclerosis. **2019**, | 1 |
| 1994 | Patient education for fatigue in people with multiple sclerosis. **2019**, | 78 |
| 1993 | Transcranial direct current stimulation (tDCS) for improving fatigue, motor function, and pain in people with multiple sclerosis. **2019**, | 1 |
| 1992 | Brain lesion distribution criteria distinguish demyelinating diseases in China. **2019**, 6, 2048-2053 | 8 |
| 1991 | Progressive dopaminergic defect in a patient with primary progressive multiple sclerosis. **2019**, 36, 101385 | 2 |
| 1990 | Inter-leg Distance Measurement as a Tool for Accurate Step Counting in Patients with Multiple Sclerosis. **2019**, 2019, 6413-6417 | 2 |
| 1989 | Complete horizontal gaze palsy due to bilateral paramedian pontine reticular formation involvement as a presentation of multiple sclerosis: a case report. **2019**, 19, 254 | 1 |
| 1988 | Frontispiece: Recent Contributions to the Coordination Chemistry of Beryllium. **2019**, 25, | |
| 1987 | Modification of CSF findings in multiple sclerosis in the era of rapidly expanding treatment options. **2019**, 19, 277-283 | 0 |
| 1986 | Instead of tweaking the diagnostic criteria for MS in those with CIS, we should develop diagnostic criteria that distinguish MS from other conditions - Yes. **2019**, 25, 766-768 | 4 |
| 1985 | Framing multiple sclerosis under a polysomnographic perspective. **2020**, 43, | 6 |

1984    Effect of omega-3 fatty acids and fish oil supplementation on multiple sclerosis: a systematic review. **2021**, 24, 569-579    20

1983    Human immunodeficiency virus and multiple sclerosis: a review of the literature. **2019**, 1, 24    2

1982    Localised grey matter atrophy in multiple sclerosis is network-based: a´coordinate-based meta-analysis. **2019**, 74, 816.e19-816.e28    8

1981    GDF-15, a mitochondrial disease biomarker, is associated with the severity of multiple sclerosis. **2019**, 405, 116429    9

1980    Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination. **2019**, 7, 145    38

1979    The spectrum of immune-mediated and inflammatory lesions of the brainstem: Clues to diagnosis. **2019**, 93, 390-405    13

1978    The accuracy of flow cytometric cell-based assay to detect anti-myelin oligodendrocyte glycoprotein (MOG) antibodies determining the optimal method for positivity judgement. **2019**, 336, 577021    11

1977    Spinal cord lesions are frequently asymptomatic in relapsing-remitting multiple sclerosis: a retrospective MRI survey. **2019**, 266, 3031-3037    9

1976    Long-term use of interferon-⊡n multiple sclerosis increases V⊡V⊡V⊡ ⊡T cells that are associated with a better outcome. **2019**, 16, 179    3

1975    MRI features associated with high likelihood of conversion of radiologically isolated syndrome to multiple sclerosis. **2019**, 36, 101381    5

1974    Longitudinal analysis of white matter and cortical lesions in multiple sclerosis. **2019**, 23, 101938    8

1973    Validation of multiple sclerosis diagnoses in the Swedish National Patient Register. **2019**, 34, 1161-1169    11

1972    Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis. **2019**, 293, 424-433    18

1971    Evaluating the efficacy and safety of Zytux (Rituximab, AryoGen pharmed) in Iranian multiple sclerosis patients: An observational study. **2019**, 36, 101419    7

1970    The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis. **2019**, 8,    18

1969    The Role of Bioactive Lipids in Cancer, Inflammation and Related Diseases. **2019**,    3

1968    Newer Treatment Approaches in Pediatric-Onset Multiple Sclerosis. **2019**, 21, 50    11

1967    The natalizumab wearing-off effect: End of natalizumab cycle, recurrence of MS symptoms. **2019**, 93, e1579-e1586    8

| 1966 | Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer. **2019**, 266, 3163-3166 | | 1 |

| 1965 | Diagnostic Approach to Intrinsic Abnormality of Spinal Cord Signal Intensity. **2019**, 39, 1824-1839 | | 5 |

| 1964 | Diagnostic Delay of Multiple Sclerosis in a Portuguese Population. **2019**, 32, 289-294 | | 9 |

| 1963 | Homocysteine, vitamin B12, and folate levels in patients with multiple sclerosis in Chinese population: A case-control study and meta-analysis. **2019**, 36, 101395 | | 10 |

| 1962 | Uncovering convolutional neural network decisions for diagnosing multiple sclerosis on conventional MRI using layer-wise relevance propagation. **2019**, 24, 102003 | | 45 |

| 1961 | Jacqueline du Pr and her alternative diagnosis. **2019**, 133, 109401 | | |

| 1960 | Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurology, The*, **2019**, 18, 269-285 | 24.1 | 407 |

| 1959 | Sleep-related disorders and their relationship with MRI findings in multiple sclerosis. **2019**, 56, 90-97 | | 25 |

| 1958 | High performance of cerebrospinal fluid immunoglobulin G analysis for diagnosis of multiple sclerosis. **2019**, 266, 902-909 | | |

| 1957 | The Diversity of Encephalitogenic CD4+ T Cells in Multiple Sclerosis and Its Animal Models. **2019**, 8, | | 25 |

| 1956 | Optical coherence tomography for diagnosing optic neuritis: Are we there yet?. **2019**, 92, 253-254 | | 13 |

| 1955 | Optical coherence tomography is highly sensitive in detecting prior optic neuritis. **2019**, 92, e527-e535 | | 37 |

| 1954 | Predictors of Evolution Into Multiple Sclerosis After a First Acute Demyelinating Syndrome in Children and Adolescents. **2018**, 9, 1156 | | 8 |

| 1953 | Evidence for a white matter lesion size threshold to support the diagnosis of relapsing remitting multiple sclerosis. **2019**, 29, 124-129 | | 2 |

| 1952 | Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. *Lancet Neurology, The*, **2019**, 18, 185-197 | 24.1 | 74 |

| 1951 | 2017 McDonald criteria for multiple sclerosis: Earlier diagnosis with reduced specificity?. **2019**, 29, 23-25 | | 17 |

| 1950 | Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study. **2019**, 33, 131-138 | | 12 |

| 1949 | Caesarean section and infant formula feeding are associated with an earlier age of onset of multiple sclerosis. **2019**, 33, 75-77 | | 8 |

| 1930 | Clinical Cases in Neurology. **2019**, | |
|---|---|---|

| 1929 | Women who contributed to past research in multiple sclerosis. **2019**, 25, 1440-1443 | 0 |
|---|---|---|

| 1928 | Structural and functional MRI correlates of T2 hyperintensities of brain white matter in young neurologically asymptomatic adults. **2019**, 29, 7027-7036 | 5 |
|---|---|---|

| 1927 | MOG antibody-associated demyelinating disease mimicking typical multiple sclerosis: A case for expanding anti-MOG testing?. **2019**, 33, 67-69 | 10 |
|---|---|---|

| 1926 | Valuation de lِِtِ de la ponction lombaire dans le cadre du bilan tiologique des uvtes : propos de 197 patients. **2019**, 40, A49 | |
|---|---|---|

| 1925 | Improving Outcomes in Pediatric Multiple Sclerosis: Current and Emerging Treatments. **2019**, 21, 137-152 | 3 |
|---|---|---|

| 1924 | Visual but not verbal working memory interferes with balance in patients after optic neuritis suggestive of multiple sclerosis. **2019**, 707, 134288 | 1 |
|---|---|---|

| 1923 | Type 2 Inflammatory Responses in Autoimmune Demyelination of the Central Nervous System: Recent Advances. **2019**, 2019, 4204512 | 4 |
|---|---|---|

| 1922 | The potential of visual physiology: An instrument with a place in MS translation. **2019**, 4, 112-113 | 0 |
|---|---|---|

| 1921 | Multiple sclerosis and sarcoidosis: A case for coexistence. **2019**, 9, 218-227 | 5 |
|---|---|---|

| 1920 | Serum-based differentiation between multiple sclerosis and amyotrophic lateral sclerosis by Random Forest classification of FTIR spectra. **2019**, 144, 4647-4652 | 10 |
|---|---|---|

| 1919 | Clinical Features of Diffuse Leptomeningeal Glioneuronal Tumor with Rapid Blindness Misdiagnosed as NMOSD and Literature Review. **2019**, 1, 434-441 | 1 |
|---|---|---|

| 1918 | Adherence to Clinical Trial Supported Evaluation of Optic Neuritis. **2019**, 26, 321-328 | 2 |
|---|---|---|

| 1917 | Gut dysbiosis and lack of short chain fatty acids in a Chinese cohort of patients with multiple sclerosis. **2019**, 129, 104468 | 52 |
|---|---|---|

| 1916 | Distinct serum and cerebrospinal fluid cytokine and chemokine profiles in autoantibody-associated demyelinating diseases. **2019**, 5, 2055217319848463 | 5 |
|---|---|---|

| 1915 | The Argentinean multiple sclerosis registry (RelevarEM): Methodological aspects and directions. **2019**, 32, 133-137 | 16 |
|---|---|---|

| 1914 | Spatial Characterisation of Fibre Response Functions for Spherical Deconvolution in Multiple Sclerosis. **2019**, 265-279 | |
|---|---|---|

| 1913 | Three-dimensional MRI sequences in MS diagnosis and research. **2019**, 25, 1700-1709 | 3 |
|---|---|---|

1894 Epidemiology and treatment of multiple sclerosis in elderly populations. **2019**, 15, 329-342    99

1893 The Central Vein Sign in Radiologically Isolated Syndrome. **2019**, 40, 776-783    19

1892 A SCA7 premutation may be a novel Mendelian modifier of MS course: A case report. **2019**, 31, 148-150

1891 The relationship between cognitive function and body mass index in multiple sclerosis patients. **2019**, 32, 37-40    12

1890 Differential diagnosis of multiple sclerosis: The better explanations in clinical practice. **2019**, 92, 1037-1038    2

1889 "Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study. **2019**, 92, e2527-e2537    17

1888 Computational Diffusion MRI. **2019**,    1

1887 Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG. **2019**, 92, e2538-e2549    38

1886 Advances in spinal cord imaging in multiple sclerosis. **2019**, 12, 1756286419840593    38

1885 Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis. **2019**, 76, 841-849    28

1884 A cell type-specific transcriptomic approach to map B cell and monocyte type I interferon-linked pathogenic signatures in Multiple Sclerosis. **2019**, 101, 1-16    10

1883 The prevalence of multiple sclerosis continues to increase in Kuwait. **2019**, 32, 74-76    11

1882 Standardization of T1w/T2w Ratio Improves Detection of Tissue Damage in Multiple Sclerosis. **2019**, 10, 334    13

1881 Novel Multiple Sclerosis Drugs in the Pipeline. **2019**, 105, 1082-1090    1

1880 The clinical significance of single or double bands in cerebrospinal fluid isoelectric focusing. A retrospective study and systematic review. **2019**, 14, e0215410    12

1879 CSF Free Light Chains as a Marker of Intrathecal Immunoglobulin Synthesis in Multiple Sclerosis: A Blood-CSF Barrier Related Evaluation in a Large Cohort. **2019**, 10, 641    23

1878 The Cerebrospinal Fluid in Multiple Sclerosis. **2019**, 10, 726    45

1877 Case report of recalcitrant allergic contact eczema successfully treated with teriflunomide. **2019**, 32, e12947

1858 Time Is Brain and Spine-Reply. **2019**, 76, 623-624

1857 Cerebrospinal fluid biomarkers for predicting development of multiple sclerosis in acute optic neuritis: a population-based prospective cohort study. **2019**, 16, 59    17

1856 The role of vitamin D and P2X7R in multiple sclerosis. **2019**, 330, 159-169    4

1855 Magnetic resonance imaging diagnosis of demyelinating diseases: An update. **2019**, 10, 32-48    5

1854 Bowel symptoms predate the diagnosis among many patients with multiple sclerosis: A 14-year cohort study. **2019**, 31, e13592    6

1853 Cortical Lesions on 7-T MRI in Multiple Sclerosis: A Window into Pathogenetic Mechanisms?. **2019**, 291, 750-751    2

1852 Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?. **2019**, 10, 280    41

1851 Illuminating an Invisible Epidemic: A Systemic Review of the Clinical and Economic Benefits of Early Diagnosis and Treatment in Inflammatory Disease and Related Syndromes. **2019**, 8,    4

1850 Impact of the McDonald Criteria 2017 on Early Diagnosis of Relapsing-Remitting Multiple Sclerosis. **2019**, 10, 188    25

1849 Characterization of gray-matter multiple sclerosis lesions using double inversion recovery, diffusion, contrast-enhanced, and volumetric MRI. **2019**, 31, 74-81    3

1848 White matter lesion loads associated with dynamic functional connectivity within attention network in patients with relapsing-remitting multiple sclerosis. **2019**, 65, 59-65    13

1847 Myalgic encephalomyelitis and chronic fatigue syndrome case definitions: effects of requiring a substantial reduction in functioning. **2019**, 7, 59-68    1

1846 Paediatric multiple sclerosis: a new era in diagnosis and treatment. **2019**, 61, 1039-1049    8

1845 Prediction of conversion to multiple sclerosis using the 2017 McDonald and 2016 MAGNIMS criteria in patients with clinically isolated syndrome: a retrospective single-centre study. **2019**, 12, 1756286419835652    2

1844 Acute effects of aerobic intensities on the cytokine response in women with mild multiple sclerosis. **2019**, 31, 82-86    3

1843 Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. **2019**, 15, 287-300    79

1842 Are children with multiple sclerosis really "old" adults. **2019**, 25, 888-890

1841 A computer-aided diagnosis of multiple sclerosis based on mfVEP recordings. **2019**, 14, e0214662    4

| 1822 | Evaluating the relationship between psychometric intelligence and cognitive functions in paediatric multiple sclerosis. **2019**, 5, 2055217319894365 | 4 |

| 1821 | The Influence of Contrast-to-Noise Ratio on the Discrimination Between Cortical and Juxtacortical Lesions in Multiple Sclerosis. **2019**, 43, 958-962 | 2 |

| 1820 | Follow up of the Multiple Sclerosis Lesion's Evolution in Brain MRI by Automated Registration Approach. **2019**, | 1 |

| 1819 | Joven de 25 años con alteración de la marcha. **2019**, 12, 4649-4649.e8 | |

| 1818 | Multiple Sklerose 2019 – Update zu Diagnostik und Therapie. **2019**, 11, 149-154 | 1 |

| 1817 | Understanding Childhood Neuroimmune Diseases of the Central Nervous System. **2019**, 7, 511 | 15 |

| 1816 | Intrathecal B-cell accumulation and axonal damage distinguish MRI-based benign from aggressive onset in MS. **2019**, 6, | 9 |

| 1815 | German translation, cultural adaption and validation of the unidimensional self-efficacy scale for multiple sclerosis: a study protocol. **2019**, 9, e029565 | 1 |

| 1814 | Diagnostic value of alternative techniques to gadolinium-based contrast agents in MR neuroimaging-a comprehensive overview. **2019**, 10, 84 | 19 |

| 1813 | Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients. **2019**, 90, 1324-1330 | 44 |

| 1812 | Diagnosis of Multiple Sclerosis. **2019**, | |

| 1811 | Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in people with multiple sclerosis. **2019**, 5, CD009903 | 5 |

| 1810 | A Framework for Estimating the Burden of Chronic Diseases: Design and Application in the Context of Multiple Sclerosis. **2019**, 10, 953 | 8 |

| 1809 | Palliative care interventions for people with multiple sclerosis. **2019**, 10, CD012936 | 3 |

| 1808 | Visual Outcomes of Plasma Exchange Treatment of Steroid-Refractory Optic Neuritis: A Retrospective Monocentric Analysis. **2019**, 46, 417-422 | 4 |

| 1807 | Relevance of cerebrospinal fluid findings in patients with multiple sclerosis and seizures. **2019**, 406, 116482 | |

| 1806 | Reasons to switch: a noninterventional study evaluating immunotherapy switches in a large German multicentre cohort of patients with relapsing-remitting multiple sclerosis. **2019**, 12, 1756286419892077 | 6 |

| 1805 | Actualisation des aspects cliniques et des critères diagnostiques de la sclérose en plaques. **2019**, 10, 118-125 | |

1804 Multiple Sclerosis in the Emirati Population: Onset Disease Characterization by MR Imaging. **2019**, 2019, 7460213    1

1803 Free Light Chains as a Novel Diagnostic Biomarker of Immune System Abnormalities in Multiple Sclerosis and HIV Infection. **2019**, 2019, 8382132    3

1802 Biological characteristics of transcription factor RelB in different immune cell types: implications for the treatment of multiple sclerosis. **2019**, 12, 115    7

1801 Long segment 3D double inversion recovery (DIR) hypersignal on MRI in glaucomatous optic neuropathy. **2019**, 19, 258    1

1800 Myelin. **2019**,    1

1799 Cranial Nerve Enhancement in Multiple Sclerosis Is Associated With Younger Age at Onset and More Severe Disease. **2019**, 10, 1085    2

1798 Unilateral motor progression in MS: Association with a critical corticospinal tract lesion. **2019**, 93, e628-e634    10

1797 Atypical Pediatric Demyelinating Diseases of the Central Nervous System. **2019**, 19, 95    9

1796 [Multiple Sclerosis: Neurorehabilitation and Symptomatic Treatment]. **2019**, 58, 339-350    1

1795 Functional Magnetic Resonance Imaging Correlations Between Fatigue and Cognitive Performance in Patients With Relapsing Remitting Multiple Sclerosis. **2019**, 10, 754    3

1794 Multiple Sclerosis. **2019**, 1190, 217-247    10

1793 Visualization of Myelin for the Diagnosis and Treatment Monitoring of Multiple Sclerosis. **2019**, 1190, 249-256    1

1792 Automated Detection and Segmentation of Multiple Sclerosis Lesions Using Ultra-High-Field MP2RAGE. **2019**, 54, 356-364    24

1791 Real-World Effectiveness and Safety of Fingolimod in Patients With Relapsing Remitting Multiple Sclerosis: A Prospective Analysis in Buenos Aires, Argentina. **2019**, 42, 163-166    3

1790 Literature Commentary: Take Two!. **2019**, 39, 279-285

1789 Amide Proton Transfer Weighted Imaging Shows Differences in Multiple Sclerosis Lesions and White Matter Hyperintensities of Presumed Vascular Origin. **2019**, 10, 1307    7

1788 Encefalomielitis aguda diseminada. Leucoencefalitis aguda hemorrágica. Otras enfermedades desmielinizantes. **2019**, 12, 4606-4615    1

1787 The (Un)Resolved Case: Blurry vision, left foot drop and brain cysts. **2019**, 3, 2514183X1986609

| | | |
|---|---|---|
| 1786 | The history of neuromyelitis optica. Part 2: 'Spinal amaurosis', or how it all began. **2019**, 16, 280 | 12 |
| 1785 | Molecular biomarkers in multiple sclerosis. **2019**, 16, 272 | 75 |
| 1784 | Association of polymorphism and multiple sclerosis in Malaysia: a pilot study. **2019**, 10, 13 | 0 |
| 1783 | Zeitgem䈀 MS-Therapie. **2019**, 20, 20-28 | |
| 1782 | Multiple sclerosis. **2019**, 267-289 | 1 |
| 1781 | Clinical and radiologic approach to 'typical' versus antibody-related optic neuritis. **2019**, 30, 412-417 | 6 |
| 1780 | . **2019**, | |
| 1779 | The Effects of Concurrent Resistance and Aerobic Exercise Training on Functional Status in Patients with Multiple Sclerosis. **2019**, 18, 452-457 | 19 |
| 1778 | Retinal correlates of neurological disorders. **2019**, 10, 2040622319882205 | 22 |
| 1777 | Computer-Aided Diagnosis of Multiple Sclerosis Using a Support Vector Machine and Optical Coherence Tomography Features. **2019**, 19, | 15 |
| 1776 | Acceleration of Double Inversion Recovery Sequences in Multiple Sclerosis With Compressed Sensing. **2019**, 54, 319-324 | 23 |
| 1775 | Biopsychosocial model of resilience in young adults with multiple sclerosis (BPS-ARMS): an observational study protocol exploring psychological reactions early after diagnosis. **2019**, 9, e030469 | 6 |
| 1774 | Update on pediatric optic neuritis. **2019**, 30, 418-425 | 11 |
| 1773 | Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 - continuity and change. **2019**, 32, 327-337 | 17 |
| 1772 | Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in. **2019**, 8, 37 | 11 |
| 1771 | Autologous haematopoietic stem cell therapy for multiple sclerosis: a review for supportive care clinicians on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation. **2019**, 13, 394-401 | 5 |
| 1770 | Protocolo diagn䈀tico del paciente con sospecha de enfermedad desmielinizante. **2019**, 12, 4634-4638 | |
| 1769 | Entropy of human leukocyte antigen and killer-cell immunoglobulin-like receptor systems in immune-mediated disorders: A pilot study on multiple sclerosis. **2019**, 14, e0226615 | 4 |

| 1750 | Multiple sclerosis - the remarkable story of a baffling disease. **2019**, 30, 511-526 | | 4 |

| 1749 | Association between pathological and MRI findings in multiple sclerosis. *Lancet Neurology, The*, **2019**, 18, 198-210 | 24.1 | 86 |

| 1748 | Brain and cord imaging features in neuromyelitis optica spectrum disorders. **2019**, 85, 371-384 | | 42 |

| 1747 | Mills' syndrome revisited. **2019**, 266, 667-679 | | 8 |

| 1746 | Autonomic symptom burden can predict disease activity in early multiple sclerosis. **2019**, 28, 250-255 | | 14 |

| 1745 | Instead of tweaking the diagnostic criteria for MS in those with CIS, we should develop diagnostic criteria that distinguish MS from other conditions - No. **2019**, 25, 768-770 | | 2 |

| 1744 | Instead of tweaking the diagnostic criteria for MS in those with CIS, we should develop diagnostic criteria that distinguish MS from other conditions - Commentary. **2019**, 25, 770-771 | | 1 |

| 1743 | Prognostic value of serum neurofilaments in patients with clinically isolated syndromes. **2019**, 92, e733-e741 | | 30 |

| 1742 | Can We Design a Nogo Receptor-Dependent Cellular Therapy to Target MS?. **2018**, 8, | | 89 |

| 1741 | Clinical 7 T MRI: Are we there yet? A review about magnetic resonance imaging at ultra-high field. **2019**, 92, 20180492 | | 32 |

| 1740 | Coexistence of Multiple Sclerosis and Alzheimer's disease: A review. **2019**, 27, 232-238 | | 15 |

| 1739 | Clinical spectrum of inflammatory central nervous system demyelinating disorders associated with antibodies against myelin oligodendrocyte glycoprotein. **2019**, 130, 104319 | | 14 |

| 1738 | Diagnostic value of the 2017 McDonald criteria in patients with a first demyelinating event suggestive of relapsing-remitting multiple sclerosis. **2019**, 26, 540-545 | | 24 |

| 1737 | International consensus on quality standards for brain health-focused care in multiple sclerosis. **2019**, 25, 1809-1818 | | 31 |

| 1736 | Misdiagnosis of multiple sclerosis: Impact of the 2017 McDonald criteria on clinical practice. **2019**, 92, 26-33 | | 66 |

| 1735 | Misdiagnosis of multiple sclerosis: If you have a hammer, everything looks like a nail?. **2019**, 92, 15-16 | | 11 |

| 1734 | No evidence of disease activity status over 3 years in a real-world cohort of relapsing remitting MS patients in Germany. **2019**, 27, 133-138 | | 8 |

| 1733 | Validation of CSF free light chain in diagnosis and prognosis of multiple sclerosis and clinically isolated syndrome: prospective cohort study in Buenos Aires. **2019**, 266, 112-118 | | 10 |

1732  The contribution of the instrumented Timed-Up-and-Go test to detect falls and fear of falling in people with multiple sclerosis. **2019**, 27, 226-231 — 4

1731  Moyamoya masquerading as relapsing remitting multiple sclerosis. **2019**, 40, 635-637 — 1

1730  CNS phenotype in X linked Charcot- Marie-Tooth disease. **2019**, 90, 1068 — 3

1729  Multiple Sclerosis and Autoimmune Neurology of the Central Nervous System. **2019**, 103, 325-336 — 12

1728  Common Symptoms in the Neurology Clinic. **2019**, 377-472

1727  The prevalence and prognostic value of myelin oligodendrocyte glycoprotein antibody in adult optic neuritis. **2019**, 396, 225-231 — 24

1726  Optic nerve double inversion recovery hypersignal in patients with clinically isolated syndrome is associated with asymptomatic gadolinium-enhanced lesion. **2019**, 25, 1888-1895 — 6

1725  Clinical utility of a molecular signature in inflammatory demyelinating disease. **2019**, 6, e520 — 8

1724  Multiple Sclerosis. **2019**, 221-251 — 2

1723  Concurrence of juvenile idiopathic arthritis and primary demyelinating disease in a young child. **2019**, 27, 20-22 — 2

1722  Multiple sclerosis - a review. **2019**, 26, 27-40 — 422

1721  Automatic segmentation of the spinal cord and intramedullary multiple sclerosis lesions with convolutional neural networks. **2019**, 184, 901-915 — 77

1720  Decision-making on radiologically isolated syndrome among Argentinean neurologists: A survey based on clinical experience. **2019**, 27, 61-64 — 5

1719  Repeatability and reproducibility of FreeSurfer, FSL-SIENAX and SPM brain volumetric measurements and the effect of lesion filling in multiple sclerosis. **2019**, 29, 1355-1364 — 59

1718  Multiple sclerosis relapse: Qualitative findings from clinician and patient interviews. **2019**, 27, 139-146 — 9

1717  Restriction spectrum imaging of white matter and its relation to neurological disability in multiple sclerosis. **2019**, 25, 687-698 — 3

1716  New versus old: Implications of evolving diagnostic criteria for relapsing-remitting multiple sclerosis. **2019**, 25, 867-870 — 18

1715  Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study. **2020**, 267, 308-316 — 9

| 1714 | Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. **2020**, 26, 912-923 | 26 |

| 1713 | Pediatric onset multiple sclerosis. **2020**, 176, 30-36 | 6 |

| 1712 | How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis. **2020**, 26, 489-500 | 11 |

| 1711 | Dissociable cognitive patterns related to depression and anxiety in multiple sclerosis. **2020**, 26, 1247-1255 | 17 |

| 1710 | Brain and spinal MRI features distinguishing MS from different AQP4 antibody serostatus NMOSD at disease onset in a cohort of Latin American patients. **2020**, 26, 945-954 | 8 |

| 1709 | Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. **2020**, 267, 3489-3498 | 39 |

| 1708 | Does Resetting the Immune System Fix Multiple Sclerosis?. **2020**, 47, 1-10 | 4 |

| 1707 | The "central vein sign" in patients with diagnostic "red flags" for multiple sclerosis: A prospective multicenter 3T study. **2020**, 26, 421-432 | 21 |

| 1706 | Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience. **2020**, 26, 1519-1531 | 19 |

| 1705 | CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease. **2020**, 68, 321-330 | 17 |

| 1704 | Monitoring diffuse injury during disease progression in experimental autoimmune encephalomyelitis with on resonance variable delay multiple pulse (onVDMP) CEST MRI. **2020**, 204, 116245 | 5 |

| 1703 | Cortical quantitative MRI parameters are related to the cognitive status in patients with relapsing-remitting multiple sclerosis. **2020**, 30, 1045-1053 | 5 |

| 1702 | Differential diagnosis of multiple sclerosis and other inflammatory CNS diseases. **2020**, 37, 101452 | 21 |

| 1701 | The multiple sclerosis gut microbiota: A systematic review. **2020**, 37, 101427 | 50 |

| 1700 | Radiologically isolated syndrome with oligoclonal bands in CSF (RIS + OCB) can be classified as high MS risk group. **2020**, 26, 869-870 | 4 |

| 1699 | Infratentorial and spinal cord lesions: Cumulative predictors of long-term disability?. **2020**, 26, 1381-1391 | 9 |

| 1698 | Internationale Brain Health Initiative und Multiple Sklerose. **2020**, 3, 107-115 | 2 |

| 1697 | Improved performance of the 2017 McDonald criteria for diagnosis of multiple sclerosis in children in a real-life cohort. **2020**, 26, 1372-1380 | 16 |

1678    Role of and genes polymorphisms in multiple sclerosis. **2020**, 130, 407-412    12

1677    Clinical, imaging and follow-up study of optic neuritis associated with myelin oligodendrocyte glycoprotein antibody: a multicentre study of 62 adult patients. **2020**, 27, 384-391    14

1676    Evoked potentials can predict future disability in people with clinically isolated syndrome. **2020**, 27, 437-444    7

1675    3D PSIR MRI at 3 Tesla improves detection of spinal cord lesions in multiple sclerosis. **2020**, 267, 406-414    9

1674    Acute effects of whole-body vibration training on neuromuscular performance and mobility in hypoxia and normoxia in persons with multiple sclerosis: A crossover study. **2020**, 37, 101454    1

1673    Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines. **2020**, 37, 101459    25

1672    Empirical Mode Decomposition-Based Filter Applied to Multifocal Electroretinograms in Multiple Sclerosis Diagnosis. **2019**, 20,    3

1671    Pediatric multiple sclerosis: from clinical basis to imaging spectrum and differential diagnosis. **2020**, 50, 776-792    11

1670    Do patients with multiple sclerosis benefit from semi-immersive virtual reality? A randomized clinical trial on cognitive and motor outcomes. **2020**, 1-7    11

1669    Diagnosis and management of central nervous system Sjğren's syndrome. **2020**, 189-209

1668    Microglial NLRP3 inflammasome activation in multiple sclerosis. **2020**, 119, 247-308    21

1667    "No evidence of disease activity": Is it an aspirational therapeutic goal in multiple sclerosis?. **2020**, 40, 101935    8

1666    Deciphering anti-MOG IgG antibodies: Clinical and radiological spectrum, and comparison of antibody detection assays. **2020**, 410, 116673    9

1665    Can semantic fluency be used as an alternative or additional measure in the abbreviated Minimal Assessment of Cognitive Function in Multiple Sclerosis (aMACFIMS)?. **2020**, 410, 116640    6

1664    The differential expression of natural killer cells in NMOSD and MS. **2020**, 71, 9-14    6

1663    The impact of modifiable risk factors on lesion burden in patients with early multiple sclerosis. **2019**, 39, 101886    2

1662    No evidence of disease activity status in patients treated with early vs. delayed subcutaneous interferon 티a. **2019**, 39, 101891    1

1661    To treat or not to treat: Sequential individualized treatment evaluation in relapsing multiple sclerosis. **2019**, 39, 101908    8

| | | |
|---|---|---|
| 1642 | Special Issue CCA for the proceedings of the 2nd symposium of the Society of CSF analysis and Clinical Neurochemistry. **2020**, 502, 199-200 | |
| 1641 | Kappa free light chains index in the differential diagnosis of Multiple Sclerosis from Neuromyelitis optica spectrum disorders and other immune-mediated central nervous system disorders. **2020**, 339, 577122 | 11 |
| 1640 | The efficacy of interferon-beta therapy in multiple sclerosis patients: investigation of the RORA gene as a predictive biomarker. **2020**, 20, 271-276 | 3 |
| 1639 | Klotho and vitamin D in multiple sclerosis: an Italian study. **2020**, 16, 842-847 | 6 |
| 1638 | Dalfampridine to Improve Balance in Multiple Sclerosis: Substudy from a Randomized Placebo-Controlled Trial. **2020**, 17, 704-709 | 3 |
| 1637 | The accuracy of standard multiple sclerosis MRI brain sequences for the diagnosis of optic neuropathy. **2020**, 38, 101521 | 3 |
| 1636 | Trigeminal neuralgia associated with multiple sclerosis: A multimodal assessment of brainstem plaques and response to Gamma Knife radiosurgery. **2020**, 26, 1877-1888 | 5 |
| 1635 | The impact of diagnostic criteria and treatments on the 20-year costs for treating relapsing-remitting multiple sclerosis. **2020**, 38, 101514 | 6 |
| 1634 | Consensus recommendations on the management of multiple sclerosis patients in Argentina. **2020**, 409, 116609 | 4 |
| 1633 | Social phobia in immune-mediated inflammatory diseases. **2020**, 128, 109890 | 3 |
| 1632 | Limited One-time Sampling Irregularity Map (LOTS-IM) for Automatic Unsupervised Assessment of White Matter Hyperintensities and Multiple Sclerosis Lesions in Structural Brain Magnetic Resonance Images. **2020**, 79, 101685 | 5 |
| 1631 | Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses. **2019**, 9, | 6 |
| 1630 | Automated volumetric assessment with artificial neural networks might enable a more accurate assessment of disease burden in patients with multiple sclerosis. **2020**, 30, 2356-2364 | 6 |
| 1629 | Selective Cerebellar Atrophy Associates with Depression and Fatigue in the Early Phases of Relapse-Onset Multiple Sclerosis. **2020**, 19, 192-200 | 9 |
| 1628 | Nursing interventions in autologous stem cell transplantation for autoimmune diseases. **2020**, 76, 3473-3482 | |
| 1627 | Single-Arm, Non-randomized, Time Series, Single-Subject Study of Fecal Microbiota Transplantation in Multiple Sclerosis. **2020**, 11, 978 | 15 |
| 1626 | Social norms in patients with relapsing-remitting multiple sclerosis: Impairment of the moral/conventional distinction?. **2020**, 15, 630-640 | |
| 1625 | The impairment of the functional system and fatigue at the onset of the disease predict reaching disability milestones in relapsing-remitting multiple sclerosis differently in female and male patients. **2021**, 121, 1699-1706 | 1 |

| | | |
|---|---|---|
| 1624 | Multiple sclerosis in a young woman with sickle cell disease. **2020**, 45, 102427 | 0 |
| 1623 | Differential diagnosis in acute inflammatory myelitis. **2020**, 46, 102481 | 1 |
| 1622 | Multiple sclerosis and COVID-19: How many are at risk?. **2021**, 28, 3369-3374 | 18 |
| 1621 | Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi. **2020**, 15, e0239453 | 3 |
| 1620 | Research on Cognition Disorders. **2020**, | |
| 1619 | Revisiting the Pathoetiology of Multiple Sclerosis: Has the Tail Been Wagging the Mouse?. **2020**, 11, 572186 | 12 |
| 1618 | Pregnancy exposure to disease-modifying drugs in multiple sclerosis: a prospective study. **2020**, 154, 214-217 | 2 |
| 1617 | Frequency and etiology of acute transverse myelitis in Southern Finland. **2020**, 46, 102562 | 1 |
| 1616 | The Administrative Prevalence of Multiple Sclerosis in Greece on the Basis of a Nationwide Prescription Database. **2020**, 11, 1012 | 3 |
| 1615 | Interval Timing in Pediatric Multiple Sclerosis: Impaired in the Subsecond Range but Unimpaired in the One-Second Range. **2020**, 11, 575780 | 0 |
| 1614 | Paediatric onset of multiple sclerosis: Analysis of chemokine and cytokine levels in the context of the early clinical course. **2020**, 46, 102467 | 1 |
| 1613 | Diverse Applications of Artificial Intelligence in Neuroradiology. **2020**, 30, 505-516 | 4 |
| 1612 | Association of multiple sclerosis with vitiligo: a systematic review and meta-analysis. **2020**, 10, 17792 | 0 |
| 1611 | HLA-DR15 Molecules Jointly Shape an Autoreactive T Cell Repertoire in Multiple Sclerosis. **2020**, 183, 1264-1281.e20 | 43 |
| 1610 | Smell as a clinical-marker for functional limitations in multiple sclerosis: A pilot study. **2020**, 46, 102508 | 2 |
| 1609 | Selective modulation of trans-endothelial migration of lymphocyte subsets in multiple sclerosis patients under fingolimod treatment. **2020**, 349, 577392 | 3 |
| 1608 | MS Spasticity: Take Control (STC) for ambulatory adults: protocol for a randomized controlled trial. **2020**, 20, 368 | 1 |
| 1607 | The weak association between neurofilament levels at multiple sclerosis onset and cognitive performance after 9 years. **2020**, 46, 102534 | 5 |

1606    Demographic and clinical characterization of multiple sclerosis in Mexico: The REMEMBer study. **2020**, 46, 102575    0

1605    Blunted neural and psychological stress processing predicts future grey matter atrophy in multiple sclerosis. **2020**, 13, 100244    5

1604    Sensitive Detection of Infratentorial and Upper Cervical Cord Lesions in Multiple Sclerosis with Combined 3D FLAIR and T2-Weighted (FLAIR3) Imaging. **2020**, 41, 2062-2067    1

1603    Accelerating Brain 3D T1-Weighted Turbo Field Echo MRI Using Compressed Sensing-Sensitivity Encoding (CS-SENSE). **2020**, 131, 109255    4

1602    Expression of Akt1 and p-Akt1 in peripheral T cell subsets of multiple sclerosis patients. **2021**, 121, 1777-1782    0

1601    Corneal epithelial dendritic cells in patients with multiple sclerosis: An in vivo confocal microscopy study. **2020**, 81, 139-143    4

1600    Prevalence of comorbidities in Multiple Sclerosis and impact on physical disability according to disease phenotypes. **2020**, 46, 102565    1

1599    Early changes in IL-21, IL-22, CCL2, and CCL4 serum cytokines after outpatient autologous transplantation for multiple sclerosis: A proof of concept study. **2020**, 34, e14114    6

1598    Ratgeber Multiple Sklerose. **2020**,

1597    Multiple sclerosis lesion activity segmentation with attention-guided two-path CNNs. **2020**, 84, 101772    12

1596    Could the performance of oral glucose tolerance test contribute to the brain health-focused care in multiple sclerosis?. **2020**, 46, 102536    0

1595    Association of Pregnancy With the Onset of Clinically Isolated Syndrome. **2020**, 77, 1496-1503    11

1594    New concepts about the role of magnetic resonance imaging in the diagnosis and follow-up of multiple sclerosis. **2020**, 62, 349-359

1593    Multiple sclerosis attack case presenting with pseudo-vestibular neuritis. **2020**, 1-5    1

1592    Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis. **2020**, 143, 3318-3330    30

1591    Urologic, neurologic, and general practice implications of the Time to be Ready to Void Test. **2021**, 64, 101372    1

1590    White Matter Lesions in Adults - a Differential Diagnostic Approach. **2020**, 192, 1154-1173    2

1589    Population-Based Incidence of Optic Neuritis in the Era of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies. **2020**, 220, 110-114    13

1588   Ultra-high field 7 T imaging in multiple sclerosis. **2020**, 33, 422-429    5

1587   Avanços no tratamento da esclerose múltipla através do anticorpo monoclonal Ocrelizumabe. **2020**, 53, 35-41

1586   Short-term outcomes of pediatric multiple sclerosis patients treated with alemtuzumab at a Canadian University multiple sclerosis clinic. **2020**, 6, 2055217320926613    2

1585   Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica. **2020**, 45, 102399    15

1584   Multiple sclerosis cortical and WM lesion segmentation at 3T MRI: a deep learning method based on FLAIR and MP2RAGE. **2020**, 27, 102335    31

1583   A Score Based on NfL and Glial Markers May Differentiate Between Relapsing-Remitting and Progressive MS Course. **2020**, 11, 608    11

1582   Co-incident primary progressive multiple sclerosis and hereditary spastic paraplegia (SPG4) - a case report. **2020**, 44, 102375    1

1581   Measurements of the corpus callosum index and fractional anisotropy of the corpus callosum and their cutoff values are useful to assess global brain volume loss in multiple sclerosis. **2020**, 45, 102388    6

1580   Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis. **2020**, 45, 102391    5

1579   Coexistence of emotional reactions and atrophic brain changes in patients with clinically isolated syndrome of multiple sclerosis. **2020**, 29, 3-10

1578   CSF oligoclonal band frequency in a Cuban cohort of patients with multiple sclerosis. comparison with Latin American countries and association with latitude. **2020**, 45, 102412    1

1577   Impact of intrathecal IgG synthesis on neurological disability in patients with multiple sclerosis. **2020**, 45, 102382    4

1576   State of the Art and Future Challenges in Multiple Sclerosis Research and Medical Management: An Insight into the 5th International Porto Congress of Multiple Sclerosis. **2020**, 9, 281-300    2

1575   Treatment of Multiple Sclerosis: A Review. **2020**, 133, 1380-1390.e2    99

1574   AI in Radiology: Where are we today in Multiple Sclerosis Imaging?. **2020**, 192, 847-853    3

1573   Structural correlates of atypical visual and motor cortical oscillations in pediatric-onset multiple sclerosis. **2020**, 41, 4299-4313    4

1572   Importance of Not MSing Cerebral White Matter Disease in Patients with Inflammatory Bowel Disease. **2020**, 65, 2527-2532

1571   A Pilot Study to Explore Patient Satisfaction With a Virtual Rehabilitation Program in Multiple Sclerosis: The RehabVR Study Protocol. **2020**, 11, 900    3

| | | |
|---|---|---|
| 1570 | Cerebrospinal Fluid IgM Levels in Association With Inflammatory Pathways in Multiple Sclerosis Patients. **2020**, 14, 569827 | 2 |
| 1569 | Imaging of the Spinal Cord in Multiple Sclerosis: Past, Present, Future. **2020**, 10, | 4 |
| 1568 | Gut microbiota-specific IgA B cells traffic to the CNS in active multiple sclerosis. **2020**, 5, | 48 |
| 1567 | Multiple Sclerosis: Shall We Target CD33?. **2020**, 11, | 6 |
| 1566 | Intrathecal kappa free light chains as markers for multiple sclerosis. **2020**, 10, 20329 | 11 |
| 1565 | Assessment of mental health, knowledge, and attitude of patients with multiple sclerosis and neuromyelitis optica spectrum disorder in response to 2019 novel coronavirus. **2021**, 42, 2891-2901 | 6 |
| 1564 | An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis. **2021**, 27, 1432-1441 | 3 |
| 1563 | Magnetic resonance imaging at baseline and follow-up to differentiate between pediatric monophasic acquired CNS demyelination and MS. **2020**, 46, 102590 | 2 |
| 1562 | Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS. **2020**, 13, 1756286420970754 | 2 |
| 1561 | Vestibular rehabilitation in multiple sclerosis: study protocol for a randomised controlled trial and cost-effectiveness analysis comparing customised with booklet based vestibular rehabilitation for vestibulopathy and a 12 month observational cohort study of the symptom reduction and recurrence rate following treatment for benign paroxysmal positional vertigo. **2020**, 20, 430 | 1 |
| 1560 | Adding brain volume measures into response criteria in multiple sclerosis: the Rio-4 score. **2021**, 63, 1031-1041 | 0 |
| 1559 | Lipid profile: causal relationship on cognitive performance in multiple sclerosis?. **2020**, 47, 9667-9676 | 4 |
| 1558 | The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review. **2020**, 80, 1901-1928 | 17 |
| 1557 | Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis. **2020**, 9, | 3 |
| 1556 | Pain Characteristics and Associations with Quality of Life in Patients with Multiple Sclerosis in Lithuania. **2020**, 56, | 0 |
| 1555 | A cross-sectional comparison of performance, neurophysiological and MRI outcomes of responders and non-responders to fampridine treatment in multiple sclerosis - An explorative study. **2020**, 82, 179-185 | 3 |
| 1554 | Utility of shape evolution and displacement in the classification of chronic multiple sclerosis lesions. **2020**, 10, 19560 | 2 |
| 1553 | The effect of tonsillectomy on John Cunningham virus serological status in multiple sclerosis patients: A retrospective case-control study. **2021**, 27, 1297-1300 | |

1552 The Use of the Central Vein Sign in the Diagnosis of Multiple Sclerosis: A Systematic Review and Meta-analysis. **2020**, 10, — 8

1551 Orexin and Psychoneurobiology: A Hidden Treasure. **2020**,

1550 Evolving relationship between respiratory functions & impairment in sleep and cognition in patients with multiple sclerosis. **2020**, 46, 102514 — 2

1549 Síndrome de Sjögren neuropsiquiátrico. **2020**, 27, 125-139

1548 Progress in the Management of Paediatric-Onset Multiple Sclerosis. **2020**, 7, — 0

1547 Synthetic MRI: Technologies and Applications in Neuroradiology. **2020**, — 9

1546 Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab. **2020**, 10,

1545 Comment je fais une IRM pour le suivi des patients avec une sclérose en plaques?. **2020**, 3, 384-388

1544 ASPIRE trial: study protocol for a double-blind randomised controlled trial of aspirin for overheating during exercise in multiple sclerosis. **2020**, 10, e039691

1543 A preliminary study of the concentration of metallic elements in the blood of patients with multiple sclerosis as measured by ICP-MS. **2020**, 10, 13112 — 6

1542 Retinal and brain damage during multiple sclerosis course: inflammatory activity is a key factor in the first 5 years. **2020**, 10, 13333 — 3

1541 Is there a correlation between dyslipidemia and cognitive impairment in patients with multiple sclerosis?. **2020**, 1-6 — 3

1540 The role of contrast-enhanced and non-contrast-enhanced MRI in the follow-up of multiple sclerosis. **2021**, 62, 916-921 — 2

1539 Autoimmune and demyelinating optic neuritis. **2020**, 95, 386-395

1538 Seasonal variation in relapse of neuromyelitis optica spectrum disorders: A retrospective study in China. **2020**, 347, 577351 — 3

1537 Reactive increase of cerebrospinal fluid white blood cell count after lumbar puncture: Fact or fiction?. **2020**, 414, 116876 — 0

1536 Combined exercise training improves cognitive functions in multiple sclerosis patients with cognitive impairment: A single-blinded randomized controlled trial. **2020**, 45, 102419 — 14

1535 12 Diffuse White Matter Hyperintensities. **2020**,

| 1534 | Pediatric Multiple Sclerosis Severity Score in a large US cohort. **2020**, 95, e1844-e1853 | 3 |

| 1533 | Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial. **2020**, 95, e745-e754 | 17 |

| 1532 | Contralateral Strength Training as Preparation for Direct Strength Training in a Patient With Unilateral Foot-Drop Because of Multiple Sclerosis: A Case Report. **2020**, 100, 1816-1824 | 1 |

| 1531 | Validation of Quantitative Scores Derived From Motor Evoked Potentials in the Assessment of Primary Progressive Multiple Sclerosis: A Longitudinal Study. **2020**, 11, 735 | 4 |

| 1530 | A Multiple -Glucosylated Peptide Epitope Efficiently Detecting Antibodies in Multiple Sclerosis. **2020**, 10, | 0 |

| 1529 | Lower extremity muscle strength across the adult lifespan in multiple sclerosis: Implications for walking and stair climbing capacity. **2020**, 139, 111025 | 4 |

| 1528 | Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-□glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab. **2020**, 15, e0235449 | 8 |

| 1527 | Incidence and prevalence of multiple sclerosis in Hungary based on record linkage of nationwide multiple healthcare administrative data. **2020**, 15, e0236432 | 3 |

| 1526 | Effect of remote ischaemic preconditioning on walking in people with multiple sclerosis: double-blind randomised controlled trial. **2020**, 2, e000022 | 5 |

| 1525 | Mitochondrial Oxidative Damage Underlies Regulatory T Cell Defects in Autoimmunity. **2020**, 32, 591-604.e7 | 28 |

| 1524 | Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice. **2020**, 45, 102428 | 20 |

| 1523 | Understanding Pediatric Neuroimmune Disorder Conflicts: A Neuroradiologic Approach in the Molecular Era. **2020**, 40, 1395-1411 | 2 |

| 1522 | The Effect of Coffee and Caffeine Consumption on Patients with Multiple Sclerosis-Related Fatigue. **2020**, 12, | 3 |

| 1521 | Validation of inter-eye difference thresholds in optical coherence tomography for identification of optic neuritis in multiple sclerosis. **2020**, 45, 102403 | 12 |

| 1520 | Optical coherence tomography for detection of asymptomatic optic nerve lesions in clinically isolated syndrome. **2020**, 95, e733-e744 | 8 |

| 1519 | Optical coherence tomography: A useful tool for identifying subclinical optic neuropathy in diagnosing multiple sclerosis. **2020**, 95, 239-240 | 4 |

| 1518 | Is Fertility Affected in Women of Childbearing Age with Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder?. **2020**, 70, 1829-1835 | 2 |

| 1517 | Paroxysmal dysarthria-ataxia syndrome: Literature review on MRI findings and report of a peculiar case with clinically isolated syndrome coexisting with anti-N-methyl-d-aspartate receptor antibodies. **2020**, 347, 577327 | 0 |

| | | |
|---|---|---|
| 1516 | Large check size pattern reversal visual evoked potentials - Full and sectorial field stimulation in multiple sclerosis and controls. **2020**, 75, 181-187 | |
| 1515 | Valid or not: A critique of Graver and Green. **2020**, 1-4 | 4 |
| 1514 | Understanding the application of diagnostic criteria for multiple sclerosis helps prevent misdiagnosis. **2020**, 192, E894 | 0 |
| 1513 | Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study. **2020**, 11, 756 | 4 |
| 1512 | Changes in Amino Acid and Acylcarnitine Plasma Profiles for Distinguishing Patients with Multiple Sclerosis from Healthy Controls. **2020**, 2020, 9010937 | 1 |
| 1511 | Regional differences in the association of cytomegalovirus seropositivity and multiple sclerosis: A systematic review and meta-analysis. **2020**, 45, 102393 | 3 |
| 1510 | A blood-based metabolomics test to distinguish relapsing-remitting and secondary progressive multiple sclerosis: addressing practical considerations for clinical application. **2020**, 10, 12381 | 3 |
| 1509 | The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. **2020**, 143, 2637-2652 | 22 |
| 1508 | Pregnancy exposure to disease-modifying drugs in multiple sclerosis: a prospective study. **2020**, 154, 214-217 | 1 |
| 1507 | Multiple sclerosis. **2020**, 48, 588-594 | 1 |
| 1506 | Investigation of the "central vein sign" in infratentorial multiple sclerosis lesions. **2020**, 45, 102409 | 3 |
| 1505 | The effect of a telerehabilitation virtual reality intervention on functional upper limb activities in people with multiple sclerosis: a study protocol for the TEAMS pilot randomized controlled trial. **2020**, 21, 713 | 2 |
| 1504 | Prognostic value of kappa free light chains determination in first-ever multiple sclerosis relapse. **2020**, 347, 577355 | 5 |
| 1503 | Serum neurofilament-light concentration and real-world outcome in MS. **2020**, 417, 117079 | 5 |
| 1502 | Fatigue in multiple sclerosis patients with different clinical phenotypes: a clinical and magnetic resonance imaging study. **2020**, 27, 2549-2560 | 5 |
| 1501 | On the STAIR-Way to Imaging Myelin with Clinical MRI. **2020**, 297, 405-406 | 1 |
| 1500 | Radiologically Isolated Syndrome: A Review for Neuroradiologists. **2020**, 41, 1542-1549 | 9 |
| 1499 | Movement Velocity as A Measure of Exercise Intensity in Persons with Multiple Sclerosis: A Validity Study. **2020**, 9, | 0 |

| 1498 | Paramagnetic Rim Lesions are Specific to Multiple Sclerosis: An International Multicenter 3T MRI Study. **2020**, 88, 1034-1042 | 28 |

| 1497 | Serum level of IL-1⬛n patients with inflammatory demyelinating disease: Marked upregulation in the early acute phase of MOG antibody associated disease (MOGAD). **2020**, 348, 577361 | 5 |

| 1496 | Advanced MRI features in relapsing multiple sclerosis patients with and without CSF oligoclonal IgG bands. **2020**, 10, 13703 | 2 |

| 1495 | Blood platelet RNA enables the detection of multiple sclerosis. **2020**, 6, 2055217320946784 | 3 |

| 1494 | Pediatric Demyelinating Disease: Emerging Patterns from Multiple Sclerosis to Anti-Myelin Oligodendrocyte Glycoprotein-Associated Encephalomyelitis. **2020**, 10, 139-151 | 2 |

| 1493 | New concepts about the role of magnetic resonance imaging in the diagnosis and follow-up of multiple sclerosis. **2020**, 62, 349-359 | 0 |

| 1492 | Kappa Index Versus CSF Oligoclonal Bands in Predicting Multiple Sclerosis and Infectious/Inflammatory CNS Disorders. **2020**, 10, | 10 |

| 1491 | Dietary supplementation with L-carnosine improves patient-reported outcomes, autonomic nervous system performance, and brain metabolism in 3 adult patients with multiple sclerosis. **2020**, 84, 63-69 | 2 |

| 1490 | Acceptability and outcomes of an individualized exergaming telePT program for veterans with multiple sclerosis: a pilot study. **2020**, 10, 18 | 5 |

| 1489 | CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment. **2020**, 41, 1023-1037 | 15 |

| 1488 | Cerebrospinal fluid lipidomic biomarker signatures of demyelination for multiple sclerosis and Guillain-Barr️syndrome. **2020**, 10, 18380 | 5 |

| 1487 | Local functional connectivity of patients with acute and remitting multiple sclerosis: A Kendall's coefficient of concordance- and coherence-regional homogeneity study. **2020**, 99, e22860 | 4 |

| 1486 | A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. **2020**, 6, 2055217320964505 | 6 |

| 1485 | Gadolinium-Enhanced 3D T1-Weighted Black-Blood MR Imaging for the Detection of Acute Optic Neuritis. **2020**, 41, 2333-2338 | 2 |

| 1484 | Concentrations of plasma-borne extracellular particles differ between multiple sclerosis disease courses and compared to healthy controls. **2020**, 45, 102446 | 6 |

| 1483 | Structured Reporting in Multiple Sclerosis Reduces Interpretation Time. **2021**, 28, 1733-1738 | 1 |

| 1482 | African Americans experience disproportionate neurodegenerative changes in the medulla and upper cervical spinal cord in early multiple sclerosis. **2020**, 45, 102429 | 5 |

| 1481 | Multiple sclerosis and nutrition: back to the future?. **2020**, 13, 1756286420936165 | 1 |

| 1480 | Serum levels of cell adhesion molecules in patients with neuromyelitis optica spectrum disorder. **2020**, 7, 1854-1861 | 1 |

| 1479 | Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients. **2020**, 17, 261 | 32 |

| 1478 | Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients. **2020**, 17, 262 | 18 |

| 1477 | Histopathology-validated recommendations for cortical lesion imaging in multiple sclerosis. **2020**, 143, 2988-2997 | 7 |

| 1476 | IgG Index Revisited: Diagnostic Utility and Prognostic Value in Multiple Sclerosis. **2020**, 11, 1799 | 5 |

| 1475 | The Agony of Choice? Preserved Affective Decision Making in Early Multiple Sclerosis. **2020**, 11, 914 | 1 |

| 1474 | Genomic, proteomic, and systems biology approaches in biomarker discovery for multiple sclerosis. **2020**, 358, 104219 | 8 |

| 1473 | The current status and challenges in multiple sclerosis management in the Philippines. **2020**, 46, 102510 | 8 |

| 1472 | 7 T imaging reveals a gradient in spinal cord lesion distribution in multiple sclerosis. **2020**, 143, 2973-2987 | 10 |

| 1471 | Free light chains kappa can differentiate between myelitis and noninflammatory myelopathy. **2020**, 7, | 6 |

| 1470 | Cortical Thinning and Ventricle Enlargement in Neuromyelitis Optica Spectrum Disorders. **2020**, 11, 872 | 2 |

| 1469 | Clinical and demographic characteristics of primary progressive multiple sclerosis in Argentina: Argentinean registry cohort study (RelevarEM). **2020**, 41, 3329-3335 | 3 |

| 1468 | A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis. **2020**, 117, 22932-22943 | 43 |

| 1467 | Probable Autoimmune Depression in a Patient With Multiple Sclerosis and Antineuronal Antibodies. **2020**, 11, 745 | 1 |

| 1466 | Akute partielle Okulomotoriusparese. **2020**, 1 | |

| 1465 | Creatine and multiple sclerosis. **2020**, 1-8 | 3 |

| 1464 | Prevalence of multiple sclerosis in rural and urban districts in Telemark county, Norway. **2020**, 45, 102352 | 5 |

| 1463 | Multiple Sclerosis as a Syndrome-Implications for Future Management. **2020**, 11, 784 | 1 |

| 1462 | Safety and Tolerability of Plasma Exchange and Immunoadsorption in Neuroinflammatory Diseases. **2020**, 9, | 4 |

| 1461 | Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders. **2020**, 10, 13890 | 20 |

| 1460 | Improved relapse recovery in paediatric compared to adult multiple sclerosis. **2020**, 143, 2733-2741 | 20 |

| 1459 | Biologic Therapy in Refractory Non-Multiple Sclerosis Optic Neuritis Isolated or Associated to Immune-Mediated Inflammatory Diseases. A Multicenter Study. **2020**, 9, | 2 |

| 1458 | [Headache in multiple sclerosis]. **2020**, 91, 926-935 | 1 |

| 1457 | Immune signatures of prodromal multiple sclerosis in monozygotic twins. **2020**, 117, 21546-21556 | 12 |

| 1456 | Different Effects of Transcranial Direct Current Stimulation on Leg Muscle Glucose Uptake Asymmetry in Two Women with Multiple Sclerosis. **2020**, 10, | 4 |

| 1455 | Objective evaluation of Nintendo Wii Fit Plus balance program training on postural stability in Multiple Sclerosis patients: a pilot study. **2020**, 43, 199-205 | 2 |

| 1454 | Alterations of the gut ecological and functional microenvironment in different stages of multiple sclerosis. **2020**, 117, 22402-22412 | 49 |

| 1453 | Extensive Healthy Donor Age/Gender Adjustments and Propensity Score Matching Reveal Physiology of Multiple Sclerosis Through Immunophenotyping. **2020**, 11, 565957 | 1 |

| 1452 | The Relationship of the Mechanisms of the Pathogenesis of Multiple Sclerosis and the Expression of Endogenous Retroviruses. **2020**, 9, | 4 |

| 1451 | Cerebrospinal fluid inflammatory biomarkers predicting interferon-beta response in MS patients. **2020**, 13, 1756286420970833 | 3 |

| 1450 | Rehabilitation Before and After Autologous Haematopoietic Stem Cell Transplantation (AHSCT) for Patients With Multiple Sclerosis (MS): Consensus Guidelines and Recommendations for Best Clinical Practice on Behalf of the Autoimmune Diseases Working Party, Nurses Group, and Patient Advocacy Committee of the European Society for Blood and Marrow Transplantation (EBMT). **2020**, 11, 556141 | 3 |

| 1449 | Low Contrast Visual Acuity Might Help to Detect Previous Optic Neuritis. **2020**, 11, 602193 | 4 |

| 1448 | Investigation of Deep-Learning-Driven Identification of Multiple Sclerosis Patients Based on Susceptibility-Weighted Images Using Relevance Analysis. **2020**, 14, 609468 | 11 |

| 1447 | The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases. **2020**, 21, | 122 |

| 1446 | Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg. **2020**, 9, | 10 |

| 1445 | Elevated Concentrations of Soluble Fas and FasL in Multiple Sclerosis Patients with Antinuclear Antibodies. **2020**, 9, | 1 |

| | | |
|---|---|---|
| 1444 | Increased socioeconomic burden in patients with primary progressive multiple sclerosis: A Danish nationwide population-based study. **2020**, 46, 102567 | 2 |
| 1443 | Spatial constraints and cognitive fatigue affect motor imagery of walking in people with multiple sclerosis. **2020**, 10, 21938 | 1 |
| 1442 | Central Nervous System Demyelination Associated With Immune Checkpoint Inhibitors: Review of the Literature. **2020**, 11, 538695 | 9 |
| 1441 | 3D Compressed Convolutional Neural Network Differentiates Neuromyelitis Optical Spectrum Disorders From Multiple Sclerosis Using Automated White Matter Hyperintensities Segmentations. **2020**, 11, 612928 | 3 |
| 1440 | Depression and anxiety in patients with multiple sclerosis treated with interferon-beta or fingolimod: Role of indoleamine 2,3-dioxygenase and pro-inflammatory cytokines. **2020**, 9, 100162 | 0 |
| 1439 | Fulminant inflammatory demyelination presenting as stroke-in-evolution in an elderly subject. **2021**, 11, e01967 | 1 |
| 1438 | Validation of the Italian version of the Multiple Sclerosis Intimacy and Sexuality Questionnaire-19. **2021**, 42, 2903-2910 | 2 |
| 1437 | The impact of lymphocytosis and CD4/CD8 ratio on the anti-JCV antibody index and clinical data in patients treated with natalizumab. **2021**, 42, 2847-2853 | 0 |
| 1436 | Adherence to a healthy lifestyle and multiple sclerosis: a case-control study from the UK Biobank. **2020**, 1-9 | 2 |
| 1435 | Short report: assessment of coping strategies in patients with neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis. **2020**, 1-11 | 2 |
| 1434 | Development, Spanish Normative Data, and Validation of a Social Cognition Battery in Prodromal Alzheimer's Disease and Multiple Sclerosis. **2021**, 36, 711-722 | 1 |
| 1433 | Identification of regulatory T cell molecules associated with severity of multiple sclerosis. **2021**, 27, 1695-1705 | 1 |
| 1432 | Clinical significance of a single cerebrospinal fluid immunoglobulin band: A retrospective study. **2021**, 27, 1451-1454 | 2 |
| 1431 | Assessing the effect of an evidence-based patient online educational tool for people with multiple sclerosis called UMIMS-understanding magnetic resonance imaging in multiple sclerosis: study protocol for a double-blind, randomized controlled trial. **2020**, 21, 1008 | 0 |
| 1430 | Gray Matter Matters: A Longitudinal Magnetic Resonance Voxel-Based Morphometry Study of Primary Progressive Multiple Sclerosis. **2020**, 11, 581537 | 4 |
| 1429 | The STING-IFN-Dependent Axis Is Markedly Low in Patients with Relapsing-Remitting Multiple Sclerosis. **2020**, 21, | 4 |
| 1428 | Altered PPARExpression Promotes Myelin-Induced Foam Cell Formation in Macrophages in Multiple Sclerosis. **2020**, 21, | 2 |
| 1427 | Double Filtration Plasmapheresis Treatment of Refractory Multiple Sclerosis Relapsed on Fingolimod: A Case Report. **2020**, 10, 7404 | 0 |

| 1426 | Neurite Orientation Dispersion and Density Imaging for Assessing Acute Inflammation and Lesion Evolution in MS. **2020**, 41, 2219-2226 | 5 |
| 1425 | Intrathecal Inflammation in Progressive Multiple Sclerosis. **2020**, 21, | 14 |
| 1424 | Real-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis. **2021**, 27, 1421-1431 | 8 |
| 1423 | A Single Session of Anodal Cerebellar Transcranial Direct Current Stimulation Does Not Induce Facilitation of Locomotor Consolidation in Patients With Multiple Sclerosis. **2020**, 14, 588671 | 0 |
| 1422 | Effects of Transcranial Direct Current Stimulation on Information Processing Speed, Working Memory, Attention, and Social Cognition in Multiple Sclerosis. **2020**, 11, 545377 | 0 |
| 1421 | Blood neurofilament light: a critical review of its application to neurologic disease. **2020**, 7, 2508-2523 | 39 |
| 1420 | Seasonal variation of onset in patients with anti-aquaporin-4 antibodies and anti-myelin oligodendrocyte glycoprotein antibody. **2020**, 349, 577431 | 5 |
| 1419 | LHON-MS - The overlaps in clinical and molecular features of both LHON and MS. **2020**, 45, 102322 | 0 |
| 1418 | Clinical manifestations and imaging features of white matter demyelination in older patients. **2020**, 48, 300060520966806 | 1 |
| 1417 | Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis. **2020**, 42, 2136-2147.e3 | 1 |
| 1416 | The Danger of Walking with Socks: Evidence from Kinematic Analysis in People with Progressive Multiple Sclerosis. **2020**, 20, | 0 |
| 1415 | Associations Between Findings From Myelin Water Imaging and Cognitive Performance Among Individuals With Multiple Sclerosis. **2020**, 3, e2014220 | 5 |
| 1414 | Caffeic Acid Phenethyl Ester Protects against Experimental Autoimmune Encephalomyelitis by Regulating T Cell Activities. **2020**, 2020, 7274342 | 5 |
| 1413 | Multiple Sklerose: Neuroinflammation und -degeneration Hand in Hand. **2020**, 2, 147-150 | |
| 1412 | Peak width of skeletonized mean diffusivity (PSMD) and cognitive functions in relapsing-remitting multiple sclerosis. **2021**, 15, 2228-2233 | 3 |
| 1411 | Acute vestibular syndrome and hearing loss mimicking labyrinthitis as initial presentation of multiple sclerosis. **2020**, 134, 110048 | 2 |
| 1410 | Clinical predictivity of thalamic sub-regional connectivity in clinically isolated syndrome: a 7-year study. **2021**, 26, 2163-2174 | 4 |
| 1409 | Deep-Learning Generated Synthetic Double Inversion Recovery Images Improve Multiple Sclerosis Lesion Detection. **2020**, 55, 318-323 | 25 |

| 1390 | Single-cell RNA-seq analysis of human CSF microglia and myeloid cells in neuroinflammation. **2020**, 7, | 26 |

| 1389 | High incidence and prevalence of MS in Mﬁe and Romsdal County, Norway, 1950-2018. **2020**, 7, | 5 |

| 1388 | The contribution of enhancing lesions in monitoring multiple sclerosis treatment: is gadolinium always necessary?. **2020**, 267, 2642-2647 | 2 |

| 1387 | Changes in oxygen saturation and the retinal nerve fibre layer in patients with optic neuritis associated with multiple sclerosis in a 6-month follow-up. **2020**, 98, 841-847 | 2 |

| 1386 | The 2013 clinical course descriptors for multiple sclerosis: A clarification. **2020**, 94, 1088-1092 | 37 |

| 1385 | Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. **2020**, 56, 102807 | 30 |

| 1384 | Functional representation of the symbol digit modalities test in relapsing remitting multiple sclerosis. **2020**, 43, 102159 | 1 |

| 1383 | Validity of the McDonald criteria in predicting second events in multiple sclerosis. **2020**, 43, 102223 | 1 |

| 1382 | Neurophysiological impairments in multiple sclerosis-Central and peripheral motor pathways. **2020**, 142, 401-417 | 11 |

| 1381 | Incidence, prevalence and characteristics of MS in Sﬁ Miguel, an island in the Atlantic. **2020**, 44, 102254 | 0 |

| 1380 | Analysis of soluble interleukin-2 receptor as CSF biomarker for neurosarcoidosis. **2020**, 7, | 6 |

| 1379 | Association of Individual-Level Factors With Visual Outcomes in Optic Neuritis: Secondary Analysis of a Randomized Clinical Trial. **2020**, 3, e204339 | 2 |

| 1378 | From Balﬂs concentric sclerosis to multiple sclerosis: a series of 6 patients. **2020**, 42, 102078 | 4 |

| 1377 | Cognitive reserve is a determinant of social and occupational attainment in patients with pediatric and adult onset multiple sclerosis. **2020**, 42, 102145 | 2 |

| 1376 | Epidemiology of multiple sclerosis in Santiago de Compostela (Spain). **2020**, 142, 267-274 | 4 |

| 1375 | A case of pure bilateral horizontal gaze palsy due to multiple sclerosis. **2020**, 8, 215-217 | |

| 1374 | The relationship between ANT1 and NFL with autophagy and mitophagy markers in patients with multiple sclerosis. **2020**, 78, 307-312 | 6 |

| 1373 | Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS. **2020**, 43, 102158 | 2 |

| 1372 | An overview of lipidomic analysis in different human matrices of multiple sclerosis. **2020**, 44, 102189 | 7 |
| 1371 | Effect of hippotherapy on walking performance and gait parameters in people with multiple sclerosis. **2020**, 43, 102203 | 9 |
| 1370 | Inflammation-related plasma and CSF biomarkers for multiple sclerosis. **2020**, 117, 12952-12960 | 39 |
| 1369 | Pharmacological treatment for chronic central neuropathic pain in people with multiple sclerosis. **2020**, | 0 |
| 1368 | Diagnosis and management of multiple sclerosis: MRI in clinical practice. **2020**, 267, 2917-2925 | 7 |
| 1367 | Non-inflammatory causes of emergency consultation in patients with multiple sclerosis. **2021**, 36, 403-411 | 0 |
| 1366 | Myelin oligodendrocyte glycoprotein-associated disorders are associated with HLA subtypes in a Chinese paediatric-onset cohort. **2020**, 91, 733-739 | 6 |
| 1365 | Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis. **2020**, 94, e2457-e2467 | 29 |
| 1364 | The IN-DEEP project "INtegrating and Deriving Evidence, Experiences, Preferences": a web information model on magnetic resonance imaging for people with multiple sclerosis. **2020**, 267, 2421-2431 | 1 |
| 1363 | BOLD signal within and around white matter lesions distinguishes multiple sclerosis and non-specific white matter disease: a three-dimensional approach. **2020**, 267, 2888-2896 | 3 |
| 1362 | Decreased second to fourth digit ratios in female multiple sclerosis patients. **2020**, 144, 105039 | 1 |
| 1361 | Promises and Limitations of Neural Stem Cell Therapies for Progressive Multiple Sclerosis. **2020**, 26, 898-912 | 17 |
| 1360 | Machine Learning and Multiparametric Brain MRI to Differentiate Hereditary Diffuse Leukodystrophy with Spheroids from Multiple Sclerosis. **2020**, 30, 674-682 | 7 |
| 1359 | Different Exosomal microRNA Profile in Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorders. **2020**, 11, 1064 | 4 |
| 1358 | Spinal Cord Involvement in MS and Other Demyelinating Diseases. **2020**, 8, | 7 |
| 1357 | Plasma Exchange or Immunoadsorption in Demyelinating Diseases: A Meta-Analysis. **2020**, 9, | 10 |
| 1356 | Changes in multiple sclerosis epidemiology in Finland over five decades. **2020**, 142, 200-209 | 3 |
| 1355 | Diagnostic accuracy of intrathecal kappa free light chains compared with OCBs in MS. **2020**, 7, | 11 |

| 1354 | Siponimod for multiple sclerosis. **2020**, | 1 |
| 1353 | Cerebrospinal fluid oligoclonal IgM test in routine practice: Comparison with quantitative assessment of intrathecal IgM synthesis. **2020**, 508, 137-145 | 4 |
| 1352 | Do you believe in Gad?. **2020**, 44, 102299 | 0 |
| 1351 | Molecular Biomarkers in the Cerebrospinal Fluid in Multiple Sclerosis. **2020**, 50, 527-533 | 1 |
| 1350 | Unilateral Optic Neuritis in Children: Experience of a Tertiary Centre. **2020**, 83, 251-258 | 0 |
| 1349 | Free light chain kappa and the polyspecific immune response in MS and CIS - Application of the hyperbolic reference range for most reliable data interpretation. **2020**, 346, 577287 | 8 |
| 1348 | Multiple sclerosis lesions in motor tracts from brain to cervical cord: spatial distribution and correlation with disability. **2020**, 143, 2089-2105 | 17 |
| 1347 | Clinical Relevance of Multiparametric MRI Assessment of Cervical Cord Damage in Multiple Sclerosis. **2020**, 296, 605-615 | 12 |
| 1346 | An investigation of knee position sense, balance, and dual task performance in different phases of menstrual cycle in females with multiple sclerosis: a pilot study. **2020**, 44, 102235 | 1 |
| 1345 | Optic neuropathy: A 15-year retrospective observational study. **2020**, 44, 102337 | 1 |
| 1344 | Epidemiology of pediatric multiple sclerosis: A systematic literature review and meta-analysis. **2020**, 44, 102260 | 15 |
| 1343 | Conversion of clinically isolated syndrome to multiple sclerosis: a prospective study. **2020**, 44, 102262 | 4 |
| 1342 | Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases. **2020**, 7, 992-1001 | 10 |
| 1341 | Analysis of MRI Data in Diagnostic Neuroradiology. **2020**, 3, 365-390 | 2 |
| 1340 | Multiple sclerosis 2017 McDonald criteria are also relevant for Tunisians. **2020**, 43, 102161 | 2 |
| 1339 | A Scope of the Social Brain in Multiple Sclerosis: Insights From Neuroimaging Studies. **2020**, 33, 90-102 | 5 |
| 1338 | Gadolinium should always be used to assess disease activity in MS - Yes. **2020**, 26, 765-766 | 4 |
| 1337 | Stress cardiomyopathy associated with the first manifestation of multiple sclerosis: a case report. **2020**, 20, 227 | 2 |

| | | |
|---|---|---|
| 1336 | Early diagnosis of secondary progressive multiple sclerosis: focus on fluid and neurophysiological biomarkers. **2021**, 268, 3626-3645 | 3 |
| 1335 | Cognitive Fatigability is Independent of Subjective Cognitive Fatigue and Mood in Multiple Sclerosis. **2020**, 33, 113-121 | 3 |
| 1334 | Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. **2020**, 15, e0234333 | 2 |
| 1333 | Visualizing the Central Nervous System: Imaging Tools for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. **2020**, 11, 450 | 15 |
| 1332 | Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab. **2020**, 44, 102297 | 21 |
| 1331 | Real world application of ocrelizumab in multiple sclerosis: Single-center experience of 128 patients. **2020**, 415, 116973 | 11 |
| 1330 | The CSF Levels of Neutrophil-Related Chemokines in Patients with Neuromyelitis Optica. **2020**, 7, 1245-1251 | 2 |
| 1329 | CSF microRNAs discriminate MS activity and share similarity to other neuroinflammatory disorders. **2020**, 7, | 8 |
| 1328 | Erythrocyte microRNAs show biomarker potential and implicate multiple sclerosis susceptibility genes. **2020**, 10, 74-90 | 3 |
| 1327 | An Overground Robotic Gait Training Program for People With Multiple Sclerosis: A Protocol for a Randomized Clinical Trial. **2020**, 7, 238 | 4 |
| 1326 | Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis. **2020**, | 1 |
| 1325 | Texture analysis in susceptibility-weighted imaging may be useful to differentiate acute from chronic multiple sclerosis lesions. **2020**, 30, 6348-6356 | 6 |
| 1324 | Impaired cognition is related to microstructural integrity in relapsing remitting multiple sclerosis. **2020**, 7, 1193-1203 | 5 |
| 1323 | First case of SARS-COV-2 sequencing in cerebrospinal fluid of a patient with suspected demyelinating disease. **2020**, 267, 3154-3156 | 78 |
| 1322 | Acoustic Speech Analytics Are Predictive of Cerebellar Dysfunction in Multiple Sclerosis. **2020**, 19, 691-700 | 8 |
| 1321 | Anxiety in Argentinian patients with multiple sclerosis: Prevalence and associated factors. **2020**, 41, 102042 | 2 |
| 1320 | Evaluating the feasibility and preliminary efficacy of a Cognitive Occupation-Based programme for people with Multiple Sclerosis (COB-MS): protocol for a feasibility cluster-randomised controlled trial. **2020**, 21, 269 | 6 |
| 1319 | The GPR17 Receptor-A Promising Goal for Therapy and a Potential Marker of the Neurodegenerative Process in Multiple Sclerosis. **2020**, 21, | 5 |

| 1318 | Corticospinal inhibition and alexithymia in multiple sclerosis patients-An exploratory study. **2020**, 41, 102039 | 1 |
| 1317 | Detection of central vein should be part of MS diagnostic criteria - No. **2020**, 26, 407-408 | 1 |
| 1316 | Degree of microstructural changes within T1-SE versus T1-GE hypointense lesions in multiple sclerosis: relevance for the definition of "black holes". **2020**, 30, 3843-3851 | 2 |
| 1315 | Intrathecal IgM as a Prognostic Marker in Multiple Sclerosis. **2020**, 24, 263-277 | 5 |
| 1314 | What role should spinal cord MRI take in the future of multiple sclerosis surveillance?. **2020**, 20, 783-797 | 6 |
| 1313 | Detection of central vein should be part of MS diagnostic criteria - Commentary. **2020**, 26, 409-410 | 1 |
| 1312 | Primary progressive multiple sclerosis presenting under the age of 18 years: Fact or fiction?. **2021**, 27, 309-314 | 4 |
| 1311 | Central vein sign for multiple sclerosis: A systematic review and meta-analysis. **2020**, 75, 479.e9-479.e15 | 5 |
| 1310 | Generation of a Model to Predict Differentiation and Migration of Lymphocyte Subsets under Homeostatic and CNS Autoinflammatory Conditions. **2020**, 21, | 1 |
| 1309 | Epidemiology of multiple sclerosis in Central Europe, update from Hungary. **2020**, 10, e01598 | 4 |
| 1308 | Targeted resequencing reveals rare variants enrichment in multiple sclerosis susceptibility genes. **2020**, 41, 1308-1320 | 0 |
| 1307 | Deciphering the neural underpinnings of alexithymia in multiple sclerosis. **2020**, 725, 134894 | 6 |
| 1306 | Wide Cytokine Analysis in Cerebrospinal Fluid at Diagnosis Identified CCL-3 as a Possible Prognostic Factor for Multiple Sclerosis. **2020**, 11, 174 | 3 |
| 1305 | Brain magnetic resonance imaging features in multiple sclerosis and neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody in a Latin American population. **2020**, 42, 102049 | 2 |
| 1304 | Effects of Transcranial Direct Current Stimulation on Hand Dexterity in Multiple Sclerosis: A Design for a Randomized Controlled Trial. **2020**, 10, | 1 |
| 1303 | A validated UHPLC-MS method for tryptophan metabolites: Application in the diagnosis of multiple sclerosis. **2020**, 185, 113246 | 14 |
| 1302 | First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study. **2020**, 42, 102059 | 4 |
| 1301 | Multi-Platform Characterization of Cerebrospinal Fluid and Serum Metabolome of Patients Affected by Relapsing-Remitting and Primary Progressive Multiple Sclerosis. **2020**, 9, | 12 |

1300    Primary lateral sclerosis: diagnosis and management. **2020**, 20, 262-269    8

1299    Serum levels of Homocysteine, Vitamin B12 and Folate in Patients with Multiple Sclerosis: an Updated Meta-Analysis. **2020**, 17, 751-761    13

1298    Race, ethnicity, and cognition in persons newly diagnosed with multiple sclerosis. **2020**, 94, e1548-e1556    8

1297    Recent Advances in Smart Biomaterials for the Detection and Treatment of Autoimmune Diseases. **2020**, 30, 1909556    7

1296    Bifrontal transcranial direct current stimulation modulates fatigue in multiple sclerosis: a randomized sham-controlled study. **2020**, 127, 953-961    11

1295    Acute Disseminated Encephalomyelitis followed by Optic Neuritis: A Rare Syndrome of Uncertain Treatment and Prognosis. **2020**, 51, 286-291    4

1294    Challenges in multiple sclerosis diagnosis: Misunderstanding and misapplication of the McDonald criteria. **2021**, 27, 250-258    13

1293    Refractory case of myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis with lumbosacral radiculitis. **2020**, 11, 126-130    3

1292    Resting-State Functional Correlates of Social Cognition in Multiple Sclerosis: An Explorative Study. **2019**, 13, 276    5

1291    CVSnet: A machine learning approach for automated central vein sign assessment in multiple sclerosis. **2020**, 33, e4283    18

1290    Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis. **2020**, 40, 319-326    2

1289    Risk HLA-DRB1 alleles differentially influence brain and lesion volumes in Japanese patients with multiple sclerosis. **2020**, 413, 116768

1288    IL-6 in the Cerebrospinal Fluid Signals Disease Activity in Multiple Sclerosis. **2020**, 14, 120    8

1287    Effects of Teriflunomide on B Cell Subsets in MuSK-Induced Experimental Autoimmune Myasthenia Gravis and Multiple Sclerosis. **2021**, 50, 671-684    3

1286    Low Seroprevalence of Lyme Disease Among Multiple Sclerosis Patients in New Brunswick. **2020**, 47, 842-844

1285    Optical coherence tomography measures correlate with brain and spinal cord atrophy and multiple sclerosis disease-related disability. **2020**, 27, 2225-2232    6

1284    Comparative Analysis of T-Cell Responses to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in Inflammatory Demyelinating Central Nervous System Diseases. **2020**, 11, 1188    4

1283    A Comprehensive Approach to Disentangle the Effect of Cerebellar Damage on Physical Disability in Multiple Sclerosis. **2020**, 11, 529    5

| 1282 | Peripapillary Vessel Density as Early Biomarker in Multiple Sclerosis. **2020**, 11, 542 | 14 |
| 1281 | Patients' perspective and usability of innovation technology in a new rehabilitation pathway: An exploratory study in patients with multiple sclerosis. **2020**, 44, 102312 | 18 |
| 1280 | Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis. **2020**, 2020, 5463451 | 6 |
| 1279 | Support vectors machine-based model for diagnosis of multiple sclerosis using the plasma levels of selenium, vitamin B12, and vitamin D3. **2020**, 20, 100382 | 1 |
| 1278 | Highly sensitive quantification of optic neuritis intrathecal biomarker CXCL13. **2020**, 44, 102281 | 0 |
| 1277 | Relapsing Demyelinating Syndromes in Children: A Practical Review of Neuroradiological Mimics. **2020**, 11, 627 | 3 |
| 1276 | Metabolic syndrome components and disease disability in egyptian multiple sclerosis patients. **2020**, 44, 102336 | 4 |
| 1275 | The retirement rate due to multiple sclerosis has decreased since 1995- A retrospective study in a Finnish central hospital. **2020**, 45, 102360 | 3 |
| 1274 | A 67-year-old man with facial droop, ataxia and vertigo. **2020**, 192, E626-E629 | 2 |
| 1273 | Impact of multiple sclerosis risk loci in postinfectious neurological syndromes. **2020**, 44, 102326 | 1 |
| 1272 | Saliva immunoglobulin free light chain analysis for monitoring disease activity and response to treatment in multiple sclerosis. **2020**, 44, 102339 | 5 |
| 1271 | Kappa Free Light Chains and IgG Combined in a Novel Algorithm for the Detection of Multiple Sclerosis. **2020**, 10, | 5 |
| 1270 | The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments. **2020**, 13, 583-597 | 3 |
| 1269 | Thalamic atrophy correlates with dysfunctional impulsivity in multiple sclerosis. **2020**, 44, 102374 | 0 |
| 1268 | Cerebrospinal Fluid Testing for Multiple Sclerosis. **2020**, 40, 369-377 | 1 |
| 1267 | Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity. **2020**, 10, 10923 | 17 |
| 1266 | A new paraplegin mutation in a patient with primary progressive multiple sclerosis. **2020**, 44, 102302 | 1 |
| 1265 | Image Domain Transfer by Deep Learning is Feasible in Multiple Sclerosis Clinical Practice. **2020**, 55, 324-325 | 2 |

| | | |
|---|---|---|
| 1246 | Toward an automatic tool for oligoclonal band detection in cerebrospinal fluid and tears for multiple sclerosis diagnosis: lane segmentation based on a ribbon univariate open active contour. **2020**, 58, 967-976 | 0 |
| 1245 | Understanding the Radiologist's Role in Evaluating Multiple Sclerosis: A Review of the Tip of the Iceberg. **2020**, 41, 275-283 | |
| 1244 | Natural killer cells in multiple sclerosis: A review. **2020**, 222, 1-11 | 20 |
| 1243 | Typique, atypique, vous avez dit n∜rite optique ?. **2020**, 11, 77-83 | |
| 1242 | Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. *Lancet Neurology, The*, **2020**, 19, 234-246 | 24.1 86 |
| 1241 | Does the multiple sclerosis (MS) map need to change again? An update of MS prevalence in Mazandaran province of Iran in 2018. **2020**, 20, 52 | 5 |
| 1240 | SWAN-Venule: An Optimized MRI Technique to Detect the Central Vein Sign in MS Plaques. **2020**, 41, 456-460 | 5 |
| 1239 | White Matter Diseases. **2020**, | 1 |
| 1238 | MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation. **2020**, 267, 1632-1642 | 17 |
| 1237 | Multiple Sclerosis Presenting as an Anterior Semicircular Canal Benign Paroxysmal Positional Vertigo: Case Report. **2021**, 100, 636S-640S | 1 |
| 1236 | Polypharmacy among patients with multiple sclerosis: a qualitative systematic review. **2020**, 19, 139-145 | 17 |
| 1235 | Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. **2020**, 87, 556-567 | 11 |
| 1234 | Nanoimmunosensor based on atomic force spectroscopy to detect anti-myelin basic protein related to early-stage multiple sclerosis. **2020**, 211, 112946 | 2 |
| 1233 | Antibody signatures in patients with histopathologically defined multiple sclerosis patterns. **2020**, 139, 547-564 | 8 |
| 1232 | Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. **2020**, 11, 247 | 110 |
| 1231 | Clinical Use of ɫFree Light Chains Index as a Screening Test for Multiple Sclerosis. **2020**, 51, 402-407 | 10 |
| 1230 | New MRI lesions and topography at 6 months of treatment initiation and disease activity during follow up in relapsing remitting multiple sclerosis patients. **2020**, 42, 148-152 | 2 |
| 1229 | Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis. **2020**, 34, 269-280 | 25 |

| 1210 | Finding the right balance with participation in exercise and sport for individuals with multiple sclerosis: protocol for a pre and post intervention feasibility study. **2020**, 10, e035378 | 1 |
|---|---|---|
| 1209 | Expansion of Neutrophils and Classical and Nonclassical Monocytes as a Hallmark in Relapsing-Remitting Multiple Sclerosis. **2020**, 11, 594 | 13 |
| 1208 | Association Between Fatigue and Motor Exertion in Patients With Multiple Sclerosis-a Prospective Study. **2020**, 11, 208 | 8 |
| 1207 | Diagnostic value of kappa free light chains in patients with one isolated band in isoelectric focusing. **2020**, 507, 205-209 | 5 |
| 1206 | Evidence of retinal anterograde neurodegeneration in the very early stages of multiple sclerosis: a longitudinal OCT study. **2020**, 41, 3175-3183 | 5 |
| 1205 | A novel neurodegenerative spectrum disorder in patients with MLKL deficiency. **2020**, 11, 303 | 7 |
| 1204 | Current Advances in Pediatric Onset Multiple Sclerosis. **2020**, 8, | 8 |
| 1203 | Possible clinical role of MOG antibody testing in children presenting with acute neurological symptoms. **2020**, 41, 2553-2559 | 2 |
| 1202 | Dietary influence on central nervous system myelin production, injury, and regeneration. **2020**, 1866, 165779 | 9 |
| 1201 | Should spinal cord MRI be systematically performed for diagnosis and follow-up of multiple sclerosis? No. **2020**, 176, 485-486 | |
| 1200 | [Multiple sclerosis and immuno-modulators of sphingosine 1-phosphate receptors]. **2020**, 36, 243-252 | 1 |
| 1199 | Effect of Eccentric Strength Training on Elbow Flexor Spasticity and Muscle Weakness in People With Multiple Sclerosis: Proof-of-Concept Single-System Case Series. **2020**, 100, 1142-1152 | 3 |
| 1198 | Activated monocytes and markers of inflammation in newly diagnosed multiple sclerosis. **2020**, 98, 549-562 | 5 |
| 1197 | Reduced Global Efficiency and Random Network Features in Patients with Relapsing-Remitting Multiple Sclerosis with Cognitive Impairment. **2020**, 41, 449-455 | 5 |
| 1196 | Alemtuzumab for relapsing multiple sclerosis in clinical practice: A four-year retrospective one-center study. **2020**, 31, 259-265 | 2 |
| 1195 | Microbiome in Multiple Sclerosis; Where Are We, What We Know and Do Not Know. **2020**, 10, | 22 |
| 1194 | Cerebrospinal Fluid Neurofilament Light Chain Is Associated with Kynurenine Pathway Metabolite Changes in Multiple Sclerosis. **2020**, 21, | 14 |
| 1193 | Is Initial Misdiagnosis Associated with Reaching Disability Milestones in Patients with Multiple Sclerosis?. **2020**, 56, | 1 |

| | | |
|---|---|---|
| 1192 | Diagnostic and therapeutic issues of inflammatory diseases of the elderly. **2020**, 176, 739-749 | 1 |
| 1191 | Light therapy for multiple sclerosis-associated fatigue: a randomized, controlled phase II trial. **2020**, 267, 2319-2327 | 2 |
| 1190 | Diagnostic revisions in multiple sclerosis. **2020**, 11, 171-175 | 1 |
| 1189 | S1 guidelines "lumbar puncture and cerebrospinal fluid analysis" (abridged and translated version). **2020**, 2, 8 | 5 |
| 1188 | A unique thymus-derived regulatory T cell subset associated with systemic lupus erythematosus. **2020**, 22, 88 | 9 |
| 1187 | Glucocorticoid receptor mutations and clinical sensitivity to glucocorticoid in Chinese multiple sclerosis patients. **2020**, 41, 2767-2771 | |
| 1186 | Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study. **2020**, 41, 2843-2851 | 4 |
| 1185 | Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. **2020**, 95, 106009 | 9 |
| 1184 | Successful disease control with alemtuzumab in MOG-IgG-associated demyelinating disease with MS-phenotype. **2020**, 42, 102108 | 1 |
| 1183 | Deep learning with diffusion basis spectrum imaging for classification of multiple sclerosis lesions. **2020**, 7, 695-706 | 18 |
| 1182 | Spectrum of anti-myelin oligodendrocyte glycoprotein antibody (MOG-Ab)-associated diseases: an Indian perspective. **2021**, 121, 927-931 | 3 |
| 1181 | Reliability of gait and dual-task measures in multiple sclerosis. **2020**, 78, 19-25 | 4 |
| 1180 | Deep DNA metagenomic sequencing reveals oral microbiome divergence between monozygotic twins discordant for multiple sclerosis severity. **2020**, 343, 577237 | 2 |
| 1179 | Application of the 2017 McDonald criteria for the diagnosis of multiple sclerosis after a first demyelinating event in patients from Argentina. **2020**, 41, 102043 | 2 |
| 1178 | Multiple Sclerosis in Children: Current and Emerging Concepts. **2020**, 40, 192-200 | 1 |
| 1177 | MRI biomarkers of disease progression and conversion to secondary-progressive multiple sclerosis. **2020**, 20, 821-834 | 6 |
| 1176 | Distribution of plaques in the cerebrum in multiple sclerosis. **2020**, 91, 901-902 | 0 |
| 1175 | Progress towards a diagnostic biomarker for MS: Central vein sign. **2020**, 26, 394-396 | 1 |

1174   Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis. **2021**, 27, 220-231   24

1173   Association of intrathecal pleocytosis and IgG synthesis with axonal damage in early MS. **2020**, 7,   9

1172   Monitoring of radiologic disease activity by serum neurofilaments in MS. **2020**, 7,   16

1171   Number of MRI T1-hypointensity corrected by T2/FLAIR lesion volume indicates clinical severity in patients with multiple sclerosis. **2020**, 15, e0231225   2

1170   The Impact of Immunomodulatory Treatment on Kappa Free Light Chains as Biomarker in Neuroinflammation. **2020**, 9,   9

1169   Five- and seven-year prognostic value of new effectiveness measures (NEDA, MEDA and six-month delayed NEDA) in relapsing-remitting multiple sclerosis. **2020**, 414, 116827   3

1168   The proportion of myeloid-derived suppressor cells in the spleen is related to the severity of the clinical course and tissue damage extent in a murine model of multiple sclerosis. **2020**, 140, 104869   9

1167   The nervous system in systemic lupus erythematosus. **2021**, 469-478

1166   Astrocyte metabolism in multiple sclerosis investigated by 1-C-11 acetate PET. **2021**, 41, 369-379   3

1165   Diagnostic value of bright spotty lesions on MRI after a first episode of acute myelopathy. **2021**, 48, 28-36   12

1164   Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study. **2021**, 27, 667-673   2

1163   Hippocampal volume is more related to patient-reported memory than objective memory performance in early multiple sclerosis. **2021**, 27, 568-578   1

1162   Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis: Multicenter study in Argentina. **2021**, 27, 579-584   3

1161   Predictive value of optical coherence tomography, multifocal visual evoked potentials, and full-field visual evoked potentials of the fellow, non-symptomatic eye for subsequent multiple sclerosis development in patients with acute optic neuritis. **2021**, 27, 391-400   4

1160   Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. **2021**, 27, 755-766   3

1159   Ongoing microstructural changes in the cervical cord underpin disability progression in early primary progressive multiple sclerosis. **2021**, 27, 28-38   8

1158   Spinal cord and brain MRI should be routinely performed during follow-up in patients with NMOSD - No. **2021**, 27, 15-16   2

1157   Classic Imaging Signs. **2021**,

1138   Speech metrics, general disability, brain imaging and quality of life in multiple sclerosis. **2021**, 28, 259-268   2

1137   Elevated IL-38 Serum Levels in Newly Diagnosed Multiple Sclerosis and Systemic Sclerosis Patients. **2021**, 30, 146-153   3

1136   The course of multiple sclerosis rewritten: a Norwegian population-based study on disease demographics and progression. **2021**, 268, 1330-1341   8

1135   Developmental venous anomalies in patients with multiple sclerosis: is that a coincidence or an ancillary finding?. **2021**, 42, 2453-2460   1

1134   Prognostic value of spinal cord MRI in multiple sclerosis patients. **2021**, 177, 571-581   2

1133   Impaired consolidation of visuomotor adaptation in patients with multiple sclerosis. **2021**, 28, 884-892   3

1132   'Posture second' strategy predicts disability progression in multiple sclerosis. **2021**, 27, 1140-1144

1131   Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis. **2021**, 5, 23-34   0

1130   Coping strategies used by patients with relapsing multiple sclerosis from Argentina: correlation with quality of life and clinical features. **2021**, 43, 126-132   3

1129   Early red nucleus atrophy in relapse-onset multiple sclerosis. **2021**, 42, 154-160   1

1128   Serum phospholipidomics reveals altered lipid profile and promising biomarkers in multiple sclerosis. **2021**, 697, 108672   9

1127   Exercise-induced changes in gait kinematics in multiple sclerosis with minimal neurological disability. **2021**, 47, 102630   2

1126   Polymorphisms in proinflammatory cytokines genes and susceptibility to Multiple Sclerosis. **2021**, 47, 102654   0

1125   Retinal asymmetry in multiple sclerosis. **2021**, 144, 224-235   4

1124   Cerebrospinal Fluid Features in Patients With Coronavirus Disease 2019 and Neurological Manifestations: Correlation with Brain Magnetic Resonance Imaging Findings in 58 Patients. **2021**, 223, 600-609   23

1123   Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis. **2021**, 289, 771-791   16

1122   Integration of the Extreme Gradient Boosting model with electronic health records to enable the early diagnosis of multiple sclerosis. **2021**, 47, 102632   2

1121   MRI signs of CNS demyelinating diseases. **2021**, 47, 102665   3

| | | |
|---|---|---|
| 1102 | Does gait bout definition influence the ability to discriminate gait quality between people with and without multiple sclerosis during daily life?. **2021**, 84, 108-113 | 1 |
| 1101 | Etiological spectrum, clinico-radiological profile and treatment outcomes of longitudinally extensive transverse myelitis - A prospective study from Northwest India. **2021**, 351, 577456 | 2 |
| 1100 | High serum neurofilament levels among Chinese patients with aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders. **2021**, 83, 108-111 | 4 |
| 1099 | Time interval between disease onset and MS diagnosis during the last decades in Latin America. **2021**, 48, 102672 | 0 |
| 1098 | Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study. **2021**, 28, 1299-1307 | 1 |
| 1097 | Structural constraints of functional connectivity drive cognitive impairment in the early stages of multiple sclerosis. **2021**, 27, 559-567 | 5 |
| 1096 | Alemtuzumab mediates the CD39 T-regulatory cell response via CD23 macrophages. **2021**, 99, 521-531 | 1 |
| 1095 | Fast automatic segmentation of thalamic nuclei from MP2RAGE acquisition at 7 Tesla. **2021**, 85, 2781-2790 | 2 |
| 1094 | Interpretation of Brain Volume Increase in Multiple Sclerosis. **2021**, 31, 401-407 | 4 |
| 1093 | Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high-dose pharmaceutical-grade biotin (MD1003). **2021**, 11, e01998 | 0 |
| 1092 | The epidemiology of multiple sclerosis in the Scottish Highlands: Prevalence, incidence and time to confirmed diagnosis and treatment initiation. **2021**, 47, 102657 | |
| 1091 | Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - No. **2021**, 27, 176-177 | 4 |
| 1090 | Measuring attack on self: The need for field-friendly methods development and research on autoimmunity in human biology. **2020**, | 1 |
| 1089 | Interleukin-15 enhances proinflammatory T-cell responses in patients with MS and EAE. **2021**, 8, | 0 |
| 1088 | Preventing multiple sclerosis misdiagnosis using the "central vein sign": A real-world study. **2021**, 48, 102671 | 1 |
| 1087 | Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal Fluid. **2021**, 54, 164-175.e6 | 51 |
| 1086 | Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: A cohort study from Germany. **2021**, 8, | 16 |
| 1085 | The sequence of structural, functional and cognitive changes in multiple sclerosis. **2021**, 29, 102550 | 4 |

1084    Epileptic seizures in multiple sclerosis: prevalence, competing causes and diagnostic accuracy. **2021**, 268, 1721-1727    8

1083    CSF levels of HoxB3 and YKL-40 may predict conversion from clinically isolated syndrome to relapsing remitting multiple sclerosis. **2021**, 48, 102697    1

1082    Multiple sclerosis identification in brain MRI images using wavelet convolutional neural networks. **2021**, 31, 778-785    6

1081    Neuromuscular and Mobility Responses to a Vibration Session in Hypoxia in Multiple Sclerosis. **2021**, 42, 307-313    0

1080    Multiple Sclerosis. **2021**, 983-1005.e5

1079    Magnetic resonance imaging of Balð concentric sclerosis: Literature review and presentation of two focused cases. **2021**, 12, 54-62

1078    Multiple Sclerosis. **2021**, 353-376

1077    Regulation of neuroinflammation by B cells and plasma cells. **2021**, 299, 45-60    4

1076    Testing social cognition in multiple sclerosis: Difference between emotion recognition and theory of mind and its influence on quality of life. **2021**, 11, e01925    2

1075    A contrast-adaptive method for simultaneous whole-brain and lesion segmentation in multiple sclerosis. **2021**, 225, 117471    16

1074    Circulating endothelial progenitor cells during pregnancy in multiple sclerosis. **2021**, 42, 1443-1451

1073    Common genetic variants in PRRC2A are associated with both neuromyelitis optica spectrum disorder and multiple sclerosis in Han Chinese population. **2021**, 268, 506-515    2

1072    Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing-remitting multiple sclerosis. **2021**, 28, 269-277

1071    Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis. **2021**, 268, 1247-1253    5

1070    The role of sensory processing difficulties, cognitive impairment, and disease severity in predicting functional behavior among patients with multiple sclerosis. **2021**, 43, 1129-1136    5

1069    Cytokine-chemokine and cognitive profile of multiple sclerosis patients with predominant optic nerve and spinal cord involvement. **2021**, 44, 411-417    3

1068    A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition. **2021**, 268, 1210-1221    40

1067    The prevalence of epileptic seizures in multiple sclerosis in a large tertiary hospital in Australia. **2021**, 7, 2055217321989767    0

1066 Implications of extreme serum neurofilament light chain levels for the management of patients with relapsing multiple sclerosis. **2021**, 14, 17562864211001977 — 0

1065 Encyclopedia of Quality of Life and Well-Being Research. **2021**, 1-2

1064 ZNS-Erkrankungen beim Erwachsenen. **2021**, 117-128

1063 Standardizing T1-w/T2-w ratio images in trigeminal neuralgia to estimate the degree of demyelination in vivo. **2021**, 32, 102798 — 1

1062 Mutual relationship between upper extremity function and core muscle endurance in patients with multiple sclerosis.

1061 Caso clínico: presentación atípica de esclerosis múltiple en una paciente de 42 años. **2021**, 3, 100082

1060 Stepwise target controllability identifies dysregulations of macrophage networks in multiple sclerosis. **2021**, 5, 337-357 — 0

1059 White Matter Pathology. **2021**, 29-46 — 1

1058 Imaging in Neuro-Ophthalmology. **2021**, 1-29

1057 Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability. **2021**, 27, 1706-1716 — 3

1056 Comparison of multi echo T relaxation and steady state approaches for myelin imaging in the central nervous system. **2021**, 11, 1369 — 2

1055 Brenda Banwell. **2021**, 609-611

1054 Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). **2021**, 14, 17562864211039648 — 13

1053 IL27 T4730C Polymorphism and Serology in Multiple Sclerosis: A Pilot Study. **2021**, 35, 2845-2853 — 0

1052 Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers. **2021**, 16, 36-42 — 8

1051 Deep Attention and Graphical Neural Network for Multiple Sclerosis Lesion Segmentation from MR Imaging Sequences. **2021**, PP, — 0

1050 Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score. **2021**, 28, 1609-1616 — 8

1049 Evolution of the Diagnostic Criteria in Multiple Sclerosis. **2021**, 75-87

| 1030 | Disruption of brainstem monoaminergic fibre tracts in multiple sclerosis as a putative mechanism for cognitive fatigue: a fixel-based analysis. **2021**, 30, 102587 | 7 |
| 1029 | Multiple sclerosis and subclinical neuropathology in healthy individuals with familial risk: A scoping review of MRI studies. **2021**, 31, 102734 | |
| 1028 | Neuroimaging Modalities in Neuroimmunology. **2021**, 29-42 | |
| 1027 | Oligoclonal Bands: Isoelectric Focusing and Immunoblotting, and Determination of Free Light Chains in the Cerebrospinal Fluid. **2021**, 29-54 | |
| 1026 | C-PK11195 plasma metabolization has the same rate in multiple sclerosis patients and healthy controls: a cross-sectional study. **2021**, 16, 2494-2498 | 0 |
| 1025 | Can powered exoskeletons improve gait and balance in multiple sclerosis? A retrospective study. **2021**, 44, 126-130 | 1 |
| 1024 | Using dual-calibrated functional MRI to map brain oxygen supply and consumption in multiple sclerosis. | 0 |
| 1023 | FLAIR-only joint volumetric analysis of brain lesions and atrophy in clinically isolated syndrome (CIS) suggestive of multiple sclerosis. **2021**, 29, 102542 | 2 |
| 1022 | Recent advances and future directions on the use of optical coherence tomography in neuro-ophthalmology. **2021**, 11, 3-15 | 4 |
| 1021 | Case Report: Efficacy of Rituximab in a Patient With Familial Mediterranean Fever and Multiple Sclerosis. **2020**, 11, 591395 | 1 |
| 1020 | Optic Neuritis. **2021**, 25-39 | |
| 1019 | Demyelinating Diseases. **2021**, 313-351 | |
| 1018 | KIF5A and the contribution of susceptibility genotypes as a predictive biomarker for multiple sclerosis. **2021**, 268, 2175-2184 | 0 |
| 1017 | Neurological disorders of COVID-19 can be explained in terms of both "loss and gain of function" states of a solution for the nervous system. **2021**, 7, 217-222 | 0 |
| 1016 | Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS. **2020**, 11, 593527 | 2 |
| 1015 | Serum neurofilament levels reflect outer retinal layer changes in multiple sclerosis. **2021**, 14, 17562864211003478 | 4 |
| 1014 | The Expanded Disability Status Scale Score and Demographic Indexes Are Correlated with the Severity of Cognitive Impairment in Multiple Sclerosis Patients. **2021**, 17, 113-120 | 7 |
| 1013 | Approach to optic neuritis: An update. **2021**, 69, 2266-2276 | 1 |

| | | |
|---|---|---|
| 1012 | Abnormalities in normal-appearing white matter from which multiple sclerosis lesions arise. **2021**, 3, fcab176 | 1 |
| 1011 | Switching treatments in clinically stable relapsing remitting multiple sclerosis patients planning for pregnancy. **2021**, 7, 20552173211001571 | 1 |
| 1010 | Toward a Remote Assessment of Walking Bout and Speed: Application in Patients With Multiple Sclerosis. **2021**, 25, 4217-4228 | 3 |
| 1009 | Use of Disease-Modifying Therapies in Multiple Sclerosis. **2021**, 493-506 | 0 |
| 1008 | A Computer-Aided Diagnosis System in the Diagnosis of Multiple Sclerosis. **2021**, 277-284 | |
| 1007 | Virtual reality for multiple sclerosis rehabilitation. | 0 |
| 1006 | Machine learning-based differentiation between multiple sclerosis and glioma WHO II°-IV° using O-(2-[18F] fluoroethyl)-L-tyrosine positron emission tomography. **2021**, 152, 325-332 | 4 |
| 1005 | A R-Script for Generating Multiple Sclerosis Lesion Pattern Discrimination Plots. **2021**, 11, | |
| 1004 | High prevalence of fatigue in contemporary patients with multiple sclerosis. **2021**, 7, 2055217321999826 | 6 |
| 1003 | Ocrelizumab in Multiple Sclerosis: A Real-World Study From Spain. **2020**, 11, 592304 | 7 |
| 1002 | [Blockade of D1-like dopaminergic receptors suppresses Th17-cell function in multiple sclerosis]. **2021**, 121, 82-89 | |
| 1001 | Twin studies on the epigenetics of selected neurological disorders and carotid artery disease. **2021**, 193-211 | |
| 1000 | Identification of hsa-miR-106a-5p as an impact agent on promotion of multiple sclerosis using multi-step data analysis. **2021**, 42, 3791-3799 | 2 |
| 999 | Clinical Approach to Pediatric Demyelinating Disease. **2021**, 469-482 | |
| 998 | Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease. **2021**, 10, e1316 | 3 |
| 997 | Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation. **2021**, 3, fcab157 | 4 |
| 996 | The changing landscape of optic neuritis: a narrative review. **2021**, 1 | 3 |
| 995 | [Current aspects of neurogenic dysfunctions of the lower urinary tract in multiple sclerosis]. **2021**, 92, 349-358 | 0 |

994    [Dysphagia in Multiple Sclerosis - an underestimated symptom?]. **2021**, 89, 168-177

993    Diagnosis of multiple sclerosis in times of MOG and AQP4 autoantibody testing - A monocentric study. **2021**, 421, 117289

992    Deep Learning Corpus Callosum Segmentation as a Neurodegenerative Marker in Multiple Sclerosis. **2021**, 31, 493-500    1

991    Immune phenotyping study revealing caveats regarding a switch from fingolimod to cladribine. **2021**, 48, 102727    4

990    Defining Benign/Burnt-Out MS and Discontinuing Disease-Modifying Therapies. **2021**, 8,    3

989    The audiovestibular manifestations as early symptoms of multiple sclerosis: a scoping review of the literature. **2021**, 1    3

988    A Bio-Psycho-Social Co-created Intervention for Young Adults With Multiple Sclerosis (ESPRIMO): Rationale and Study Protocol for a Feasibility Study. **2021**, 12, 598726    2

987    Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation. **2021**, 27, 1939-1947    5

986    Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis. **2021**, 32, 573-595    10

985    Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care. *Lancet Neurology, The*, **2021**, 20, 136-149    24.1    19

984    Comparaciħ entre las secuencias axiales densidad de protones y T2 en lesiones medulares cervicales de pacientes con esclerosis mħtiple. **2021**, 85, 057-061    1

983    Epidemiology and clinical features of demyelinating disorders in India. **2021**, 9, 266-273    0

982    Prevalence and Risk Factors of Dysphagia in Patients with Multiple Sclerosis. **2021**, 1    1

981    Amyloidoma mimicking multiple sclerosis. **2021**,

980    Serum vitamin d inversely correlates with depression scores in people with multiple sclerosis. **2021**, 48, 102732    1

979    Ozanimod for relapsing-remitting multiple sclerosis.

978    The Value of Self-Reported Cognitive Performance in low, medium and high EDSS.

977    Classification of multiple sclerosis based on patterns of CNS regional atrophy covariance. **2021**, 42, 2399-2415    3

| 976 | An Interview-Based Assessment of the Experience of Cognitive Impairment in Multiple Sclerosis: The Cognitive Assessment Interview (CAI). **2021**, 12, 637895 | 0 |
| 975 | Functional neurological disorder and multiple sclerosis: a systematic review of misdiagnosis and clinical overlap. **2021**, 1 | 8 |
| 974 | Phelan McDermid Syndrome: Multiple Sclerosis as a Rare but Treatable Cause for Regression-A Case Report. **2021**, 22, | 0 |
| 973 | Correlation of cortical lesions of multiple sclerosis at double inversion recovery with cognition screening scores. **2021**, 57, | 0 |
| 972 | Optical Coherence Tomography Angiography of Peripapillary Vessel Density in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Comparative Study. **2021**, 10, | 7 |
| 971 | Smartphone-based symbol-digit modalities test reliably captures brain damage in multiple sclerosis. **2021**, 4, 36 | 10 |
| 970 | Neurofibromatosis Type 1 with Highly Active Relapsing-Remitting Multiple Sclerosis (RRMS). **2021**, 8, 002190 | 1 |
| 969 | Association of serum levels and receptor genes BsmI, TaqI and FokI polymorphisms of vitamin D with the severity of multiple sclerosis. **2021**, 84, 75-81 | 2 |
| 968 | Optimizing EEG source reconstruction with concurrent fMRI-derived spatial priors. | |
| 967 | Interferon beta 1a (Rebif ) in relapsing remitting multiple sclerosis. **2021**, 82, 707-715 | |
| 966 | Recent advances in development of nanomedicines for multiple sclerosis diagnosis. **2021**, 16, 024101 | 2 |
| 965 | Patient Satisfaction With the Quality of Counseling Provided by Advanced Practice Nurses Specialized in Multiple Sclerosis: A Quantitative Analysis. **2021**, 53, 99-103 | 0 |
| 964 | Transient monocular visual impairment as an initial symptom of COVID-19 infection in an individual with multiple sclerosis receiving teriflunomide. **2021**, 42, 1661-1664 | 1 |
| 963 | Investigating efficient CNN architecture for multiple sclerosis lesion segmentation. **2021**, 8, 014504 | 2 |
| 962 | Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapy. **2021**, 268, 2895-2899 | 2 |
| 961 | Models of the Blood-Brain Barrier: Tools in Translational Medicine.. **2020**, 2, 623950 | 10 |
| 960 | The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia. **2021**, 27, 913-921 | 7 |
| 959 | Memantine for Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Trials. **2020**, 11, 574748 | 2 |

| 958 | Study protocol for a randomised controlled trial of a web-based behavioural lifestyle programme for emPOWERment in early Multiple Sclerosis (POWER@MS1). **2021**, 11, e041720 | 2 |

| 957 | Bruch's membrane opening-minimum rim width: An alternative OCT biomarker study for multiple sclerosis. **2021**, 31, 2141-2149 | 1 |

| 956 | A Prospective, Observational, Cohort Study to Assess the Efficacy and Safety of Prolonged-Release Fampridine in Cognition, Fatigue, Depression, and Quality of Life in Multiple Sclerosis Patients: The FAMILY Study. **2021**, 38, 1536-1551 | 1 |

| 955 | Identifying Early Neuropsychological Indicators of Cognitive Involvement in Multiple Sclerosis. **2021**, 17, 323-337 | 3 |

| 954 | Development and evaluation of an interactive web-based decision-making programme on relapse management for people with multiple sclerosis (POWER@MS2)-study protocol for a randomised controlled trial. **2021**, 22, 139 | 4 |

| 953 | High-intensity interval training and energy management education, compared with moderate continuous training and progressive muscle relaxation, for improving health-related quality of life in persons with multiple sclerosis: study protocol of a randomized controlled superiority trial with six months' follow-up. **2021**, 21, 65 | 2 |

| 952 | Risk of Psychiatric Disorders in Multiple Sclerosis: A Nationwide Cohort Study in an Asian Population. **2021**, 17, 587-604 | 3 |

| 951 | The TGF-βsuperfamily cytokine Activin-A is induced during autoimmune neuroinflammation and drives pathogenic Th17 cell differentiation. **2021**, 54, 308-323.e6 | 13 |

| 950 | Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis. **2021**, 27, 1948-1959 | 2 |

| 949 | Rituximab for people with multiple sclerosis. | 78 |

| 948 | Cerebrospinal fluid proteome shows disrupted neuronal development in multiple sclerosis. **2021**, 11, 4087 | 4 |

| 947 | Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study. **2021**, 268, 2922-2932 | 8 |

| 946 | Diagnosis and Treatment of Multiple Sclerosis: A Review. **2021**, 325, 765-779 | 99 |

| 945 | Predisposing Factors for Sexual Dysfunction in Multiple Sclerosis. **2021**, 12, 618370 | 4 |

| 944 | Compressive Cervical Myelopathy in Patients With Demyelinating Disease of the Central Nervous System: Improvement After Surgery Despite a Late Diagnosis. **2021**, 13, e13161 | 1 |

| 943 | Early Predictors of 9-Year Disability in Pediatric Multiple Sclerosis. **2021**, 89, 1011-1022 | 3 |

| 942 | Clinical and radiological features of MS, NMOSD, and MOGAD, and evolution of the diagnostic processes in Thailand. **2021**, 9, 282-291 | 0 |

| 941 | Differences in physical, mental, and social functions between males and females in multiple sclerosis: A multicenter cross-sectional study in China. **2021**, 48, 102693 | 1 |

| | | |
|---|---|---|
| 940 | Neuroimaging of Spinal Cord and Cauda Equina Disorders. **2021**, 27, 225-263 | 1 |
| 939 | COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review. **2021**, 48, 102734 | 9 |
| 938 | Incidence and clinical outcome of Coronavirus disease 2019 in a cohort of 11,560 Brazilian patients with multiple sclerosis. **2021**, 1352458520978354 | 6 |
| 937 | Clinical and Prognostic Analysis of Autoantibody-Associated CNS Demyelinating Disorders in Children in Southwest China. **2021**, 12, 642664 | 1 |
| 936 | Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer's Disease and Other Neurological Disorders. **2021**, 15, 647783 | 1 |
| 935 | Effector T Helper Cells Are Selectively Controlled During Pregnancy and Related to a Postpartum Relapse in Multiple Sclerosis. **2021**, 12, 642038 | 1 |
| 934 | Rationale and design of the brain magnetic resonance imaging protocol for FutureMS: a longitudinal multi-centre study of newly diagnosed patients with relapsing-remitting multiple sclerosis in Scotland. | 2 |
| 933 | Linear brain atrophy measures in multiple sclerosis and clinically isolated syndromes: a 30-year follow-up. **2021**, | 2 |
| 932 | A pilot study of the impact of an exercise intervention on brain structure, cognition, and psychosocial symptoms in individuals with relapsing-remitting multiple sclerosis. **2021**, 7, 65 | 2 |
| 931 | Pathology-supported genetic testing as a method for disability prevention in multiple sclerosis (MS). Part II. Insights from two MS cases. **2021**, 36, 1169-1181 | 1 |
| 930 | Clinical predictors to cognitive impairment in multiple sclerosis patients. **2021**, 57, | 6 |
| 929 | Neurologic Features Associated With SARS-CoV-2 Infection in Children: A Case Series Report. **2021**, 36, 853-866 | 16 |
| 928 | Multiple sclerosis limited to spinal cord lesions. **2021**, 12, 111-115 | 0 |
| 927 | Treatment of Women with Multiple Sclerosis Planning Pregnancy. **2021**, 23, 11 | 10 |
| 926 | Cerebrospinal Fluid Biomarkers of Myeloid and Glial Cell Activation Are Correlated With Multiple Sclerosis Lesional Inflammatory Activity. **2021**, 15, 649876 | 1 |
| 925 | Shear wave elastography evaluation of brachial plexus in multiple sclerosis. **2021**, 2841851211002828 | 0 |
| 924 | Multiparametric Quantitative MRI in Neurological Diseases. **2021**, 12, 640239 | 4 |
| 923 | [Differential diagnostics of autoimmune inflammatory spinal cord diseases]. **2021**, 92, 293-306 | 1 |

| | | |
|---|---|---|
| 922 | Compensatory image of the stability of people with multiple sclerosis and atrial vertigo based on posturography examination. **2021**, 11, 7027 | 1 |
| 921 | Serum level of brain-derived neurotrophic factor in patients with relapsingremitting multiple sclerosis: a potential biomarker for disease activity. **2021**, 57, | 2 |
| 920 | Optical coherence tomography angiography helps distinguish multiple sclerosis from AQP4-IgG-seropositive neuromyelitis optica spectrum disorder. **2021**, 11, e02125 | 2 |
| 919 | Subclinical anterior optic pathway involvement in early multiple sclerosis and clinically isolated syndromes. **2021**, 144, 848-862 | 3 |
| 918 | Untreated patients with multiple sclerosis: A study of French expert centers. **2021**, 28, 2026-2036 | 3 |
| 917 | Cervical cord myelin abnormality is associated with clinical disability in multiple sclerosis. **2021**, 27, 2191-2198 | 1 |
| 916 | [Spastic paresis of the arms and flaccid paralysis of the legs in secondary progressive multiple sclerosis]. **2021**, 92, 1061-1063 | |
| 915 | Interaction between Neurons and the Oligodendroglial Lineage in Multiple Sclerosis and Its Preclinical Models. **2021**, 11, | |
| 914 | Clinically isolated syndrome: diagnosis and risk of developing clinically definite multiple sclerosis. **2021**, | |
| 913 | Validity of the Italian multiple sclerosis neuropsychological screening questionnaire. **2021**, 42, 4583-4589 | |
| 912 | Magnetic resonance imaging in the diagnosis of non-tumorous multifocal brain lesions mimicking multiple sclerosis. **2021**, 49, 89-97 | |
| 911 | Isolated Cognitive Decline in Neurologically Stable Patients with Multiple Sclerosis. **2021**, 11, | 1 |
| 910 | Genetic Variation in WNT9B Increases Relapse Hazard in Multiple Sclerosis. **2021**, 89, 884-894 | 2 |
| 909 | Cannabidiol and Other Cannabinoids in Demyelinating Diseases. **2021**, 22, | 2 |
| 908 | Early factors associated with later conversion to multiple sclerosis in patients presenting with isolated myelitis. **2021**, | 0 |
| 907 | Illuminating the in vitro effects of Epstein-Barr virus and vitamin D on immune response in multiple sclerosis patients. **2021**, 27, 260-271 | 3 |
| 906 | Involvement of cytotoxic Eomes-expressing CD4 T cells in secondary progressive multiple sclerosis. **2021**, 118, | 11 |
| 905 | Detection of Optic Neuritis on Routine Brain MRI without and with the Assistance of an Image Postprocessing Algorithm. **2021**, 42, 1130-1135 | 0 |

| 904 | Early multiple sclerosis: diagnostic challenges in clinically and radiologically isolated syndrome patients. **2021**, 34, 277-285 | 0 |
|---|---|---|
| 903 | Probing the Brain-Body Connection Using Transcranial Magnetic Stimulation (TMS): Validating a Promising Tool to Provide Biomarkers of Neuroplasticity and Central Nervous System Function. **2021**, 11, | 4 |
| 902 | Recommendations for the coordination of Neurology and Neuroradiology Departments in the management of patients with multiple sclerosis. **2021**, | |
| 901 | [From neuromyelitis optica to neuromyelitis optica spectrum disorder: from clinical syndrome to diagnistic classification]. **2021**, 92, 307-316 | 1 |
| 900 | Cerebrospinal fluid findings in patients with psychotic symptoms-a retrospective analysis. **2021**, 11, 7169 | 3 |
| 899 | Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective: A Review. **2021**, 78, 351-364 | 11 |
| 898 | Multiple Sclerosis Relapse Presenting as Sensorineural Hearing Loss. **2021**, 96, 767-768 | 0 |
| 897 | Perceived Fatigue Impact and Cognitive Variability in Multiple Sclerosis. **2021**, 1-11 | 1 |
| 896 | Effectiveness of Brainstem Auditory Evoked Potentials Scoring in Evaluating Brainstem Dysfunction and Disability Among Individuals With Multiple Sclerosis. **2021**, 30, 255-265 | 0 |
| 895 | Axonal loss in major sensorimotor tracts is associated with impaired motor performance in minimally disabled multiple sclerosis patients. **2021**, 3, fcab032 | 5 |
| 894 | Evaluation of Retinal Layer Thickness Parameters as Biomarkers in a Real-World Multiple Sclerosis Cohort. **2021**, 13, 59-69 | 5 |
| 893 | Machine learning-optimized Combinatorial MRI scale (COMRISv2) correlates highly with cognitive and physical disability scales in Multiple Sclerosis patients. | 1 |
| 892 | Dedicated 3D-T2-STIR-ZOOMit Imaging Improves Demyelinating Lesion Detection in the Anterior Visual Pathways of Patients with Multiple Sclerosis. **2021**, 42, 1061-1068 | 0 |
| 891 | Myelin and axon pathology in multiple sclerosis assessed by myelin water and multi-shell diffusion imaging. **2021**, 144, 1684-1696 | 15 |
| 890 | Multiple sclerosis, rituximab, and COVID-19. **2021**, 8, 938-943 | 14 |
| 889 | IgGs-Abzymes from the Sera of Patients with Multiple Sclerosis Recognize and Hydrolyze miRNAs. **2021**, 22, | 3 |
| 888 | Disease Progression and Obstetric Outcomes of Women with Multiple Sclerosis at a Reference Center in Northeastern Brazil. **2021**, 43, 165-171 | |
| 887 | Latent representation learning in biology and translational medicine. **2021**, 2, 100198 | 4 |

886 | Longitudinally Extensive Transverse Myelitis: A Retrospective Study Differentiating Neuromyelitis Optica Spectrum Disorder From Other Etiologies. **2021**, 13, e13968

885 | Analysis of Associations of Genetic Predisposition Markers Identified in Genome-Wide Studies with Multiple Sclerosis. **2021**, 51, 316-321

884 | Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study. **2021**, 12, 614715 | 6

883 | Gluten intolerance antibodies in multiple sclerosis and clinically isolated syndrome : Coexistent or coincidental?. **2021**, 12, 116-121 | 1

882 | Potential Role of CHI3L1+ Astrocytes in Progression in MS. **2021**, 8, | 2

881 | Secondary progressive sclerosis in Russia, medical and social characteristics of patients and urgent tasks of therapy. **2021**, 7-13 | 1

880 | Kinesiophobia in Stroke Patients, Multiple Sclerosis and Parkinson's Disesase. **2021**, 11, | 3

879 | 3D-Fast Gray Matter Acquisition with Phase Sensitive Inversion Recovery Magnetic Resonance Imaging at 3 Tesla: Application for detection of spinal cord lesions in patients with multiple sclerosis. **2021**, 16, e0247813 | 1

878 | Demographic features, behavioral measures, and clinical factors as predictors of cognitive function in patients with multiple sclerosis. **2021**, 49, 102758 | 0

877 | Maternal multiple sclerosis is not a risk factor for neurodevelopmental disorders in offspring. **2021**, 7, 20552173211017301

876 | Lower lymphocyte counts and older age are associated with reduced multiple sclerosis disease activity during dimethyl fumarate treatment. **2021**, 49, 102781 | 4

875 | Serum inflammatory markers in patients with multiple sclerosis and their association with clinical manifestations and MRI findings. **2021**, 1 | 1

874 | Brain microstructural and metabolic alterations detected in vivo at onset of the first demyelinating event. **2021**, 144, 1409-1421 | 7

873 | Differential patterns of parafoveal and peripapillary vessel density in multiple sclerosis and neuromyelitis optica spectrum disorder. **2021**, 49, 102780 | 8

872 | Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. **2021**, 49, 102695 | 4

871 | The effects of supervised versus home Pilates-based core stability training on lower extremity muscle strength and postural sway in people with multiple sclerosis. **2021**, 13524585211012202 | 1

870 | Early neuropsychological markers of cognitive involvement in multiple sclerosis. **2021**, 423, 117349 | 1

869 | Pathology-supported genetic testing as a method for disability prevention in multiple sclerosis (MS). Part I. Targeting a metabolic model rather than autoimmunity. **2021**, 36, 1151-1167 | 2

| 868 | Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America. **2021**, 79, 305-309 | 1 |
| 867 | Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis of. **2021**, 12, 651511 | 3 |
| 866 | Corneal Subbasal Nerve Plexus Evaluation by Confocal Microscopy in Multiple Sclerosis: A Potential New Biomarker. **2021**, 46, 1452-1459 | 4 |
| 865 | Seasonal patterns of relapse and disability in Danish MS patients: A population-based cohort study. **2021**, 49, 102739 | 1 |
| 864 | Altered distributions in circulating follicular helper and follicular regulatory T cells accountable for imbalanced cytokine production in multiple sclerosis. **2021**, 205, 75-88 | 1 |
| 863 | Longitudinal imaging of T-cells and inflammatory demyelination in a preclinical model of multiple sclerosis using F-FAraG PET and MRI. **2021**, | 3 |
| 862 | Case Report: Antibodies to the N-Methyl-D-Aspartate Receptor in a Patient With Multiple Sclerosis. **2021**, 12, 664364 | 0 |
| 861 | Thermal Liquid Biopsy (TLB) of Blood Plasma as a Potential Tool to Help in the Early Diagnosis of Multiple Sclerosis. **2021**, 11, | 3 |
| 860 | Longitudinal analysis of T1w/T2w ratio in patients with multiple sclerosis from first clinical presentation. **2021**, 27, 2180-2190 | 3 |
| 859 | Dual-Task Cost and Related Clinical Features in Patients With Multiple Sclerosis. **2021**, 25, 211-233 | 1 |
| 858 | Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. **2021**, | 8 |
| 857 | Susceptibility-weighted Imaging: Technical Essentials and Clinical Neurologic Applications. **2021**, 299, 3-26 | 16 |
| 856 | The Evolution of Neurofilament Light Chain in Multiple Sclerosis. **2021**, 15, 642384 | 11 |
| 855 | Co-existence of multiple sclerosis and germinoma in an adult male: Case report. **2021**, 12, 177 | |
| 854 | Magnetoencephalography and High-Density Electroencephalography Study of Acoustic Event Related Potentials in Early Stage of Multiple Sclerosis: A Pilot Study on Cognitive Impairment and Fatigue. **2021**, 11, | 1 |
| 853 | MRI characteristics of Japanese macaque encephalomyelitis: Comparison to human diseases. **2021**, 31, 480-492 | 0 |
| 852 | A Retrospective Exploratory Analysis on Cardiovascular Risk and Cognitive Dysfunction in Multiple Sclerosis. **2021**, 11, | 2 |
| 851 | Perinatal Depression and Anxiety in Women With Multiple Sclerosis: A Population-Based Cohort Study. **2021**, 96, e2789-e2800 | 1 |

| 850 | miR-155 as an Important Regulator of Multiple Sclerosis Pathogenesis. A Review. **2021**, 22, | 8 |

| 849 | Systematic Assessment of Medical Diagnoses Preceding the First Diagnosis of Multiple Sclerosis. **2021**, | 5 |

| 848 | A Novel Method to Measure Venular Perivascular Spaces in Patients with MS on 7T MRI. **2021**, 42, 1069-1072 | 1 |

| 847 | Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study. **2021**, 18, 1166-1174 | 10 |

| 846 | Evaluation of Prolonged Walking in Persons with Multiple Sclerosis: Reliability of the Spatio-Temporal Walking Variables during the 6-Minute Walk Test. **2021**, 21, | 2 |

| 845 | Assessment of cognitive functions in patients with multiple sclerosis applying the normative values of the Rao's brief repeatable battery in the Portuguese population. **2021**, 21, 170 | 0 |

| 844 | Disability progression in multiple sclerosis is associated with plasma neuroactive steroid profile. **2021**, 42, 5241-5247 | 2 |

| 843 | Improving MS patients' understanding of treatment risks and benefits in clinical consultations: A randomised crossover trial. **2021**, 49, 102737 | 1 |

| 842 | Speech Pathology-Specific Questionnaire for Persons with Multiple Sclerosis (SMS): adaptation, validation and preliminary assessment of the diagnostic potential. **2021**, 49, 102796 | 1 |

| 841 | Can pulse steroid therapy increase the risk of infection by COVID-19 in patients with multiple sclerosis?. **2021**, 203, 106563 | 4 |

| 840 | Stereotyped B-cell responses are linked to IgG constant region polymorphisms in multiple sclerosis. | 2 |

| 839 | A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues. **2021**, 18, 1602-1622 | 1 |

| 838 | Defining the disease course of TNF blockers-associated Multiple Sclerosis. **2021**, 353, 577525 | 3 |

| 837 | Scoring the 10-year risk of ambulatory disability in multiple sclerosis: the RoAD score. **2021**, 28, 2533-2542 | 3 |

| 836 | Subclinical atherosclerosis in patients with relapsing-remitting multiple sclerosis. **2021**, 1 | 1 |

| 835 | Multiple sclerosis: prevalence of the 'central vein' sign in white matter lesions on gadolinium-enhanced susceptibility-weighted images. **2021**, 34, 470-475 | 0 |

| 834 | Current role of evoked potentials in multiple sclerosis diagnostics and monitoring. **2021**, 22, 132-138 | |

| 833 | Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study. **2021**, 27, 2284-2287 | 4 |

| 814 | Prevalence and determinants of falls in persons with multiple sclerosis without a clinical disability. **2021**, 49, 102771 | 1 |

| 813 | Disruption of the Atrophy-based Functional Network in Multiple Sclerosis Is Associated with Clinical Disability: Validation of a Meta-Analytic Model in Resting-State Functional MRI. **2021**, 299, 159-166 | 0 |

| 812 | Reduction in circulating vitamin D binding protein in patients with multiple sclerosis. **2021**, 21, 168 | 3 |

| 811 | Multiple sclerosis in Kenya: Demographic and clinical characteristics of a registry cohort. **2021**, 7, 2055217321102278 | 0 |

| 810 | Gene expression profiles of YAP1, TAZ, CRB3, and VDR in familial and sporadic multiple sclerosis among an Iranian population. **2021**, 11, 7713 | 1 |

| 809 | Classification of neurological diseases using multi-dimensional CSF analysis. **2021**, 144, 2625-2634 | 6 |

| 808 | Multiple sclerosis lesion segmentation from brain MRI using U-Net based on wavelet pooling. **2021**, 16, 1459-1467 | 2 |

| 807 | Machine learning classifier to identify clinical and radiological features relevant to disability progression in multiple sclerosis. **2021**, 268, 4834-4845 | 4 |

| 806 | ACR Appropriateness Criteria  Myelopathy: 2021 Update. **2021**, 18, S73-S82 | 1 |

| 805 | Digital Twins for Multiple Sclerosis. **2021**, 12, 669811 | 32 |

| 804 | Multimodal peripheral fluid biomarker analysis in clinically isolated syndrome and early multiple sclerosis. **2021**, 50, 102809 | 0 |

| 803 | Differentiation between multiple sclerosis and neuromyelitis optica spectrum disorder using optical coherence tomography angiography. **2021**, 11, 10697 | 2 |

| 802 | Quantitative signal properties from standardized MRIs correlate with multiple sclerosis disability. **2021**, 8, 1096-1109 | 1 |

| 801 | MPRAGE to MP2RAGE UNI translation via generative adversarial network improves the automatic tissue and lesion segmentation in multiple sclerosis patients. **2021**, 132, 104297 | 2 |

| 800 | Un caso di vertigine a esordio acuto/subacuto in un adolescente. **2021**, 24, 130-137 | |

| 799 | In Vivo Induction of Regulatory T Cells Via CTLA-4 Signaling Peptide to Control Autoimmune Encephalomyelitis and Prevent Disease Relapse. **2021**, 8, 2004973 | 4 |

| 798 | Kappa-Free Light Chains in CSF Predict Early Multiple Sclerosis Disease Activity. **2021**, 8, | 8 |

| 797 | Can serum glial fibrillary acidic protein (GFAP) solve the longstanding problem of diagnosis and monitoring progressive multiple sclerosis. **2021**, 50, 102931 | 1 |

| | | |
|---|---|---|
| 796 | COVID-19 in a temporal relation to the onset of multiple sclerosis. **2021**, 50, 102863 | 5 |
| 795 | The relationship of HLA-G 14-bp insertion/deletion genetic polymorphism to the risk of multiple sclerosis and its clinical phenotypes. **2021**, 57, | 2 |
| 794 | Use of a panel of four microRNAs in CSF as a predicted biomarker for postoperative neoangiogenesis in moyamoya disease. **2021**, 27, 908-918 | 1 |
| 793 | Elucidating distinct clinico-radiologic signatures in the borderland between neuromyelitis optica and multiple sclerosis. **2021**, 1 | 1 |
| 792 | Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals. **2021**, 50, 102778 | 3 |
| 791 | The Smartphone App haMSter for Tracking Patient-Reported Outcomes in People With Multiple Sclerosis: Protocol for a Pilot Study. **2021**, 10, e25011 | 2 |
| 790 | Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres. **2021**, 13524585211012227 | 2 |
| 789 | Exosomes From Subjects With Multiple Sclerosis Express EBV-Derived Proteins and Activate Monocyte-Derived Macrophages. **2021**, 8, | 4 |
| 788 | Network Damage Predicts Clinical Worsening in Multiple Sclerosis: A 6.4-Year Study. **2021**, 8, | 5 |
| 787 | Modern Technologies in the Rehabilitation of Patients with Multiple Sclerosis and Their Potential Application in Times of COVID-19. **2021**, 57, | 6 |
| 786 | Assessing brain injury topographically using MR neurite orientation dispersion and density imaging in multiple sclerosis. **2021**, 31, 1003-1013 | 0 |
| 785 | Interplay Between Cognitive and Bowel/Bladder Function in Multiple Sclerosis. **2021**, | 0 |
| 784 | Myelopathies in patients older than 50: not to miss inflammatory etiologies. **2021**, 50, 102826 | |
| 783 | Association between familial Mediterranean fever and multiple sclerosis: A case series from the JIR cohort and systematic literature review. **2021**, 50, 102834 | 0 |
| 782 | Sleep disturbance and memory dysfunction in early multiple sclerosis. **2021**, 8, 1172-1182 | 1 |
| 781 | Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry. **2021**, 16, e0250820 | 4 |
| 780 | Sensitivity of T1/T2-weighted ratio in detection of cortical demyelination is similar to magnetization transfer ratio using post-mortem MRI. **2021**, 13524585211014760 | 2 |
| 779 | The Epidemiology of COVID-19 and MS-Related Characteristics in a National Sample of People With MS in China. **2021**, 12, 682729 | 0 |

| 778 | Videoconferencing and Multiple Sclerosis Management: Stopgap or Stay Tuned?. **2021**, 1-4 | 0 |
| 777 | Perturbed Microbiota/Immune Homeostasis in Multiple Sclerosis. **2021**, 8, | 7 |
| 776 | SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients. **2021**, 11, 10299 | 4 |
| 775 | OCT Variability Prevents Their Use as Robust Biomarkers in Multiple Sclerosis. **2021**, 15, 2025-2036 | 2 |
| 774 | False Positive Results in SARS-CoV-2 Serological Tests for Samples From Patients With Chronic Inflammatory Diseases. **2021**, 12, 666114 | 8 |
| 773 | Serum Short-Chain Fatty Acids and Associations With Inflammation in Newly Diagnosed Patients With Multiple Sclerosis and Healthy Controls. **2021**, 12, 661493 | 11 |
| 772 | Insights on the Relationship Between Hippocampal Connectivity and Memory Performances at the Early Stage of Multiple Sclerosis. **2021**, 12, 667531 | 1 |
| 771 | N,N-Dimethylglycine in patients with progressive multiple sclerosis: result of a pilot double-blind, placebo, controlled randomized clinical trial. **2021**, 3, 29 | 2 |
| 770 | Simultaneous T and mapping of multiple sclerosis lesions with radial RARE-EPI. **2021**, 86, 1383-1402 | 0 |
| 769 | MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study. **2021**, 424, 117385 | 2 |
| 768 | Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy. **2021**, 18, 1353-1374 | 7 |
| 767 | RISCOP-Cognitive profile in a Portuguese cohort of radiological isolated syndrome patients: A case-control study. **2021**, 50, 102832 | |
| 766 | Identification and diagnosis of Secondary Progressive Multiple Sclerosis during the clinical encounter: Results from a physician survey. **2021**, 50, 102858 | 0 |
| 765 | Prevalence of neuromyelitis optica spectrum disorder in Belo Horizonte, Southeast Brazil. **2021**, 50, 102807 | 7 |
| 764 | Fear and anxiety in patients with multiple sclerosis during COVID-19 pandemic; report of an Iranian population. **2021**, 50, 102798 | 10 |
| 763 | Multiple sclerosis patients have reduced resting and increased activated CD4CD25FOXP3T regulatory cells. **2021**, 11, 10476 | 3 |
| 762 | Cortical activity and gait parameter characteristics in people with multiple sclerosis during unobstructed gait and obstacle avoidance. **2021**, 86, 226-232 | 3 |
| 761 | Long-term trajectory of acquired demyelinating syndrome and multiple sclerosis in children. **2021**, 63, 1059-1065 | 0 |

| | | |
|---|---|---|
| 760 | Pediatric inflammatory demyelinating disorders and mimickers: How to differentiate with MRI?. **2021**, 20, 102801 | 0 |
| 759 | Cervical spinal degenerative disease in multiple sclerosis. **2021**, 28, 2497-2502 | 0 |
| 758 | A matter of atrophy: differential impact of brain and spine damage on disability worsening in multiple sclerosis. **2021**, 268, 4698-4706 | 3 |
| 757 | Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies. **2021**, 13524585211010294 | 2 |
| 756 | Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS). **2021**, 13, 207-223 | 1 |
| 755 | Early-Onset Alcohol Dependence and Multiple Sclerosis: Diagnostic Challenges. **2021**, 18, | 2 |
| 754 | Mass Cytometry Identifies Expansion of T-bet B Cells and CD206 Monocytes in Early Multiple Sclerosis. **2021**, 12, 653577 | 5 |
| 753 | Rabies vaccination and multiple sclerosis relapse: A retrospective cohort study. **2021**, 51, 102906 | 0 |
| 752 | Leg movement activity during sleep in multiple sclerosis with and without RLS. **2021**, | 1 |
| 751 | Differential Binding of Autoantibodies to MOG Isoforms in Inflammatory Demyelinating Diseases. **2021**, 8, | 2 |
| 750 | Skin and gut imprinted helper T cell subsets exhibit distinct functional phenotypes in central nervous system autoimmunity. **2021**, 22, 880-892 | 2 |
| 749 | Update on brain MRI for the diagnosis and follow-up of MS patients. **2021**, 50, 104067 | 0 |
| 748 | Non-standard computer perimetry in the diagnosis of some optic neuropathies. **2021**, 14, 75-87 | |
| 747 | Freiburg Neuropathology Case Conference : A´42-year-old Patient with Progressive Neurological Deficits, Multiple Brain Lesions and Accompanying Affection of Peripheral Nerves. **2021**, 31, 529-535 | 0 |
| 746 | Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort. **2021**, 1 | 3 |
| 745 | Pre-contrast T1-weighted imaging of the spinal cord may be unnecessary in patients with multiple sclerosis. **2021**, 31, 9316-9323 | |
| 744 | Effect of Whole-Body Cryotherapy on Morphological, Rheological and Biochemical Indices of Blood in People with Multiple Sclerosis. **2021**, 10, | 1 |
| 743 | Cerebrospinal Fluid Findings in 541 Patients With Clinically Isolated Syndrome and Multiple Sclerosis: A Monocentric Study. **2021**, 12, 675307 | 6 |

| | | |
|---|---|---|
| 742 | Macular vessel density differs in multiple sclerosis and neuromyelitis optica spectrum disorder: An optical coherence tomography angiography study. **2021**, 16, e0253417 | 2 |
| 741 | Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis. **2021**, 12, 701752 | 8 |
| 740 | The prevalence of anti-neurofascin-155 antibodies in patients with neuromyelitis optica spectrum disorders. **2021**, 206, 1-11 | 3 |
| 739 | Distinguishing the Diagnosis and Management of Sleep Disturbance and Sleep Disorders in Multiple Sclerosis. **2021**, 56, 157-174 | 0 |
| 738 | Designing a Self-Perception Cognitive Questionnaire for Italian Multiple Sclerosis Patients (Sclerosi Multipla Autovalutazione Cognitiva, SMAC). A Preliminary Exploratory Pilot Study. **2021**, 12, 668933 | 0 |
| 737 | Memory B Cells in Multiple Sclerosis: Emerging Players in Disease Pathogenesis. **2021**, 12, 676686 | 5 |
| 736 | Assessment of Macular Function by Multifocal Electroretinogram in Patients with Multiple Sclerosis Treated with Fingolimod. **2021**, 38, 3986-3996 | 1 |
| 735 | 10-Weeks of resistance training improves sleep quality and cardiac autonomic control in persons with multiple sclerosis. **2021**, 1-9 | 0 |
| 734 | Pregnancy-induced effects on memory B-cell development in multiple sclerosis. **2021**, 11, 12126 | 0 |
| 733 | A Pilot Study of 24-h Motor Activity Patterns in Multiple Sclerosis: Pre-Planned Follow-Up at 2 Years. **2021**, 3, 366-376 | |
| 732 | Effects of low vs. high frequency local vibration on mild-moderate muscle spasticity: Ultrasonographical and functional evaluation in patients with multiple sclerosis. **2021**, 51, 102930 | 2 |
| 731 | Nonlesional diffusely abnormal appearing white matter in clinically isolated syndrome: Prevalence, association with clinical and MRI features, and risk for conversion to multiple sclerosis. **2021**, 31, 981-994 | 1 |
| 730 | Genes and environment in multiple sclerosis: Impact of temporal changes in the sex ratio on recurrence risks. **2021**, 13524585211020221 | 1 |
| 729 | Neutrophil-lymphocyte ratio as a marker for disability and activity in multiple sclerosis. **2021**, 51, 102921 | 1 |
| 728 | Stressful life events and the risk of primary progressive multiple sclerosis: A population-based case-control study. **2021**, 51, 102937 | |
| 727 | Prenatal and perinatal factors associated with developing multiple sclerosis later in life: A systematic review and meta-analysis. **2021**, 20, 102823 | 1 |
| 726 | Resting-State Brain Network Deficits in Multiple Sclerosis Participants: Evidence from Electroencephalography and Graph Theoretical Analysis. **2021**, 11, 359-367 | 0 |
| 725 | Description and preliminary experience with Virtual Visit Assessment (ViVA) during the COVID-19 pandemic, a structured virtual management protocol for patients with multiple sclerosis. **2021**, 1 | 3 |

| 724 | Evaluation of Month of Birth in Neuromyelitis Optica Spectrum Disorders (NMSOD) and Multiple Sclerosis (MS). **2021**, 2021, 8874999 | 1 |
| 723 | State-of-the-Art Review: Demyelinating Diseases in Indonesia. **2021**, 2021, 1278503 | |
| 722 | Audio and vestibular analyses in patient with multiple sclerosis: a case–control study. 1-6 | 0 |
| 721 | Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis. **2021**, 90, 477-489 | 6 |
| 720 | Quantitative magnetic resonance imaging of brain anatomy and in vivo histology. **2021**, 3, 570-588 | 22 |
| 719 | Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. **2021**, 78, 726-735 | 4 |
| 718 | Multiple sclerosis projection in Tehran, Iran using Bayesian structural time series. **2021**, 21, 235 | 2 |
| 717 | Brainstem lesions are associated with diffuse spinal cord involvement in early multiple sclerosis. **2022**, 22, | |
| 716 | Serotonergic drug repurposing in multiple sclerosis: A new possibility for disease-modifying therapy. 13, | 0 |
| 715 | More Than Meets the Eye: Isolated Bilateral Abducens Nerve Palsy as the Initial Presentation of Multiple Sclerosis. **2022**, | |
| 714 | Functional connectivity in the dorsal network of the cervical spinal cord is correlated with diffusion tensor imaging indices in relapsing-remitting multiple sclerosis. **2022**, 103127 | 0 |
| 713 | Turning when using a smartphone in persons with and without neurologic conditions: an observational study. (Preprint). | |
| 712 | Optical Coherence Tomography and Optical Coherence Tomography with Angiography in Multiple Sclerosis. **2022**, 10, 1386 | 1 |
| 711 | Role of Multiple Vitamin D-Related Polymorphisms in Multiple Sclerosis Severity: Preliminary Findings. **2022**, 13, 1307 | |
| 710 | 18F-FDOPA and MRI Findings in a Case of Multiple Sclerosis. Publish Ahead of Print, | 0 |
| 709 | Relationship between cognition and treatment adherence to disease-modifying therapy in multiple sclerosis: a prospective, cross-sectional study. **2022**, 12, | |
| 708 | Recent advances in the longitudinal segmentation of multiple sclerosis lesions on magnetic resonance imaging: a review. | 0 |
| 707 | High-dimensional immune profiling identifies a biomarker to monitor dimethyl fumarate response in multiple sclerosis. **2022**, 119, | 1 |

706   Cautious optimism for the future of migraine treatment. **2022**, 52, 1112-1114

705   Acute posterior multifocal placoid pigment epitheliopathy resembling multiple sclerosis. practneurol-2022-003463

704   The relationship between stress, anxiety, and depression levels and pseudobulbar affect in patients with Multiple Sclerosis. 1-27

703   Can strength training modify voluntary activation, contractile properties and spasticity in Multiple Sclerosis?: a randomized controlled trial.. **2022**, 113932    0

702   Immune aging in multiple sclerosis is characterized by abnormal CD4 T cell activation and increased frequencies of cytotoxic CD4 T cells with advancing age. **2022**, 82, 104179    0

701   Clinical and diagnostic spectrum of optic neuritis: A single-center retrospective study of disorders associated with multiple sclerosis, anti-aquaporin-4 and anti-myelin oligodendrocyte glycoprotein antibodies. **2022**, 221, 107381

700   Is BDNF related to spatial-temporal gait parameters in people with multiple sclerosis? An observational study. **2022**, 66, 104064    0

699   How to choose initial treatment in multiple sclerosis patients: a case-based approach. **2022**, 80, 159-172

698   Differential diagnosis of demyelinating diseases: what's new?. **2022**, 80, 137-142

697   Neurologic adverse events of cancer immunotherapy. **2022**, 80, 270-280

696   D1 Receptor Blockade Suppresses the Function of Th-17 Cells in Multiple Sclerosis. **2022**, 52, 494-499

695   The relationship between cognition, education, and employment in multiple sclerosis patients. **2022**, 8, 205521732211183

694   Trail Making Test Could Predict Impairment in Cognitive Domains in Patients with Multiple Sclerosis: A Study of Diagnostic Accuracy.

693   Validation of a Denoising Method Using Deep Learning Based Reconstruction to Quantify Multiple Sclerosis Lesion Load on Fast FLAIR Imaging. **2022**, 43, 1099-1106    0

692   Potential Utility of Natural Products against Oxidative Stress in Animal Models of Multiple Sclerosis. **2022**, 11, 1495    0

691   Association between speech rate measures and cognitive function in people with relapsing and progressive multiple sclerosis. **2022**, 8, 205521732211198

690   Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis.    1

689   Characteristic retinal atrophy pattern allows differentiation between pediatric MOGAD and MS after a single optic neuritis episode.    0

670    The comorbidity and cognition in multiple sclerosis (CCOMS) neuroimaging protocol: Study rationale, MRI acquisition, and minimal image processing pipelines. 1,

669    Progressive Multiple Sclerosis. **2022**, 28, 1083-1103    0

668    Changes of retinal structure and visual function in patients with demyelinating transverse myelitis.

667    Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis. 135245852211186    1

666    Ocrelizumab-induced vulvovaginal pyoderma gangrenosum in a patient with relapsing-remitting multiple sclerosis. **2022**,    0

665    Differentiating central nervous system demyelinating disorders: The role of clinical, laboratory, imaging characteristics and peripheral blood type I interferon activity. 13,    1

664    Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosis. 13,    0

663    Goal-Setting in Multiple Sclerosis-Related Spasticity Treated with Botulinum Toxin: The GASEPTOX Study. **2022**, 14, 582    0

662    Screening for severe drug-drug interactions in patients with multiple sclerosis: A comparison of three drug interaction databases. 13,

661    Integrated single cell transcriptomics of cerebrospinal fluid cells in early Multiple Sclerosis.

660    Pediatric Acquired Demyelinating Disorders. **2022**, 28, 1104-1130

659    MULT°PL SKLEROZDA ANALOJ°K AKIL YRME.

658    Juvenile Idiopathic Arthritis, Uveitis and Multiple Sclerosis: Description of Two Patients and Literature Review. **2022**, 10, 2041

657    Effect of GBCA Use on Detection and Diagnostic Performance of the Central Vein Sign: Evaluation Using a 3T FLAIR* Sequence in Patients With Suspected Multiple Sclerosis.    1

656    Diagnosis of Multiple Sclerosis. **2022**, 28, 1006-1024

655    Myelin Oligodendrocyte GlycoproteinAssociated Disorders. **2022**, 28, 1171-1193

654    EpsteinBarr virus and multiple sclerosis.    7

653    Myelin oligodendrocyte glycoprotein-associated disease is associated with BANK1, RNASET2 and TNIP1 polymorphisms. **2022**, 577937    0

652    Relaxometry and brain myelin quantification with synthetic MRI in MS subtypes and their associations with spinal cord atrophy. **2022**, 103166

651    Younger age at multiple sclerosis onset is associated with worse outcomes at age 50. jnnp-2022-329353

650    Fatigue in Multiple Sclerosis Is Associated with Reduced Expression of Interleukin-10 and Worse Prospective Disease Activity. **2022**, 10, 2058    0

649    Multiple sclerosis diagnosis and phenotype identification by multivariate classification of in vivo frontal cortex metabolite profiles. **2022**, 12,

648    Biomarkers in Multiple Sclerosis.

647    Progressive motor impairment from critical demyelinating lesions of the cervicomedullary junction. 135245852211144    0

646    The CELLO Trial: Protocol of a Planned Phase 4 Study to Assess the Efficacy of Ocrelizumab in Patients With Radiologically Isolated Syndrome. **2022**, 104143

645    Dual Mechanism of Action of Curcumin in Experimental Models of Multiple Sclerosis. **2022**, 23, 8658    1

644    In vivo confocal microscopy of corneal nerve fiber damage in early course of multiple sclerosis.

643    Results of a study of the quality of life in patients with highly active multiple sclerosis in Russia. **2022**, 14, 9-15

642    CSF amyloid is not a prognostic marker in multiple sclerosis patients.. **2022**, 104096    0

641    Peripheral Nerve Involvement at First Diagnosis of Multiple Sclerosis. Publish Ahead of Print,

640    Cognitive impairment in multiple sclerosis phenotypes: Neuropsychological assessment in a portuguese sample. 1-10

639    Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4+ and CD8+ T´cell-SARS-CoV-2 response: comparison with a homemade interferon-release assay. **2022**, 122, 841-849    1

638    Genetics of multiple sclerosis: lessons from polygenicity. **2022**, 21, 830-842    2

637    CTGF/CCN2 has a possible detrimental role in the inflammation and the remyelination failure in the early stages of multiple sclerosis. **2022**, 371, 577936

636    Spectrum of pediatric acquired demyelinating syndromes (PADS) of the central nervous system in a tropical developing country: A 10-year retrospective study. **2022**, 104, 74-81

635    Central nervous system (CNS) inflammatory demyelinating diseases (IDDs) associated with COVID-19: A case series and review. **2022**, 371, 577939    1

634 Longitudinal visualization for exploratory analysis of multiple sclerosis lesions. **2022**, 107, 208-219 0

633 The heterogeneity of tissue destruction between iron rim lesions and non-iron rim lesions in multiple sclerosis: A diffusion MRI study. **2022**, 66, 104070 1

632 Clinical use of CSF neopterin levels in CNS demyelinating diseases. **2022**, 441, 120385

631 Association of self-reported adherence to the Mediterranean diet with anthropometric indices, comorbidities, and degree of disability in patients with multiple sclerosis. **2022**, 66, 104060 2

630 Seeing is believing: Identifying remyelination in the central nervous system. **2022**, 66, 102269 1

629 Identification of disability status in persons with multiple sclerosis by lower limb neuromuscular function Emphasis on rate of force development. **2022**, 67, 104082 0

628 Central vein sign in patients with inflammatory lesion of the upper cervical spinal cord on susceptibility weighted imaging at 3 tesla. Preliminary results. **2022**, 93, 11-14 0

627 MR imaging in children with transverse myelitis and acquired demyelinating syndromes. **2022**, 67, 104068

626 Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis. **2022**, 67, 104081

625 Pattern of thalamic nuclei atrophy in early relapse-onset multiple sclerosis. **2022**, 67, 104083

624 Validation of a brief cross-cultural cognitive screening test in Multiple Sclerosis. **2022**, 67, 104091 1

623 The age at onset of relapsing-remitting multiple sclerosis has increased over the last five decades. **2022**, 68, 104103 1

622 Delayed cognitive processing and treatment status quo bias in early-stage multiple sclerosis. **2022**, 68, 104138

621 Effects of hippotherapy simulation exercise vs. conventional home exercises on muscle strength and balance in people with multiple sclerosis: A randomized controlled trial. **2022**, 68, 104111

620 Associated factors of potential drug-drug interactions and drug Food interactions in patients with multiple sclerosis. **2022**, 13, 204062232211083 0

619 Dynamics of Inflammatory and Neurodegenerative Biomarkers after Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. **2022**, 23, 10946 1

618 Factors and strategies affecting motor imagery ability in people with multiple sclerosis: a systematic review. **2022**, 1

617 Correlation between patient-reported manual ability and three objective measures of upper limb function in people with Multiple Sclerosis. 0

| 616 | Validity and reliability characteristics of the Silhouettes Fatigue Scale in measuring multiple sclerosis-related fatigue in Turkish-speaking adults. | 0 |

| 615 | Functional Performance, Leg Muscle Strength, and Core Muscle Endurance in Multiple Sclerosis Patients With Mild Disability: A Cross-Sectional Study. **2022**, 26, 729-747 | 0 |

| 614 | Re-examining the characteristics of pediatric multiple sclerosis in the era of antibody-associated demyelinating syndromes. **2022**, 41, 8-18 | 0 |

| 613 | sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients. **2022**, 67, 104176 | 0 |

| 612 | Transcranial direct current stimulation for spasticity in patients with multiple sclerosis: Exploring novel routes. **2022**, 67, 104191 | 0 |

| 611 | Improvement in the multiple sclerosis functional composite score by multi-function swing suspension training program. **2022**, 67, 104174 | 0 |

| 610 | Interpreting the clinical importance of the relationship between subjective fatigue and cognitive impairment in multiple sclerosis (MS): How BICAMS performance is affected by MS-related fatigue. **2022**, 67, 104161 | 0 |

| 609 | Cognitive-motor interference in people with mild to moderate multiple sclerosis, in comparison with healthy controls. **2022**, 67, 104181 | 0 |

| 608 | Clinical onset of CNS demyelinating disease after COVID-19 vaccination: denovo disease?. **2022**, 67, 104175 | 0 |

| 607 | Stages of brain volume loss and performance in the Brief International Cognitive Assessment for Multiple Sclerosis. **2022**, 67, 104183 | 0 |

| 606 | Prevalence of multiple sclerosis in Guangzhou, China: A population-based case-finding prospective study. **2022**, 68, 104151 | 0 |

| 605 | Cut-off evaluation of intrathecal oligoclonal bands of IgM in relapsing-remitting multiple sclerosis; a retrospective study. **2022**, 68, 104188 | 0 |

| 604 | Multiple sclerosis and migraine: Links, management and implications. **2022**, 68, 104152 | 0 |

| 603 | Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis. **2022**, 68, 104167 | 2 |

| 602 | Core stability-based balance training and kinesio taping for balance, trunk control, fear of falling and walking capacity in patients with multiple sclerosis: A randomized single-blinded study. **2022**, 68, 104178 | 0 |

| 601 | EpsteinBarr virus antibody in newly diagnosed multiple sclerosis patients and its association with relapse severity and lesion location. **2022**, 68, 104149 | 0 |

| 600 | That would have been the perfect thing after diagnosisdevelopment of a digital lifestyle management application in multiple sclerosis. **2022**, 15, 175628642211187 | 0 |

| 599 | Expression analysis of miRNAs from the DLK1-DIO3 locus in CD4+ and CD14+ cells in patients with relapsing-remitting multiple sclerosis. **2022**, 122, 52 | 0 |

| | | |
|---|---|---|
| 598 | Detection of lesions in the optic nerve with magnetic resonance imaging using a 3D convolutional neural network. **2022**, 36, 103187 | 0 |
| 597 | A comparative assessment of myelin-sensitive measures in multiple sclerosis patients and healthy subjects. **2022**, 36, 103177 | 0 |
| 596 | Differential diagnosis of multiple sclerosis in children. **2022**, 122, 60 | 0 |
| 595 | Functional connectivity dynamics reflect disability and multi-domain clinical impairment in patients with relapsing-remitting multiple sclerosis. **2022**, 36, 103203 | 0 |
| 594 | Pathologie inflammatoire du´systḕe nerveux central. **2022**, 57-74 | 0 |
| 593 | Cortical lesions, central vein sign, and paramagnetic rim lesions in multiple sclerosis: Emerging machine learning techniques and future avenues. **2022**, 36, 103205 | 1 |
| 592 | Immunotherapy-responsive recurrent extensive white matter disease without neuronal or glial surface antibodies: A case report. **2022**, 2, 100142 | 0 |
| 591 | Timely intervention, monitoring and education MATTERS in MS (TIME MATTERS in MS): Development of a globally applicable quality improvement tool. **2022**, 8, 205521732211240 | 0 |
| 590 | Multiple sclerosis. **2022**, 81, 173-183 | 0 |
| 589 | Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic. | 0 |
| 588 | The Brave New World of Early Treatment of Multiple Sclerosis: Using the Molecular Biomarkers CXCL13 and Neurofilament Light to Optimize Immunotherapy. **2022**, 10, 2099 | 0 |
| 587 | Somatosensory evoked potentials and their relation to microstructural damage in patients with multiple sclerosisA whole brain DTI study. 13, | 0 |
| 586 | Reliability and acceptance of dreaMS, a software application for people with multiple sclerosis: a feasibility study. | 0 |
| 585 | Optical Coherence Tomography in Chronic Relapsing Inflammatory Optic Neuropathy, Neuromyelitis Optica and Multiple Sclerosis: A Comparative Study. **2022**, 12, 1140 | 0 |
| 584 | Validation of cognitive screening questionnaire for neurological disorders (CSQND) for screening of cognitive complaints among patients with multiple sclerosis. **2022**, 58, | 0 |
| 583 | Factors Related to the Progression of Clinically Isolated Syndrome to Multiple Sclerosis: A Retrospective Study in Lithuania. **2022**, 58, 1178 | 0 |
| 582 | Application of the International Interocular Difference Thresholds into Practice: Localising the Patient Experience. 1-8 | 0 |
| 581 | Hybrid and vaccine-induced immunity against SAR-CoV -2 in MS patients on different disease-modifying therapies. **2022**, 9, 1643-1659 | 0 |

580    Gadolinium-enhanced brain lesions in multiple sclerosis relapse. **2022**, 37, 557-563    0

579    Rapid, non-contact multifocal visual assessment in multiple sclerosis.    0

578    Evaluation of CSF kappa free light chains for the diagnosis of multiple sclerosis (MS): a comparison with oligoclonal bands (OCB) detection via isoelectric focusing (IEF) coupled with immunoblotting. jclinpath-2022-208354    0

577    The Role of Multiple Sclerosis Therapies on the Dynamic of Human Gut Microbiota.    0

576    T Lymphocyte Serotonin 5-HT7 Receptor Is Dysregulated in Natalizumab-Treated Multiple Sclerosis Patients. **2022**, 10, 2418    1

575    Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target. 13,    2

574    An algorithm to determine the date when the McDonald criteria are met for the diagnosis of relapsing-remitting multiple sclerosis. **2022**,    0

573    The Prevalence, Demographics, Clinical Features, Neuroimaging, and Interethnic Differences of MOG Disease in Malaysia with Global Perspectives. **2022**, 104168    0

572    Model of the Relationship of Religiosity and Happiness of Multiple Sclerosis Patients from Poland: The Role of Mediating and Moderating Variables. **2022**, 13, 862    0

571    Torso based balance weighting versus tailored physical therapy program in postural control in patients with multiple sclerosis. **2022**, 22, 142-147    0

570    The mSteps pilot study: Analysis of the distance walked using a novel smartphone application in multiple sclerosis. 135245852211240    0

569    Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment. **2022**,    0

568    Vaccination willingness in association with personality traits in patients with multiple sclerosis in the course of SARS-CoV-2 pandemic. **2022**, 12,    0

567    Neurodegeneration and humoral response proteins in cerebrospinal fluid associate with pediatric-onset multiple sclerosis and not monophasic demyelinating syndromes in childhood. 135245852211253    0

566    Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses. **2022**, 19,    2

565    Optic Neuritis in Multiple Sclerosis A Review of Molecular Mechanisms Involved in the Degenerative Process. **2022**, 44, 3959-3979    0

564    Multiple sclerosis in sarcoidosis patients: Two case reports. **2022**, 10,    0

563    Evaluation of Disability Progression in Multiple Sclerosis via Magnetic-Resonance-Based Deep Learning Techniques. **2022**, 23, 10651    0

| 562 | The role of machine learning in developing non-magnetic resonance imaging based biomarkers for multiple sclerosis: a´systematic´review. **2022**, 22, | 0 |
| 561 | Astrocytic SARM1 promotes neuroinflammation and axonal demyelination in experimental autoimmune encephalomyelitis through inhibiting GDNF signaling. **2022**, 13, | 0 |
| 560 | The Translatability of Multiple Sclerosis Animal Models for Biomarkers Discovery and Their Clinical Use. **2022**, 23, 11532 | 0 |
| 559 | Intrathecal B cell-related markers for an optimized biological investigation of multiple sclerosis patients. **2022**, 12, | 0 |
| 558 | Association of spinal cord lesions with cognition in multiple sclerosis. **2022**, 47, 1040-1049 | 0 |
| 557 | Cytokine Secretion Dynamics of Isolated PBMC after Cladribine Exposure in RRMS Patients. **2022**, 23, 10262 | 0 |
| 556 | Good prospects for optic neuropathies. **2022**, | 0 |
| 555 | Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis. | 0 |
| 554 | MRI Findings and Topographic Distribution of Lesions in Metronidazole-Induced Encephalopathy. **2022**, | 0 |
| 553 | Response to the letter synthetic double inversion recovery (DIR) and phase-sensitive inversion recovery (PSIR) images showed better delineation of multiple sclerosis plaques. **2022**, 64, 1915-1916 | 0 |
| 552 | IL-27 shapes the immune properties of human astrocytes and their impact on encountered human T lymphocytes. **2022**, 19, | 0 |
| 551 | Treatable Ataxias: How to Find the Needle in the Haystack?. **2022**, 15, 206-226 | 0 |
| 550 | Predictive Factors for Magnetic Resonance Imaging Changes Suggestive of Demyelination in Adult Patients with Uveitis Scanned Prior to Commencing Adalimumab Therapy. 1-9 | 0 |
| 549 | Progressive motor neuron syndromes with single CNS lesions and CSF oligoclonal bands: never forget solitary sclerosis!. | 0 |
| 548 | Safety and efficacy of tyrosine kinase inhibitors for the treatment of multiple sclerosis: A systematic review and meta-analysis from randomized controlled trials. 13, | 0 |
| 547 | Clinical and Genetic Analysis in Pediatric Patients with Multiple Sclerosis and Related Conditions: Focus on DR Genes of the Major Histocompatibility Complex. **2022**, 16, | 0 |
| 546 | Sensitivity and Specificity of Central Vein Sign as a Diagnostic Biomarker in Egyptian Patients with Multiple Sclerosis. Volume 18, 1985-1992 | 0 |
| 545 | Neurofilament light chain in blood as a diagnostic and predictive biomarker for multiple sclerosis: A systematic review and meta-analysis. **2022**, 17, e0274565 | 0 |

| | | |
|---|---|---|
| 526 | Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging. 10.1212/WNL.0000000000201465 | 1 |
| 525 | Sensitivity and specificity of visual evoked potentials for early diagnosis of demyelinating diseases. **2022**, 2, 193-198 | 0 |
| 524 | Dorsal medulla surface texture: Differentiating neuromyelitis optica spectrum disorder from multiple sclerosis. | 0 |
| 523 | COVID-19 Pandemisi ve Karantina Döneminde Çocuklarda Otoimmün Hastalıkların Sıklığının Pandemi Öncesi Döneme Göre Değerlendirilmesi. | 0 |
| 522 | Asymptomatic MRI lesions in pediatric-onset AQP4-IgG positive NMOSD. **2022**, 104215 | 0 |
| 521 | Cognitive dual-task cost depends on the complexity of the cognitive task, but not on age and disease. 13, | 0 |
| 520 | Cholesterol levels in plasma and cerebrospinal fluid in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis. **2022**, 105889 | 0 |
| 519 | Identification of specific causes of myelopathy in a large cohort of patients initially diagnosed with transverse myelitis. **2022**, 442, 120425 | 1 |
| 518 | Remission of idiopathic retroperitoneal fibrosis by ofatumumab as a disease-modifying therapy for multiple sclerosis. **2022**, 29, 100428 | 0 |
| 517 | Neurologic autoimmune diseases. **2022**, 887-975 | 0 |
| 516 | Mills Syndrome. **2022**, 122, 138 | 0 |
| 515 | An Analysis of Clinico-radiological Features and Outcome in Patients with Longitudinally Extensive Transverse Myelitis. **2022**, 70, 1925 | 0 |
| 514 | Effects of pulsed electromagnetic field therapy on fatigue, walking performance, depression, and quality of life in adults with multiple sclerosis: a randomized placebo-controlled trial. **2022**, 26, 100449 | 0 |
| 513 | B cell depletion attenuates CD27 signaling of T helper cells in multiple sclerosis. | 0 |
| 512 | Oligoclonal M bands and cervical spinal cord lesions predict early secondary progressive multiple sclerosis. 13, | 0 |
| 511 | Diagnostic performance of artificial intelligence in multiple sclerosis: a systematic review and meta-analysis. | 0 |
| 510 | A gene regulatory network approach harmonizes genetic and epigenetic signals and reveals repurposable drug candidates for multiple sclerosis. | 0 |
| 509 | An Update on Diagnostic Laboratory Biomarkers for Multiple Sclerosis. **2022**, 22, 675-688 | 1 |

| 508 | Early remission in multiple sclerosis is linked to altered coherence of the Cerebellar Network. **2022**, 20, | 1 |
| 507 | Aerospace Medicine Clinic. **2022**, 93, 764-766 | 0 |
| 506 | Reliability and validity of the Turkish version of speech pathology-specific questionnaire for persons with multiple sclerosis (SMS-TR). 1-8 | 0 |
| 505 | Toward In Vivo MRI of the Tissue Proton Exchange Rate in Humans. **2022**, 12, 815 | 1 |
| 504 | Prior optic neuritis detection on peripapillary ring scans using deep learning. | 0 |
| 503 | Isokinetic Resistance Training for Ankle Plantarflexor Spasticity and Muscle Weakness in People with Multiple Sclerosis: A Proof-of-Concept Case Series. | 0 |
| 502 | Correlation analysis between foveal avascular zone and near peripheral retinal hypoperfusion in multiple sclerosis: a wide field optical coherence tomography angiography study. 9, | 0 |
| 501 | Change in upper limb function in people with multiple sclerosis treated with nabiximols: a quantitative kinematic pilot study. | 0 |
| 500 | Lesion follows function: video-oculography compared with MRI to diagnose internuclear ophthalmoplegia in patients with multiple sclerosis. | 0 |
| 499 | Prefrontal hemodynamics during forward and backward walking, with and without a cognitive task, in people with MS: An fNIRS study. | 0 |
| 498 | The association between PD-1 gene polymorphisms and susceptibility to multiple sclerosis. 1-8 | 0 |
| 497 | Microglial/macrophage activation in the cerebrospinal fluid of neuromyelitis optica spectrum disorders. | 0 |
| 496 | Updates and advances in multiple sclerosis neurotherapeutics. | 1 |
| 495 | Immunopathogenesis, Diagnosis, and Treatment of Multiple Sclerosis. **2022**, | 0 |
| 494 | Persistent MRI-negative lupus myelitis-disease presentation, immunological profile and outcome. 13, | 0 |
| 493 | Multiple Sclerosis Followed by Neuromyelitis Optica Spectrum Disorder. **2023**, 10, e200037 | 0 |
| 492 | Neurofilament Light Chain Levels Are Predictive of Clinical Conversion in Radiologically Isolated Syndrome. **2023**, 10, e200044 | 0 |
| 491 | Automated segmentation of multiple sclerosis lesions based on convolutional neural networks. 1-19 | 0 |

| | | |
|---|---|---|
| 490 | Somatosensory evoked potentials and magnetic resonance imaging of the central nervous system in early multiple sclerosis. | 0 |
| 489 | Diagnosis and treatment of progressive multiple sclerosis: A position paper. | 0 |
| 488 | Validation of the Czech Version of the Dysphagia in Multiple Sclerosis Questionnaire (DYMUS). | 0 |
| 487 | Involvement of NINJ2 Protein in Inflammation and Blood Brain Barrier Transmigration of Monocytes in Multiple Sclerosis. **2022**, 13, 1946 | 0 |
| 486 | Serum and CSF Biomarkers Predict Active Early Cognitive Decline Rather Than Established Cognitive Impairment at the Moment of RRMS Diagnosis. **2022**, 12, 2571 | 1 |
| 485 | Whole-brain propagation delays in multiple sclerosis, a combined tractography - magnetoencephalography study. JN-RM-0938-22 | 0 |
| 484 | No seasonality in the risk of multiple sclerosis in an equatorial country: A case control ecological study. 135245852211300 | 0 |
| 483 | Fecal Lcn-2 level is a sensitive biological indicator for gut dysbiosis and intestinal inflammation in multiple sclerosis. 13, | 0 |
| 482 | Measurement of D-dimer in cerebrospinal fluid using a luminescent oxygen channeling immunoassay. 13, | 0 |
| 481 | New lesion segmentation for multiple sclerosis brain images with imaging and lesion-aware augmentation. 16, | 0 |
| 480 | Multiple Sclerosis Diagnosis Using Machine Learning and Deep Learning: Challenges and Opportunities. **2022**, 22, 7856 | 4 |
| 479 | Investigating the role of common and rare variants in multiplex multiple sclerosis families reveals an increased burden of common risk variation. **2022**, 12, | 0 |
| 478 | A Review of Compartmentalised Inflammation and Tertiary Lymphoid Structures in the Pathophysiology of Multiple Sclerosis. **2022**, 10, 2604 | 0 |
| 477 | Semisupervised white matter hyperintensities segmentation on MRI. | 0 |
| 476 | Metabolic Syndrome parameters and Multiple Sclerosis disease outcomes: a Portuguese cross-sectional study. **2022**, 104370 | 0 |
| 475 | Correlation between ERβ gene polymorphism and multiple sclerosis and neuromyelitis optica. **2022**, 101, e31126 | 0 |
| 474 | Patient's perspective in clinical practice to assess and predict disability in multiple sclerosis. **2022**, 12, | 0 |
| 473 | Primary angiitis of the central nervous system as a mimic of multiple sclerosis: A case report. **2022**, 577991 | 0 |

| 472 | Inflammatory Optic Neuropathy as a Presenting Feature of Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy. 194187442211326 | 0 |
| 471 | Genetic risk variants for multiple sclerosis are linked to differences in alternative pre-mRNA splicing. 13, | 0 |
| 470 | Tablet app-based dexterity training in multiple sclerosis (TAD-MS): a randomized controlled trial. 1-11 | 0 |
| 469 | Trans-Endothelial Migration of Memory T Cells Is Impaired in Alemtuzumab-Treated Multiple Sclerosis Patients. **2022**, 11, 6266 | 0 |
| 468 | CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis. | 1 |
| 467 | Case Report and Clinical Reasoning: Fulminant Liver Failure and Invasive Aspergillosis Following Ocrelizumab Treatment in a 21 Year-Old Woman. 194187442211303 | 0 |
| 466 | Clinical Reasoning: A 6-Year-Old Girl With Right-Sided Pain and Weakness. 10.1212/WNL.0000000000201481 | 0 |
| 465 | Quantification and Proximal-to-Distal Distribution Pattern of Tibial Nerve Lesions in Relapsing-Remitting Multiple Sclerosis. | 0 |
| 464 | Trends in the environmental risks associated with earlier onset in multiple sclerosis. **2022**, 104250 | 2 |
| 463 | Involvement of the central nervous system in patient with chronic inflammatory demyelinating polyneuropathy: a case report. **2022**, 13, 77-87 | 0 |
| 462 | Effect of Estimated Blood Volume and Body Mass Index on GFAP and NfL Levels in the Serum and CSF of Patients With Multiple Sclerosis. **2023**, 10, e200045 | 1 |
| 461 | Pathogenic and clinical implications of serum protein biomarkers in idiopathic transverse myelitis. | 0 |
| 460 | Development of the Web-Based Spanish Version of the Barthel Index in Patients with Multiple Sclerosis. **2022**, 19, 13965 | 0 |
| 459 | A proposed new taxonomy of cognitive phenotypes in multiple sclerosis: The International Classification of Cognitive Disorders in MS (IC-CoDiMS). 135245852211279 | 0 |
| 458 | Toward an Automatic Assessment of Cognitive Dysfunction in Relapsing-Remitting Multiple Sclerosis Patients Using Eye Movement Analysis. **2022**, 22, 8220 | 0 |
| 457 | Oral health-related quality of life is more strongly correlated with mental health than with oral health in relapsing-remitting multiple sclerosis. | 0 |
| 456 | Brain age gap in neuromyelitis optica spectrum disorders and multiple sclerosis. jnnp-2022-329680 | 0 |
| 455 | Quantitative spinal cord MRI and sexual dysfunction in multiple sclerosis. **2022**, 8, 205521732211321 | 1 |

| 454 | Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review. 13, | 0 |
| 453 | Glucocorticoids and COVID-19. **2022**, 185, 106511 | 1 |
| 452 | Contemporary study of multiple sclerosis disability in South East Wales. jnnp-2022-330013 | 0 |
| 451 | Perturbation-based Balance Training to improve postural responses and falls in people with multiple sclerosis: a randomized controlled trial. 1-7 | 0 |
| 450 | Argentinean consensus recommendations for the use of telemedicine in clinical practice in adult people with multiple sclerosis. | 0 |
| 449 | MCAM+ brain endothelial cells contribute to neuroinflammation by recruiting pathogenic CD4+ T lymphocytes. | 1 |
| 448 | Performance in information processing speed is associated with parietal white matter tract integrity in multiple sclerosis. 13, | 0 |
| 447 | Training-dependent plasticity and far transfer effect enhanced by Bobath rehabilitation in Multiple Sclerosis. **2022**, 68, 104241 | 0 |
| 446 | K index utility as diagnostic and prognostic biomarker in the assessment of patients with suspected Multiple Sclerosis. **2022**, 373, 577992 | 0 |
| 445 | Epidemiologic trends of multiple sclerosis in Puerto Rico (2013⊠020). **2022**, 68, 104240 | 0 |
| 444 | B-lymphocyte-guided retreatment contributes to establish good effectiveness and safety profile in MS patients treated with rituximab. **2022**, 68, 104218 | 0 |
| 443 | Objective perimetry and progression of multiple sclerosis. **2022**, 29, 100430 | 0 |
| 442 | Posterior tibial nerve stimulation as a neuromodulation therapy in treatment of neurogenic overactive bladder in multiple sclerosis: A prospective randomized controlled study. **2022**, 68, 104252 | 0 |
| 441 | Modulation of salivary ICAM-1 and SIRT1 by disease modifying drugs in undepressed relapsing-remitting multiple sclerosis patients. **2022**, 68, 104257 | 0 |
| 440 | Brain volumetric correlates of remotely versus in-person administered symbol digit modalities test in multiple sclerosis. **2022**, 68, 104247 | 0 |
| 439 | Ocrelizumab treatment in newly diagnosed multiple sclerosis patients with previous Hodgkin's lymphoma. **2022**, 2, 100151 | 0 |
| 438 | Feasibility of a smartphone app to monitor patient reported outcomes in multiple sclerosis: The haMSter interventional trial. **2022**, 8, 205520762211353 | 0 |
| 437 | Demyelinating syndromes and movement disorders. **2023**, 567-584 | 0 |

| 436 | Reply to the Letter: Abnormal cerebrospinal fluid composition can accompany CNS involvement in COVID-19 2022, 80, 979-982 | 0 |
| 435 | Bright light therapy as a non-pharmacological treatment option for multiple sclerosis-related fatigue: A randomized sham-controlled trial. 2022, 8, 205521732211332 | 1 |
| 434 | Association of the retinal vasculature, intrathecal immunity, and disability in multiple sclerosis. 13, | 0 |
| 433 | Optical coherence tomography as a prognostic tool for disability progression in MS: a systematic review. | 0 |
| 432 | Multiple sclerosis patients response to COVID-19 pandemic and vaccination in Egypt. 2022, 58, | 0 |
| 431 | Commercial volumetric MRI reporting tools in multiple sclerosis: a systematic review of the evidence. | 0 |
| 430 | Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers in Primary Progressive Multiple Sclerosis and Hereditary Spastic Paraplegia Type 4. 2022, 23, 13466 | 0 |
| 429 | Limb apraxia in individuals with Multiple Sclerosis: is there a role of semi-immersive virtual reality in treating the Cinderella of neuropsychology?. 2022, 104405 | 1 |
| 428 | Maternal Multiple Sclerosis and Offspring Cognitive and Behavioral Development: What Do We Know until Now?. 2022, 9, 1716 | 0 |
| 427 | Synthetic Post-Contrast Imaging through Artificial Intelligence: Clinical Applications of Virtual and Augmented Contrast Media. 2022, 14, 2378 | 0 |
| 426 | Persistence with Botulinum Toxin Treatment for Spasticity Symptoms in Multiple Sclerosis. 2022, 14, 774 | 1 |
| 425 | The Impact of Highly Effective Treatment in Pediatric-Onset Multiple Sclerosis: A Case Series. 2022, 9, 1698 | 0 |
| 424 | Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD. 13, | 1 |
| 423 | Alterations of Thalamic Nuclei Volumes and the Intrinsic Thalamic Structural Network in Patients with Multiple Sclerosis-Related Fatigue. 2022, 12, 1538 | 0 |
| 422 | Working memory dysfunction differs between secondary progressive and relapsing multiple sclerosis: effects of clinical phenotype, age, disease duration, and disability. 2022, 104411 | 0 |
| 421 | In silico clinical trials for relapsing-remitting multiple sclerosis with MS TreatSim. 2022, 22, | 0 |
| 420 | Brief International Cognitive Assessment for MS (BICAMS) and global brain volumes in early stages of MS  a longitudinal correlation study. 2022, 104398 | 0 |
| 419 | A continuum of languishing to flourishing: exploring experiences of psychological resilience in multiple sclerosis family caregivers. 2022, 17, | 0 |

| 418 | Immune-mediated diseases involving central and peripheral nervous systems. | o |
| 417 | Machine learning-optimized Combinatorial MRI scale (COMRISv2) correlates highly with cognitive and physical disability scales in Multiple Sclerosis patients. 2, | o |
| 416 | Resting-state functional MRI in multicenter studies on multiple sclerosis: a report on raw data quality and functional connectivity features from the Italian Neuroimaging Network Initiative. | o |
| 415 | Ensemble machine learning identifies genetic loci associated with future worsening of disability in people with multiple sclerosis. **2022**, 12, | o |
| 414 | Multiplex Analysis of Serum Cytokine Profiles in Systemic Lupus Erythematosus and Multiple Sclerosis. **2022**, 23, 13829 | o |
| 413 | Analysis of herpesvirus infection and genome single nucleotide polymorphism risk factors in multiple sclerosis, Volga federal district, Russia. 13, | o |
| 412 | The relation between the symbol digit modalities test, fatigue, depression, and anxiety symptoms in a Belgian MS cohort. | o |
| 411 | Neurofilament light chains in serum as biomarkers of axonal damage in early MS lesions: a histologicalŠerological correlative study. | o |
| 410 | Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis. **2023**, 10, e200052 | 1 |
| 409 | Cognitive deficits in multiple sclerosis: Auditory and Visual Attention and inhibitory Control. | o |
| 408 | Mitochondrial Impairments in Peripheral Blood Mononuclear Cells of Multiple Sclerosis Patients. **2022**, 11, 1633 | o |
| 407 | Periventricular diffusion gradient of normal-appearing white matter and its transcriptional signatures in normal aging and multiple neurological diseases. | o |
| 406 | Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis. **2023**, 10, e200049 | 1 |
| 405 | Integration of small RNAs from plasma and cerebrospinal fluid for classification of multiple sclerosis. 13, | o |
| 404 | VEP Score of a Left Eye Had Predictive Values for Achieving NEDA-3 over Ten Years in Patients with Multiple Sclerosis. **2022**, 22, 8849 | o |
| 403 | Health-related quality of life in Japanese patients with multiple sclerosis. | o |
| 402 | What is the potential of paramagnetic rim lesions as diagnostic indicators in multiple sclerosis?. 1-9 | o |
| 401 | Objective and subjective measures of daily physical activity in persons with Multiple Sclerosis beginning a rehabilitation regime: A cross-sectional study. **2022**, 68, 104394 | o |

| 400 | Characteristics of cognitive impairment in multiple sclerosis patients depending on different risk factors. **2021**, 39-48 | 0 |
| 399 | Chasing Shadows: Cytologically detected Shadow Cells in the Cerebrospinal Fluid of Patients with Multiple Sclerosis. **2022**, 104420 | 0 |
| 398 | Subtypes of Relapsing-Remitting Multiple Sclerosis Identified by Network Analysis. | 0 |
| 397 | Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome. | 0 |
| 396 | Prognostic Significance of Neurofilament light in Fingolimod therapy for Multiple Sclerosis: A Systemic Review and Meta-Analysis based on Randomized Control Trials. **2022**, 104416 | 0 |
| 395 | Longitudinal Postvaccine SARS-CoV-2 Immunoglobulin G Titers, Memory B-Cell Responses, and Risk of COVID-19 in Multiple Sclerosis Over 1 Year. **2023**, 10, e200043 | 0 |
| 394 | Comparing pre- and post-diagnosis presentations of multiple sclerosis and other inflammatory diseases in primary care: an agnostic study of French and British health records.. | 0 |
| 393 | Multiple sclerosis progression: time for a new mechanism-driven framework. **2022**, | 0 |
| 392 | Optical coherence tomography (OCT) measurements and cognitive performance in multiple sclerosis: a systematic review and meta-analysis. | 0 |
| 391 | Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: Onset Following Acute COVID-19 Infection, a Case Series. | 0 |
| 390 | Experience of remote rehabilitation for patients with multiple sclerosis. **2022**, 122, 69 | 0 |
| 389 | Patient Satisfaction in a Multidisciplinary Multiple Sclerosis Care Unit: A Swiss Single-centre Study. **2022**, 18, 142 | 0 |
| 388 | Comparative effectiveness of natalizumab versus ocrelizumab in multiple sclerosis: a real-world propensity score matched study. **2022**, 15, 175628642211429 | 0 |
| 387 | Effect of immersive virtual reality training on hand-to-mouth task performance in people with Multiple Sclerosis: A quantitative kinematic study. **2023**, 69, 104455 | 0 |
| 386 | Changes in diffusion tensor imaging indices in basal ganglia and thalamus of patients with Relapsing-Remitting Multiple Sclerosis and relation with clinical conditions: A case-control study. **2023**, 10, 100465 | 0 |
| 385 | Early onset multiple sclerosis and the effect of disease onset age on neurological disability in multiple sclerosis. **2023**, 224, 107528 | 0 |
| 384 | Mobility and balance rehabilitation in multiple sclerosis: A systematic review and dose-response meta-analysis. **2023**, 69, 104424 | 0 |
| 383 | Relapsing-remitting and primary progressive multiple sclerosis treated with ocrelizumab: A comparative study. **2023**, 69, 104441 | 0 |

| 382 | Effect of multiple sclerosis disease-modifying therapies on the real-world effectiveness of two doses of BBIBP-CorV (Sinopharm) vaccine. **2023**, 444, 120518 | 0 |
| --- | --- | --- |
| 381 | Liposome-based nanoparticles impact on regulatory and effector phenotypes of macrophages and T cells in multiple Sclerosis patients. **2023**, 292, 121930 | 0 |
| 380 | Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with´multiple sclerosis in the USA. **2023**, 12, | 0 |
| 379 | Facial emotion impairment in multiple sclerosis is linked to modifying observation strategies of emotional faces. **2023**, 69, 104439 | 0 |
| 378 | Experiences of health tracking in mobile apps for multiple sclerosis: A qualitative content analysis of user reviews. **2023**, 69, 104435 | 0 |
| 377 | Sensitivity of conventional cognitive tests in multiple sclerosis: Application of item response theory. **2023**, 69, 104440 | 0 |
| 376 | Clinical correlates of state and trait anxiety in multiple sclerosis. **2023**, 69, 104431 | 0 |
| 375 | Cognitive fatigue-related sensory gating deficits in people with multiple sclerosis. **2023**, 176, 105950 | 0 |
| 374 | Age-related blood transcriptional regulators affect disease progression in pediatric multiple sclerosis. **2023**, 176, 105953 | 0 |
| 373 | Arzneimittelversorgung bei Multipler Sklerose. **2022**, 139-159 | 0 |
| 372 | Circulating CCR6 + ILC proportions are lower in multiple sclerosis patients. **2022**, 11, | 0 |
| 371 | Fragiles but Resilient. The Key Strategies to Cope with Pandemic in Persons with Multiple Sclerosis. A Controlled Web Survey. **2021**, 3, 31-49 | 0 |
| 370 | Association between brain volume and disability over time in multiple sclerosis. **2022**, 8, 205521732211442 | 0 |
| 369 | Multiple sclerosis in children. **2022**, 870-877 | 0 |
| 368 | Percentage brain volume change in multiple sclerosis mainly reflects white matter and cortical volume. | 0 |
| 367 | High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation in multiple sclerosis: preliminary clinical results of approbation of the method. **2022**, 27, 25-35 | 0 |
| 366 | Improving the detection of new lesions in multiple sclerosis with a cascaded 3D fully convolutional neural network approach. 16, | 0 |
| 365 | Blood Metabolomics May Discriminate a Sub-Group of Patients with First Demyelinating Episode in the Context of RRMS with Increased Disability and MRI Characteristics Indicative of Poor Prognosis. **2022**, 23, 14578 | 0 |

| | | |
|---|---|---|
| 364 | Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD. **2023**, 10, e200065 | 0 |
| 363 | Mass cytometry reveals cladribine-induced resets among innate lymphoid cells in multiple sclerosis. **2022**, 12, | 0 |
| 362 | Immune Response after COVID-19 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs. **2022**, 10, 3034 | 0 |
| 361 | Conceptualization, use, and outcomes associated with compassion in the care of people with multiple sclerosis: a scoping review. | 0 |
| 360 | Diagnostik der Neuromyelitis-optica-Spektrum-Erkrankung (NMOSD) und der MOG-Antikörper-assoziierten Erkrankung (MOGAD). **2022**, 239, 1315-1324 | 0 |
| 359 | Microstates in multiple sclerosis: an electrophysiological signature of altered large-scale networks functioning?. | 0 |
| 358 | External validation of a clinical prediction model in multiple sclerosis. 135245852211360 | 0 |
| 357 | Not all roads lead to the immune system: the genetic basis of multiple sclerosis severity. | 0 |
| 356 | Excess costs of multiple sclerosis: a register-based study in Sweden. | 0 |
| 355 | Separation Imaging for Diagnosis of Multiple Sclerosis versus Neuromyelitis Optica Spectrum Disorder. | 0 |
| 354 | Demyelinating diseases of the central nervous system registry for patients with traditional Chinese medicine: Rationale and design of a prospective, multicenter, observational study. 13, | 0 |
| 353 | Myelin heterogeneity for assessing normal appearing white matter myelin damage in multiple sclerosis. | 0 |
| 352 | Serum Neurofilament Identifies Patients With Multiple Sclerosis With Severe Focal Axonal Damage in a 6-Year Longitudinal Cohort. **2023**, 10, e200055 | 0 |
| 351 | Turning and multitask gait unmask gait disturbance in mild-to-moderate multiple sclerosis: Underlying specific cortical thinning and connecting fibers damage. | 1 |
| 350 | Endocannabinoid levels in peripheral blood mononuclear cells of multiple sclerosis patients treated with dimethyl fumarate. **2022**, 12, | 0 |
| 349 | Treatment of multiple sclerosis-related trigeminal neuralgia with onabotulinumtoxinA. **2022**, 62, 1322-1328 | 0 |
| 348 | Present and future of the diagnostic work-up of multiple sclerosis: the imaging perspective. | 0 |
| 347 | Effect of fingolimod therapy on quantitative macular changes among patients with relapsing-remitting multiple sclerosis: a four-year follow-up study from Oman. **2022**, 22, | 0 |

| 346 | Multiple sclerosis iron rim lesions are linked to impaired cervical spinal cord integrity using the T1/T2-weighted ratio. | 0 |
| 345 | Two Single Nucleotide Polymorphisms in the Purinergic Receptor P2X7 Gene Are Associated with Disease Severity in Multiple Sclerosis. **2022**, 23, 15381 | 0 |
| 344 | Evaluation of Selected Oxidant/Antioxidant Parameters in Patients with Relapsing-Remitting Multiple Sclerosis Undergoing Disease-Modifying Therapies. **2022**, 11, 2416 | 0 |
| 343 | Neuroaxonal and Glial Markers in Patients of the Same Age With Multiple Sclerosis. **2023**, 10, e200078 | 0 |
| 342 | Redox State of Human Serum Albumin in Multiple Sclerosis: A Pilot Study. **2022**, 23, 15806 | 0 |
| 341 | Frequent somatic mosaicism in T lymphocyte subsets in individuals with and without multiple sclerosis. 13, | 0 |
| 340 | The Clinical and Epidemiological Profile of Paediatric-Onset Multiple Sclerosis in Poland. **2022**, 11, 7494 | 0 |
| 339 | A novel eye-movement impairment in multiple sclerosis indicating wide-spread cortical damage. | 0 |
| 338 | Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies. jnnp-2022-330175 | 0 |
| 337 | Pseudo-Label Assisted Nnu-Net (PLAn) Enables Automatic Segmentation of 7T MRI From a Single Acquisition. | 0 |
| 336 | Selective vulnerability of brainstem and cervical spinal cord regions in people with non-progressive multiple sclerosis of Black or African American and European ancestry. 135245852211395 | 0 |
| 335 | Multiple Sclerosis Presenting as Intracranial Hypertension in the Setting of COVID-19 Infection. | 0 |
| 334 | Berlin Registry of Neuroimmunological entities (BERLimmun): protocol of a prospective observational study. **2022**, 22, | 0 |
| 333 | Evaluating the central vein sign in paediatric-onset multiple sclerosis: A case series study. 135245852211423 | 0 |
| 332 | Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis. 135245852211419 | 1 |
| 331 | Frequency of NMOSD misdiagnosis in a cohort from Latin America: Impact and evaluation of different contributors. 135245852211362 | 0 |
| 330 | Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement. 135245852211342 | 0 |
| 329 | Magnetization transfer saturation reveals subclinical optic nerve injury in pediatric-onset multiple sclerosis. 135245852211375 | 0 |

| 328 | Treatment of neuromyelitis optica spectrum disorder: revisiting the complement system and other aspects of pathogenesis. | 0 |
| 327 | Task-based functional MRI challenges in clinical neuroscience: Choice of the best head motion correction approach in multiple sclerosis. 16, | 0 |
| 326 | Diagnose und Therapie der Multiplen Sklerose. **2022**, 05, 292-300 | 0 |
| 325 | The different damage patterns of short-, middle- and long-range connections between patients with relapse-remitting multiple sclerosis and neuromyelitis optica spectrum disorder. 13, | 0 |
| 324 | Polysomnographic diagnosis of REM sleep behavior disorder: a change is needed. | 0 |
| 323 | Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis. 135245852211391 | |
| 322 | Estimated Prevalence of AQP4 positive Neuromyelitis Optica Spectrum Disorder and MOG Antibody Associated Disease in São Paulo, Brazil. **2022**, 104488 | 0 |
| 321 | Investigation of image-derived input functions for non-invasive quantification of myelin density using [11C]MeDAS PET. **2022**, 264, 119772 | 0 |
| 320 | Effect of deep gray matter atrophy on information processing speed in early relapsing- remitting multiple sclerosis. | 0 |
| 319 | Adipokines in multiple sclerosis patients are related to clinical and radiological measures. | 0 |
| 318 | The efficacy and safety of ginger supplementation in patients with multiple sclerosis: A rationale and study protocol for a double-blind randomized controlled trial. **2023**, 6, | 0 |
| 317 | Association Between Body Mass Index and Response to Disease-Modifying Therapies in Patients With Relapsing-Remitting Multiple Sclerosis at King Abdulaziz University Hospital: A Retrospective Study. **2022**, | 0 |
| 316 | Energy expenditure and perceived effort during uphill and downhill walking in people with multiple sclerosis. | 0 |
| 315 | Association of paramagnetic rim lesions and retinal layer thickness in patients with multiple sclerosis. 135245852211384 | 0 |
| 314 | CNS inflammatory demyelinating events after COVID-19 vaccines: A case series and systematic review. 13, | 0 |
| 313 | Leistungsfähigkeit der McDonald-Kriterien von 2017. | 0 |
| 312 | The Role of Multiple Sclerosis Therapies on the Dynamic of Human Gut Microbiota. | 0 |
| 311 | Clinical Neuroimaging in Pediatric Dysimmune Disorders of the Central Nervous System. **2022**, | 0 |

| 310 | New Contrast Enhancement Method for Multiple Sclerosis Lesion Detection. | 0 |
|-----|--------------------------------------------------------------------------|---|
| 309 | Effect of exergaming in people with restless legs syndrome with multiple sclerosis: a single-blind randomized controlled trial. **2022**, 104480 | 0 |
| 308 | Exercise therapy for fatigue in multiple sclerosis. **2022**, 2022, | 0 |
| 307 | Vitamin D Supplementation Practices among Multiple Sclerosis Patients and Professionals. **2022**, 11, 7278 | 1 |
| 306 | Burden and trends of multiple sclerosis in China from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. **2022**, 12, e066335 | 0 |
| 305 | Brain connectivity changes underlying depression and fatigue in relapsing-remitting multiple sclerosis: a systematic review. | 0 |
| 304 | Neural precursor cells tune striatal connectivity through the release of IGFBPL1. **2022**, 13, | 0 |
| 303 | Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis. 135245852211342 | 0 |
| 302 | Dropout rate in randomised controlled trials of balance and gait rehabilitation in multiple sclerosis: is it expected to be different for virtual reality-based interventions? A systematic review with meta-analysis and meta-regression. | 0 |
| 301 | Integrated single-cell transcriptomics of cerebrospinal fluid cells in treatment-naïve multiple sclerosis. **2022**, 19, | 0 |
| 300 | Multi-Disease Validation of the RUDAS for Cognitive Screening in Alzheimer's Disease, Parkinson's Disease, and Multiple Sclerosis. **2022**, 1-13 | 0 |
| 299 | Radial diffusivity reflects general decline rather than specific cognitive deterioration in multiple sclerosis. **2022**, 12, | 0 |
| 298 | Advances in nanotechnology versus stem cell therapy for the theranostics of multiple sclerosis disease. | 0 |
| 297 | Improvement in time to multiple sclerosis diagnosis: 25-year retrospective analysis from New York State MS Consortium (NYSMSC). 135245852211402 | 0 |
| 296 | Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab. 13, | 0 |
| 295 | Enlarged choroid plexus related to cortical atrophy in multiple sclerosis. | 0 |
| 294 | Quantitative susceptibility mapping of the normal-appearing white matter as a potential new marker of disability progression in multiple sclerosis. | 0 |
| 293 | Psychophysical Evaluation of Visual vs. Computer-Aided Detection of Brain Lesions on Magnetic Resonance Images. | 0 |

| 292 | Validity of serum neurofilament light chain as a prognostic biomarker of disease activity in multiple sclerosis. | 0 |
| 291 | Obesity is associated with myelin oligodendrocyte glycoprotein antibody-associated disease in acute optic neuritis. **2022**, 12, | 0 |
| 290 | Determinants of early working impairments in multiple sclerosis. 13, | 0 |
| 289 | A case for including optic nerve lesions in the McDonald criteria. | 0 |
| 288 | Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter Study. 10.1212/WNL.0000000000201662 | 0 |
| 287 | Central nervous system tumefactive demyelinating lesions: Risk factors of relapse and follow-up observations. 13, | 0 |
| 286 | Myelin Basic Protein in Oligodendrocyte-Derived Extracellular Vesicles as a Diagnostic and Prognostic Biomarker in Multiple Sclerosis: A Pilot Study. **2023**, 24, 894 | 0 |
| 285 | A Systematic Review and Meta-Analysis of the Brief Cognitive Assessment for Multiple Sclerosis (BICAMS) International Validations. **2023**, 12, 703 | 0 |
| 284 | The gut microbiota in multiple sclerosis varies with disease activity. **2023**, 15, | 0 |
| 283 | Lower corticospinal excitability and greater fatigue among people with multiple sclerosis experiencing pain. **2023**, 9, 205521732211433 | 0 |
| 282 | XCL1, a serum biomarker in neurological diseases; HTLV-1-associated myelopathy and multiple sclerosis. **2023**, 174, 105962 | 0 |
| 281 | An Overview of the History, Pathophysiology, and Pharmacological Interventions of Multiple Sclerosis. **2023**, | 0 |
| 280 | Elevated neurofilament light chain CSF/serum ratio indicates impaired CSF outflow in idiopathic intracranial hypertension. **2023**, 20, | 0 |
| 279 | Retinal ganglion cell loss is associated with future disability worsening in early relapsing remitting multiple sclerosis. | 0 |
| 278 | Cerebral Venous Sinus Thrombosis induced By Hypercoagulation in Patient With Systemic Lupus Erythematosus: A Case Report and Literature Review. Volume 14, 1-6 | 0 |
| 277 | Lesion location across diagnostic regions in multiple sclerosis. **2023**, 37, 103311 | 0 |
| 276 | Long Term Misdiagnosis of Neuromyelitis Optica Spectrum Disorder Patients with Multiple Sclerosis. | 0 |
| 275 | Pediatric Multiple Sclerosis: Experience of a Tertiary Care Center. **2023**, 54, 058-063 | 0 |

| 274 | Differential DNA methylation associated with multiple sclerosis and disease modifying treatments in an underrepresented minority population. 13, | 0 |
|---|---|---|
| 273 | Combining in vivo proton exchange rate (kex) MRI with quantitative susceptibility mapping to further stratify the gadolinium-negative multiple sclerosis lesions. 16, | 0 |
| 272 | Palliative care in multiple sclerosis. **2023**, 129-138 | 0 |
| 271 | Leukocyte Telomere Length Predicts Severe Disability in Relapsing-Remitting Multiple Sclerosis and Correlates with Mitochondrial DNA Copy Number. **2023**, 24, 916 | 0 |
| 270 | Hepatotoxicity of Drugs Used in Multiple Sclerosis, Diagnostic Challenge, and the Role of HLA Genotype Susceptibility. **2023**, 24, 852 | 0 |
| 269 | Sixteen syndrome: a rare presentation of central demyelination. **2023**, 16, e250440 | 0 |
| 268 | Early Predictors of Disability and Cognition in Multiple Sclerosis Patients: A Long-Term Retrospective Analysis. **2023**, 12, 685 | 0 |
| 267 | Subtypes of relapsing-remitting multiple sclerosis identified by network analysis. 4, | 0 |
| 266 | Therapy of women with multiple sclerosis: an analysis of the use of drugs that may have adverse effects on the unborn child in the event of (unplanned) pregnancy. **2023**, 14, 204209862211438 | 0 |
| 265 | The Relationship between Depression, Anxiety, Fatigue, and the Symbol Digit Modalities Test in Persons with Multiple Sclerosis. **2023**, 2, 74-79 | 0 |
| 264 | Relationship Between Dual-task Walking and Cognitive Functions in Persons with Multiple Sclerosis. **2023**, 2, 57-61 | 0 |
| 263 | Dimethyl Fumarate Treatment Reduces the Amount but Not the Avidity of the Epstein﹣Barr Virus Capsid-Antigen-Specific Antibody Response in Multiple Sclerosis: A Pilot Study. **2023**, 24, 1500 | 0 |
| 262 | Resilience, Stress, Well-Being, and Sleep Quality in Multiple Sclerosis. **2023**, 12, 716 | 0 |
| 261 | Paradigm shifts in multiple sclerosis management: Implications for daily clinical practice. **2023**, | 0 |
| 260 | Clinical-Radiological Mismatch in Multiple Sclerosis Patients during Acute Relapse: Discrepancy between Clinical Symptoms and Active, Topographically Fitting MRI Lesions. **2023**, 12, 739 | 0 |
| 259 | Effects of multi-task training on motor and cognitive performances in multiple sclerosis patients without clinical disability: a single-blinded randomized controlled trial. | 0 |
| 258 | Protocol for an exploratory, randomised, single-blind clinical trial of aerobic exercise to promote remyelination in multiple sclerosis. **2023**, 13, e061539 | 0 |
| 257 | Determining the Prognostic Characteristics of People with Multiple Sclerosis with Bowel and Bladder Dysfunction as the Initial Presentation: A Cohort Study. **2023**, 2, 62-67 | 0 |

256    Effect of smoking on disease activity in multiple sclerosis patients treated with dimethyl fumarate or fingolimod. **2023**, 104513    o

255    Assessment of Motor Evoked Potentials in Multiple Sclerosis. **2023**, 23, 497    o

254    Cerebrospinal fluid proteomics indicates immune dysregulation and neuronal dysfunction in antibody associated autoimmune encephalitis. **2023**, 135, 102985    o

253    Efficacy and safety of repeated low-dose rituximab therapy in relapsing-remitting multiple sclerosis: A retrospective case series study. **2023**, 70, 104518    o

252    Assessment of intelligence quotient in patients with neuromyelitis optica spectrum disease and multiple sclerosis. **2023**, 70, 104492    o

251    Multiple sclerosis-related heat sensitivity linked to absence of DMT prescription and subjective hand impairment but not autonomic or corticospinal dysfunction. **2023**, 70, 104514    o

250    Factors associated with the misdiagnosis of neuromyelitis optica spectrum disorder. **2023**, 70, 104498    o

249    The epidemiology and burden of neuromyelitis optica spectrum disorder, multiple sclerosis, and MOG antibody-associated disease in a province in Thailand: A population-based study. **2023**, 70, 104511    o

248    Utility of the tibial nerve somatosensory evoked potentials in differentiating between neuromyelitis optica spectrum disorders and multiple sclerosis. **2023**, 70, 104503    o

247    Characterization of a late-onset multiple sclerosis Portuguese cohort. **2023**, 70, 104506    o

246    Late-onset multiple sclerosis in Iran: A report on demographic and disease characteristics. **2023**, 70, 104493    o

245    Cognitive impairment in multiple sclerosis: Utility of electroencephalography. **2023**, 70, 104502    o

244    Neuro rehabilitation effectiveness based on virtual reality and tele rehabilitation in people with multiple sclerosis in Argentina: Reavitelem study. **2023**, 70, 104499    o

243    Chinese herbal medicine for people with multiple sclerosis: Protocol for a systematic review and meta-analysis. **2023**, 58, 102220    o

242    Molecular biomarkers and cognitive impairment in multiple sclerosis: State of the field, limitations, and future direction A systematic review and meta-analysis. **2023**, 146, 105035    o

241    Is there a role for herpes simplex virus type 1 in multiple sclerosis?. **2022**, 105084    o

240    Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis. **2022**, 5, e2248664    o

239    Automatic detection of active and inactive multiple sclerosis plaques using the Bayesian approach in susceptibility-weighted imaging. 028418512211430    o

| 238 | Novel CSF Biomarkers Tracking Autoimmune Inflammatory and Neurodegenerative Aspects of CNS Diseases. **2023**, 13, 73 | 0 |
|---|---|---|
| 237 | Optic neuritis: current challenges in diagnosis and management. **2023**, 36, 10-18 | 0 |
| 236 | Association of daily physical activity with brain volumes and cervical spinal cord areas in multiple sclerosis. 135245852211437 | 0 |
| 235 | Turning when using a smartphone in persons with and without neurologic conditions: an observational study (Preprint). | 0 |
| 234 | Contrast-Enhanced 3D Spin Echo T1-Weighted Sequence Outperforms 3D Gradient Echo T1-Weighted Sequence for the Detection of Multiple Sclerosis Lesions on 3.0 T Brain MRI. **2022**, Publish Ahead of Print, | 0 |
| 233 | Novel Moving Steady-State Visual Evoked Potential Stimulus to Assess Afferent and Efferent Dysfunction in Multiple Sclerosis. **2023**, 1-1 | 0 |
| 232 | What is a clinically isolated syndrome in the 21st century?. 135245852211498 | 0 |
| 231 | Tumefactive Demyelination in MOG Ab–Associated Disease, Multiple Sclerosis, and AQP-4-IgG–Positive Neuromyelitis Optica Spectrum Disorder. 10.1212/WNL.0000000000206820 | 0 |
| 230 | Cerebrospinal fluid neurofilament light chains and CXCL13 as predictive factors for clinical course of multiple sclerosis. | 0 |
| 229 | High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple sclerosis. 14, | 0 |
| 228 | Multiple Sclerosis in Mongolia; the First Study Exploring Predictors of Disability and Depression in Mongolian MS Patients. **2023**, 30, 15-26 | 0 |
| 227 | T 1 /T 2 ratio from 3T MRI improves multiple sclerosis cortical lesion contrast. | 0 |
| 226 | Cortical lesions at diagnosis predict long-term cognitive impairment in multiple sclerosis: a 20-year study. | 0 |
| 225 | In vivo corneal confocal microscopy in multiple sclerosis: Can it differentiate disease relapse in multiple sclerosis?. **2023**, | 0 |
| 224 | Interoceptive and metacognitive facets of fatigue in multiple sclerosis. | 0 |
| 223 | Correspondence among gray matter atrophy and atlas-based neurotransmitter maps is clinically relevant in multiple sclerosis. | 0 |
| 222 | Family health conditions and parental occupational status modify the relationship between pediatric-onset multiple sclerosis and parental health-related quality of life. 135245852211444 | 0 |
| 221 | Fully Automatic Method for Reliable Spinal Cord Compartment Segmentation in Multiple Sclerosis. **2023**, 44, 218-227 | 0 |

| 202 | ADC restriction is not associated with clinical response to plasma exchange following a cerebral attack of multiple sclerosis. **2023**, 73, 104676 | 0 |
| 201 | Clinical and fringe benefits of rituximab in multiple sclerosis treatment in a poor resource setting: Case series and cost analysis. **2023**, 73, 104673 | 0 |
| 200 | Neuroimmunological Disorders. **2023**, 41, 315-330 | 0 |
| 199 | The role of multiple sclerosis therapies on the dynamic of human gut microbiota. **2023**, 378, 578087 | 0 |
| 198 | Neural bases of motor fatigue in multiple sclerosis: A multimodal approach using neuromuscular assessment and TMS-EEG. **2023**, 180, 106073 | 0 |
| 197 | Application of diagnostic criteria for optic neuritis. **2023**, 22, 375-376 | 0 |
| 196 | rTMS ameliorates depression/anxiety-like behaviors in experimental autoimmune encephalitis by inhibiting neurotoxic reactive astrocytes. **2023**, 331, 352-361 | 0 |
| 195 | Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes. **2023**, 74, 104695 | 0 |
| 194 | Determination of sensitivities and specificities of cerebrospinal fluid free light chains to diagnose multiple sclerosis- a multicentric case-control study. **2023**, 74, 104717 | 0 |
| 193 | Cerebrospinal fluid sulfatide isoforms lack diagnostic utility in separating progressive from relapsing-remitting multiple sclerosis. **2023**, 74, 104705 | 0 |
| 192 | Clinical diagnostic utility of transcranial magnetic stimulation in neurological disorders. Updated report of an IFCN committee. **2023**, 150, 131-175 | 0 |
| 191 | Do cardiovascular disease comorbidities affect the cognitive function of Multiple Sclerosis patients?. **2023**, 112, 20-24 | 0 |
| 190 | Automated Computerized Neuropsychological Diagnostics in Multiple Sclerosis. **2022**, 33, 138-148 | 0 |
| 189 | The prevalence and incidence of multiple sclerosis over the past 20 years in northern Japan. **2023**, 73, 104696 | 0 |
| 188 | Neurodiagnostic Studies in Children. **2022**, 725-754 | 0 |
| 187 | Neuro-immune crosstalk in depressive symptoms of multiple sclerosis. **2023**, 177, 106005 | 0 |
| 186 | Pregnancy planning and management for women with multiple sclerosis: what has changed over the last 15 years? An Italian single-center experience. **2023**, 70, 104526 | 0 |
| 185 | Feasibility and usability of a new home-based immersive virtual reality headset-based dexterity training in multiple sclerosis. **2023**, 71, 104525 | 0 |

| 184 | Sexual dysfunction in female and male people with multiple sclerosis: disability, depression and hormonal status matter. **2023**, 30, 991-1000 | 0 |
| 183 | Change in Insomnia and Depressive Symptoms During COVID-19: A Prospective Longitudinal Study of Iranian Women with Multiple Sclerosis. 1-16 | 0 |
| 182 | Assessment of oligoclonal bands in cerebrospinal fluid and serum of dogs with meningoencephalitis of unknown origin. **2023**, 18, e0280864 | 0 |
| 181 | Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. **2023**, 22, 268-282 | 1 |
| 180 | Multiple sclerosis and circadian rhythms: Can diet act as a treatment?. **2023**, 237, | 0 |
| 179 | Specific alterations in NKG2D+ T lymphocytes in relapsing-remitting and progressive multiple sclerosis patients. **2023**, 71, 104542 | 0 |
| 178 | Should trigeminal neuralgia be considered a clinically isolated syndrome?. 135245852211498 | 0 |
| 177 | Brain and Spinal Cord MRI Findings in Thai Multiple Sclerosis Patients. **2023**, 9, 27 | 1 |
| 176 | A Multicenter Longitudinal MRI Study Assessing LeMan-PV Software Accuracy in the Detection of White Matter Lesions in Multiple Sclerosis Patients. | 0 |
| 175 | Antibodies to calnexin and mutated calreticulin are common in human sera. **2023**, 71, 103380 | 0 |
| 174 | Decipher potential biomarkers of diagnosis and disease activity for NMOSD with AQP4 using LC-MS/MS and Simoa. **2023**, 116, 109761 | 0 |
| 173 | Clinically Manifest Infections Do Not Increase the Relapse Risk in People with Multiple Sclerosis Treated with Disease-Modifying Therapies: A Prospective Study. **2023**, 12, 1023 | 0 |
| 172 | Omics approaches to understanding the efficacy and safety of disease-modifying treatments in multiple sclerosis. 14, | 1 |
| 171 | Overlapping anti-NMDAR encephalitis and multiple sclerosis: A case report and literature review. 14, | 0 |
| 170 | Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study. 14, | 0 |
| 169 | Gut Microbiota Changes during Dimethyl Fumarate Treatment in Patients with Multiple Sclerosis. **2023**, 24, 2720 | 0 |
| 168 | Volumetric changes in hypothalamic subunits in patients with relapsing remitting multiple sclerosis. **2023**, 65, 899-905 | 0 |
| 167 | Multifaceted Analysis of Cerebrospinal Fluid and Serum from Progressive Multiple Sclerosis Patients: Potential Role of Vitamin C and Metal Ion Imbalance in the Divergence of Primary Progressive Multiple Sclerosis and Secondary Progressive Multiple Sclerosis. **2023**, 22, 743-757 | 0 |

| 166 | How does neurovascular unit dysfunction contribute to multiple sclerosis?. **2023**, 178, 106028 | 1 |
|---|---|---|
| 165 | Longitudinal Assessment of Multiple Sclerosis Lesion Load With Synthetic Magnetic Resonance ImagingA Multicenter Validation Study. **2023**, 58, 320-326 | 0 |
| 164 | Phenotyping variants of tumefactive demyelinating lesions according to clinical and radiological featuresA case series. 14, | 0 |
| 163 | The uncertainty period preceding the clinical defined SPMS diagnosis and the applicability of objective classifiers A Danish single center study. **2023**, 71, 104546 | 0 |
| 162 | Cerebrospinal fluid immunoglobulins in primary progressive multiple sclerosis are pathogenic. | 0 |
| 161 | In-person and remote administrations of the symbol digit modalities test are interchangeable among persons with multiple sclerosis. **2023**, 71, 104553 | 0 |
| 160 | A unified classification approach rating clinical utility of protein biomarkers across neurologic diseases. **2023**, 89, 104456 | 0 |
| 159 | Reader Response: Frequency of Asymptomatic Optic Nerve Enhancement in a Large Retrospective Cohort of Patients With Aquaporin-4+ NMOSD. **2023**, 100, 309.2-310 | 0 |
| 158 | Multicenter Evaluation of AI-generated DIR and PSIR for Cortical and Juxtacortical Multiple Sclerosis Lesion Detection. **2023**, 307, | 0 |
| 157 | Microchimerism in multiple sclerosis: The association between sex of offspring and MRI features in women with multiple sclerosis. 17, | 0 |
| 156 | Neuropathologically informed imaging of cortical grey matter lesions in MS A pilot study. **2023**, 71, 104555 | 0 |
| 155 | The Importance of Optical Coherence Tomography in the Diagnosis of Atypical or Subclinical Optic Neuritis: A Case Series Study. **2023**, 12, 1309 | 0 |
| 154 | Faster progression to multiple sclerosis disability is linked to neuronal pathways associated with neurodegeneration: An ethnicity study. **2023**, 18, e0280515 | 0 |
| 153 | Antibodies to expanded virus antigen panels show elevated diagnostic sensitivities in multiple sclerosis and optic neuritis. **2023**, 254, 54-64 | 0 |
| 152 | Long-term clinical, imaging and cognitive outcomes association with MS immunopathology. **2023**, 10, 339-352 | 0 |
| 151 | Clinical Validation of a Multi-protein, Serum-based Assay for Disease Activity Assessments in Multiple Sclerosis. | 0 |
| 150 | The role of systemic immune inflammatory index in showing active lesion in patients with multiple sclerosis. **2023**, 23, | 0 |
| 149 | Incremental validity of brief and abbreviated neuropsychological tests toward predicting functional outcomes in multiple sclerosis. 1-11 | 0 |

148    Effect of deep gray matter atrophy on information processing speed in early relapsing-remitting multiple sclerosis. **2023**, 71, 104560    o

147    Association of volumetric MRI measures and disability in MS patients of the same age: Descriptions from a birth year cohort. **2023**, 71, 104568    o

146    Predictive factors of multiple sclerosis relapse after the first demyelinating event: A 5-year follow-up. **2023**, 71, 104566    o

145    High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis. **2023**, 30, 1389-1399    o

144    ATR-FTIR spectroscopy of plasma supported by multivariate analysis discriminates multiple sclerosis disease. **2023**, 13,    o

143    Evaluation of the safety profile of COVID-19 vaccines in patients with MS, NMOSD, and MOGAD.    o

142    Intrathecal versus Peripheral Inflammatory Protein Profile in MS Patients at Diagnosis: A Comprehensive Investigation on Serum and CSF. **2023**, 24, 3768    o

141    Prominent role of executive functioning on the Phonemic Fluency Test in people with multiple sclerosis. 1-5    o

140    Immunization status in patients with multiple sclerosis: A cross-sectional, monocenter study in Austria. **2023**, 30, 1400-1408    o

139    Neuropsychiatric Status of Patients With Multiple Sclerosis Across Disease Duration Intervals.    o

138    Case report: First manifestation of multiple sclerosis temporally correlated with COVID-19 vaccination. 14,    o

137    Risk HLA Variants Affect the T-Cell Repertoire in Multiple Sclerosis. **2023**, 10, e200093    o

136    Imaging of Central Nervous System Demyelinating Disorders. **2023**, 29, 292-323    o

135    Magnetic transferrin nanoparticles (MTNs) assay as a novel isolation approach for exosomal biomarkers in neurological diseases. **2023**, 27,    o

134    Modifiable risk factors of COVID-19 in patients with multiple sclerosis: a single-centre case-control study. **2023**, 270, 1835-1842    o

133    Lessons from immunotherapies in multiple sclerosis. **2023**, 293-311    o

132    CNS demyelinating events in primary Sjögren's syndrome: A single-center case series on the clinical phenotype. 14,    o

131    Effects of Tele-Pilates and Tele-Yoga on Biochemicals, Physical, and Psychological Parameters of Females with Multiple Sclerosis. **2023**, 12, 1585    o

130 Serum Neurofilaments and OCT Metrics Predict EDSS-Plus Score Progression in Early Relapse-Remitting Multiple Sclerosis. **2023**, 11, 606 | o

129 Microstructural alterations in different types of lesions and their perilesional white matter in relapsing-remitting multiple sclerosis based on diffusion kurtosis imaging. **2023**, 71, 104572 | o

128 High-Dose Intravenous Steroid Treatment Seems to Have No Long-Term Negative Effect on Bone Mineral Density of Young and Newly Diagnosed Multiple Sclerosis Patients: A Pilot Study. **2023**, 11, 603 | o

127 Concurrent diagnoses of Tuberous sclerosis and multiple sclerosis. **2023**, 71, 104586 | o

126 A Mechanistic Insight into Sources of Error of Visual Working Memory in Multiple Sclerosis. | o

125 Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies. **2023**, 9, 205521732311547 | o

124 Aglycosylated extracellular loop of inwardly rectifying potassium channel 4.1 (KCNJ10) provides a target for autoimmune neuroinflammation. **2023**, 5, | o

123 Visual Outcomes Following Plasma Exchange for Optic Neuritis: An International Multicenter Retrospective Analysis of 395 Optic Neuritis Attacks. **2023**, | o

122 Neural Surface Antibodies and Neurodegeneration: Clinical Commonalities and Pathophysiological Relationships. **2023**, 11, 666 | o

121 Using The Virtual Brain to study the relationship between structural and functional connectivity in patients with multiple sclerosis: a multicenter study. | o

120 Lesiones inflamatorias del troncoencéfalo: claves diagnósticas en RM. **2023**, | o

119 The Acute Optic Neuritis Network (ACON): Study protocol of a non-interventional prospective multicenter study on diagnosis and treatment of acute optic neuritis. 14, | o

118 A case of primary progressive multiple sclerosis with improvement in cognitive impairment by anti-CD20 monoclonal antibody therapy. **2023**, 63, 152-158 | o

117 Acute central nervous system inflammation following COVID-19 vaccination: An observational cohort study. 135245852311547 | o

116 Cognitive skill learning in multiple sclerosis: A meaningful component of the neuropsychological profile. **2023**, 166, 105959 | o

115 Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs. **2023**, 80, 397 | o

114 A 10-Year Single-Center Study of the Clinical Characteristics of Optic Neuritis-Related NMOSD, MS, and Double Seronegative Optic Neuritis, Together with Factors Predicting Visual Outcomes. **2023**, 7, 16 | o

113 The serum kynurenine pathway metabolic profile is associated with overweight and obesity in multiple sclerosis. **2023**, 72, 104592 | o

| 94 | The effect of ginger (Zingiber officinale) supplementation on clinical, biochemical, and anthropometric parameters in patients with multiple sclerosis: a double-blind randomized controlled trial. | 0 |

| 93 | Results of treatment with alemtuzumab in a Spanish cohort of patients with multiple sclerosis in the real world: The RealMS study. 14, | 0 |

| 92 | Functional or Psychogenic Neurological Symptoms in Children and Adolescents. **2023**, 193-204 | 0 |

| 91 | Editorial: Automatic methods for multiple sclerosis new lesions detection and segmentation. 17, | 0 |

| 90 | Lifespan Neurodegeneration Of The Human Brain In Multiple Sclerosis. | 0 |

| 89 | Inflammatory Activity After Diverse Fertility Treatments. **2023**, 10, e200106 | 0 |

| 88 | A highly challenging balance training intervention for people with multiple sclerosis: a feasibility trial. **2023**, 9, | 0 |

| 87 | Magnetic-resonance imaging semiology of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) in subjects from Russian Federation. **2023**, 28, 13-24 | 0 |

| 86 | Neurophysiological and clinical biomarkers of secondary progressive multiple sclerosis: A cross-sectional study. 14, | 0 |

| 85 | Treatment Patterns and Persistence on Disease Modifying Drugs for Multiple Sclerosis and its Associated Factors. | 0 |

| 84 | A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies. | 0 |

| 83 | Toll-like receptor 10 is down-regulated in serum of patients with relapsing remitting multiple sclerosis but not associated with Epstein-Barr virus. | 0 |

| 82 | Visually Evoked Potential as Prognostic Biomarker for Neuroaxonal Damage in Multiple Sclerosis From a Multicenter Longitudinal Cohort. **2023**, 10, e200092 | 0 |

| 81 | Potential Protective Role of Pregnancy and Breastfeeding in Delaying Onset Symptoms Related to Multiple Sclerosis. **2023**, 59, 619 | 0 |

| 80 | Prefrontal hemodynamics during forward and backward walking, with and without a cognitive task, in people with multiple sclerosis. **2023**, 59, | 0 |

| 79 | Performance of McDonald 2017 multiple sclerosis diagnostic criteria and evaluation of genetic ancestry in patients with a first demyelinating event in Argentina. 135245852311572 | 0 |

| 78 | An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis. **2023**, 24, 495-509 | 0 |

| 77 | Les traitements de la sclérose en plaques. **2023**, 68, 23-27 | 0 |

| 76 | Un accompagnement multidisciplinaire indispensable pour la prise en´charge de la scl´fose en plaques. **2023**, 68, 14-18 | 0 |
| 75 | Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study. | 0 |
| 74 | Patterns of inflammation, microstructural alterations, and sodium accumulation define multiple sclerosis subtypes after 15 years from onset. 17, | 0 |
| 73 | Multiple Sclerosis Disease Evolution Assessment in Brain MRI Lesions Based on Texture and Multi-Scale Amplitude Modulation-Frequency Modulation (AM-FM) Features. **2023**, 11, 29918-29933 | 0 |
| 72 | Identification of the pathogenesis features of various phenotypes of multiple sclerosis based on the study of the morphological functional connectivity of subcortical gray matter structures. **2023**, 3, 27-42 | 0 |
| 71 | Locomotor Strategy to Perform 6-Minute Walk Test in People with Multiple Sclerosis: A Prospective Observational Study. **2023**, 23, 3407 | 0 |
| 70 | Retrospective cohort study to devise a treatment decision score predicting adverse 24-month radiological activity in early multiple sclerosis. **2023**, 16, 175628642311618 | 0 |
| 69 | Three-dimensional multi-parameter brain mapping using MR fingerprinting. | 0 |
| 68 | Diffusion-based structural connectivity patterns of multiple sclerosis phenotypes. | 0 |
| 67 | Acute Lower Extremity Weakness in a Pediatric Gymnast. 000992282311622 | 0 |
| 66 | Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment. | 0 |
| 65 | Disease characteristics of idiopathic transverse myelitis with serum neuronal and astroglial damage biomarkers. **2023**, 13, | 0 |
| 64 | CD4+T cell mitochondrial genotype in Multiple Sclerosis: a cross-sectional and longitudinal analysis. | 0 |
| 63 | Effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) Add-On Therapy to a Standard Treatment in Individuals with Multiple Sclerosis and Concomitant Symptoms of Depression Results from a Randomized Clinical Trial and Pilot Study. **2023**, 12, 2525 | 0 |
| 62 | Cognitive deficits in multiple sclerosis: Auditory and visual attention and inhibitory control. 1-8 | 0 |
| 61 | Twelve Weeks of Intermittent Caloric Restriction Diet Mitigates Neuroinflammation in Midlife Individuals with Multiple Sclerosis: A Pilot Study with Implications for Prevention of Alzheimer Disease. **2023**, 1-11 | 0 |
| 60 | Metabolic Insights into Iron Deposition in Relapsing-Remitting Multiple Sclerosis via 7T Magnetic Resonance Spectroscopic Imaging. | 0 |
| 59 | Chitinase-3-like 1-protein in CSF: a novel biomarker for progression in patients with multiple sclerosis. | 0 |

| 58 | Multiple Sclerosis Patients COVID-19 Catching Ratios and Disease Profiles. | 0 |
|---|---|---|
| 57 | Utility of the visual system to monitor neurodegeneration in multiple sclerosis. 16, | 0 |
| 56 | On a 5-year-old girl with multiple sclerosis treated with natalizumab. | 0 |
| 55 | Double inversion recovery to detect cervical spinal cord multiple sclerosis lesions. | 0 |
| 54 | Droplet-based forward genetic screening of astrocyte microglia cross-talk. **2023**, 379, 1023-1030 | 0 |
| 53 | Multiple sclerosis presenting with progressive visual impairment independent of relapse activity: A case report. **2023**, 3, 100172 | 0 |
| 52 | Swept-Source Optical Coherence Tomography Thresholds in Differentiating Clinical Outcomes in a Real-World Cohort of Treatment-Naïve Multiple Sclerosis Patients. **2023**, 13, 591 | 0 |
| 51 | Guía de práctica clínica: tratamiento agudo de las enfermedades inflamatorio-desmielinizantes del sistema nervioso central: esclerosis múltiple, espectro de la neuromielitis óptica, encefalomielitis diseminada aguda, enfermedades asociadas a anticuerpos antiglicoproteína de la membrana del oligodendrocito, mielitis aguda y neuritis óptica. Elaborada por el Grupo de Trabajo de Enfermedades Desmielinizantes. Sociedad Neurológica Argentina. **2023**, | 0 |
| 50 | Protein biomarkers in multiple sclerosis. **2023**, 3, 54-63 | 0 |
| 49 | Efficacy and safety of monoclonal antibody therapy in patients with neuromyelitis optica spectrum disorder: A systematic review and network meta-analysis. 14, | 0 |
| 48 | Antibodies against the flotillin-1/2 complex in patients with multiple sclerosis. **2023**, 5, | 0 |
| 47 | Multiple Sclerosis: A Review with a Focus on the Middle East and North Africa Region. **2023**, 1-22 | 0 |
| 46 | How does multiple sclerosis affect sexual satisfaction in patients' spouses?. 14, | 0 |
| 45 | Short- and Long-Term Humoral and Cellular Immune Responses to SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies. **2023**, 11, 786 | 0 |
| 44 | Serum proteins for monitoring and predicting visual function in patients with recent optic neuritis. **2023**, 13, | 0 |
| 43 | THE ROLE OF MRI IN DIFFERENTIATING DEMYELINATING AND INFLAMMATORY (NOT INFECTIOUS) MYELOPATHIES. **2023**, | 0 |
| 42 | Multiplex Analysis of Cerebrospinal Fluid and Serum Exosomes MicroRNAs of Untreated Relapsing Remitting Multiple Sclerosis (RRMS) and Proposing Noninvasive Diagnostic Biomarkers. | 0 |
| 41 | Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccine. **2023**, 9, 205521732311651 | 0 |

40    Guidelines on the Use of Therapeutic Apheresis in Clinical Practice Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. **2023**, 38, 77-278    0

39    Diet-related inflammation increases the odds of multiple sclerosis: Results from a large population-based prevalent case-control study in Jordan. 10,    0

38    Functional Connectivity and Disability in Multiple Sclerosis: a Cross-sectional Study.    0

37    Optical coherence tomography angiography measurements in multiple sclerosis: a systematic review and meta-analysis. **2023**, 20,    0

36    Multiple Sclerosis. **2023**, 843-853    0

35    Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.    0

34    COVID-19 infection after SARS-CoV-2 mRNA vaccination in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD patients during the Omicron subvariant BA.1/2 wave in Singapore.    0

33    Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing emitting multiple sclerosis patients: a monocentric longitudinal observational study.    0

32    Assessment of Functional Capacity of Immune System in Patients with Multiple Sclerosis using QuantiFERON Monitor. **2023**, 2023, 1-8    0

31    Safety and Effectiveness of Cladribine in Multiple Sclerosis: Real-World Clinical Experience From 5 Tertiary Hospitals in Portugal. Publish Ahead of Print,    0

30    Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab. **2023**, 10, e200104    0

29    Association of body mass index and physical activity with fatigue, depression, and anxiety among Iranian patients with multiple sclerosis. 14,    0

28    Pilot Lightweight Denoising Algorithm for Multiple Sclerosis on Spine MRI.    0

27    Functional and structural readouts for early detection of retinal involvement in multiple sclerosis. 17,    0

26    The prevalence and risk factors of anxiety in multiple sclerosis: A systematic review and meta-analysis. 17,    0

25    Incorporating the Central Vein Sign Into the Diagnostic Criteria for Multiple Sclerosis.    0

24    Short-term surrogate biomarkers of chronic lesion expansion.    0

23    Diagnosis of multiple sclerosis using optical coherence tomography supported by artificial intelligence. **2023**, 74, 104725    0

| 22 | Differential Associations of Mobility With Fronto-Striatal Integrity and Lesion Load in Older Adults With and Without Multiple Sclerosis. 154596832311647 | 0 |
|---|---|---|
| 21 | Decision Making About Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Stated Preferences and Real-World Choices. | 0 |
| 20 | Validation of an iPad version of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). **2023**, 74, 104723 | 0 |
| 19 | Top Ten Tips Palliative Care Clinicians Should Know about Multiple Sclerosis. | 0 |
| 18 | Clinical and Imaging Outcomes after Vitamin D Supplementation in Patients with Multiple Sclerosis: A Systematic Review. **2023**, 15, 1945 | 0 |
| 17 | Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosis. jnnp-2022-330796 | 0 |
| 16 | Trigeminal neuralgia in multiple sclerosis: Association with demyelination and progression. **2023**, 74, 104727 | 0 |
| 15 | Perception of Quality of Life and Fatigue in Multiple Sclerosis Patients Treated with High-Dose Vitamin D. **2023**, 7, 12 | 0 |
| 14 | Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity cohort study. **2023**, 91, 104573 | 0 |
| 13 | Imaging cortical lesions in multiple sclerosis. Publish Ahead of Print, | 0 |
| 12 | White blood cell count profiles in anti-aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder and anti-myelin oligodendrocyte glycoprotein antibody-associated disease. **2023**, 13, | 0 |
| 11 | Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2. **2023**, 123, 37 | 0 |
| 10 | Free light chains as a reliable biomarker of intrathecal synthesis in the diagnosis of CNS inflammatory diseases. **2023**, 578091 | 0 |
| 9 | Le malattie demielinizzanti nel bambino e nell dolescente: non solo sclerosi multipla. **2023**, 42, 211-212 | 0 |
| 8 | Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine. **2023**, 12, 1243 | 0 |
| 7 | Influence of Residual Quadrupolar Interaction on Quantitative Sodium Brain Magnetic Resonance Imaging of Patients With Multiple Sclerosis. Publish Ahead of Print, | 0 |
| 6 | Socioeconomic, Clinical, and Laboratory Parameters Differentiating Pediatric Patients With MOG Antibody ssociated Disease and Multiple Sclerosis. 088307382311702 | 0 |
| 5 | Troubles de la m moire et du comportement chez un homme de 49 ans. **2023**, | 0 |

| 4 | A pro-inflammatory diet in people with multiple sclerosis is associated with an increased rate of relapse and increased FLAIR lesion volume on MRI in early multiple sclerosis: A prospective cohort study. 135245852311677 | 0 |
| 3 | Improved detection of juxtacortical lesions using highly accelerated double inversion-recovery MRI in patients with multiple sclerosis. **2023**, | 0 |
| 2 | The rising role of magnetic resonance imaging biomarkers in diagnosing multiple sclerosis. | 0 |
| 1 | Central nervous system demyelinating diseases: glial cells at the hub of pathology. 14, | 0 |